US20210324014A1 - A new oncolytic virus platform to treat cancers with myxoma virus - Google Patents
A new oncolytic virus platform to treat cancers with myxoma virus Download PDFInfo
- Publication number
- US20210324014A1 US20210324014A1 US17/357,624 US202117357624A US2021324014A1 US 20210324014 A1 US20210324014 A1 US 20210324014A1 US 202117357624 A US202117357624 A US 202117357624A US 2021324014 A1 US2021324014 A1 US 2021324014A1
- Authority
- US
- United States
- Prior art keywords
- myxv
- pharmaceutical composition
- gene
- cancer
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000700562 Myxoma virus Species 0.000 title claims abstract description 372
- 206010028980 Neoplasm Diseases 0.000 title claims description 196
- 244000309459 oncolytic virus Species 0.000 title description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 212
- 102000013462 Interleukin-12 Human genes 0.000 claims abstract description 152
- 108010065805 Interleukin-12 Proteins 0.000 claims abstract description 152
- 229940117681 interleukin-12 Drugs 0.000 claims abstract description 143
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 136
- 230000014509 gene expression Effects 0.000 claims abstract description 123
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 123
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 118
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 118
- 108090000738 Decorin Proteins 0.000 claims abstract description 71
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 71
- 102000004237 Decorin Human genes 0.000 claims abstract description 68
- 230000000694 effects Effects 0.000 claims abstract description 39
- 210000004027 cell Anatomy 0.000 claims description 209
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 125
- 201000011510 cancer Diseases 0.000 claims description 102
- 230000003612 virological effect Effects 0.000 claims description 62
- 102000004127 Cytokines Human genes 0.000 claims description 50
- 108090000695 Cytokines Proteins 0.000 claims description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- 101001000206 Homo sapiens Decorin Proteins 0.000 claims description 25
- 230000001093 anti-cancer Effects 0.000 claims description 23
- 102000045840 human DCN Human genes 0.000 claims description 20
- 230000037449 immunogenic cell death Effects 0.000 claims description 16
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 13
- 102000057041 human TNF Human genes 0.000 claims description 13
- 230000002238 attenuated effect Effects 0.000 claims description 12
- 102100037850 Interferon gamma Human genes 0.000 claims description 11
- 108010074328 Interferon-gamma Proteins 0.000 claims description 11
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 10
- 201000008968 osteosarcoma Diseases 0.000 claims description 10
- 238000007910 systemic administration Methods 0.000 claims description 8
- 102000003814 Interleukin-10 Human genes 0.000 claims description 7
- 108090000174 Interleukin-10 Proteins 0.000 claims description 7
- 108010002350 Interleukin-2 Proteins 0.000 claims description 7
- 102000000588 Interleukin-2 Human genes 0.000 claims description 7
- 108090001005 Interleukin-6 Proteins 0.000 claims description 6
- 102000004889 Interleukin-6 Human genes 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 5
- 201000010893 malignant breast melanoma Diseases 0.000 claims description 5
- 238000007911 parenteral administration Methods 0.000 claims description 5
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 5
- 230000035899 viability Effects 0.000 claims description 5
- 108700019146 Transgenes Proteins 0.000 abstract description 63
- 238000000034 method Methods 0.000 abstract description 20
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 2
- 241000700605 Viruses Species 0.000 description 96
- 235000018102 proteins Nutrition 0.000 description 60
- 239000005090 green fluorescent protein Substances 0.000 description 39
- 239000000203 mixture Substances 0.000 description 39
- 241001465754 Metazoa Species 0.000 description 36
- 241000699666 Mus <mouse, genus> Species 0.000 description 34
- 208000015181 infectious disease Diseases 0.000 description 32
- 238000011282 treatment Methods 0.000 description 29
- 230000004083 survival effect Effects 0.000 description 28
- 241001529936 Murinae Species 0.000 description 26
- 238000003780 insertion Methods 0.000 description 26
- 230000037431 insertion Effects 0.000 description 26
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 25
- 230000002601 intratumoral effect Effects 0.000 description 25
- 239000003814 drug Substances 0.000 description 24
- 230000035772 mutation Effects 0.000 description 22
- 230000000174 oncolytic effect Effects 0.000 description 19
- 238000003556 assay Methods 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 18
- 238000012217 deletion Methods 0.000 description 17
- 230000037430 deletion Effects 0.000 description 17
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 16
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 16
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 238000001990 intravenous administration Methods 0.000 description 16
- 230000004048 modification Effects 0.000 description 16
- 238000012986 modification Methods 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 15
- 201000001441 melanoma Diseases 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 15
- 206010039491 Sarcoma Diseases 0.000 description 14
- 230000004614 tumor growth Effects 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 13
- 229940124597 therapeutic agent Drugs 0.000 description 13
- 238000011740 C57BL/6 mouse Methods 0.000 description 12
- 102100030698 Interleukin-12 subunit alpha Human genes 0.000 description 12
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 12
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 12
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 12
- 210000001185 bone marrow Anatomy 0.000 description 12
- 210000002865 immune cell Anatomy 0.000 description 12
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 12
- 230000003833 cell viability Effects 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 230000000259 anti-tumor effect Effects 0.000 description 10
- 102000034287 fluorescent proteins Human genes 0.000 description 10
- 108091006047 fluorescent proteins Proteins 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 230000002779 inactivation Effects 0.000 description 10
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 10
- 206010009944 Colon cancer Diseases 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 230000006798 recombination Effects 0.000 description 9
- 238000005215 recombination Methods 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 239000012491 analyte Substances 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 230000022534 cell killing Effects 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102000016942 Elastin Human genes 0.000 description 7
- 108010014258 Elastin Proteins 0.000 description 7
- 102100036701 Interleukin-12 subunit beta Human genes 0.000 description 7
- 101710187487 Interleukin-12 subunit beta Proteins 0.000 description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 230000005860 defense response to virus Effects 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- -1 e.g. Proteins 0.000 description 7
- 229920002549 elastin Polymers 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 210000003501 vero cell Anatomy 0.000 description 7
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 6
- 102000004082 Calreticulin Human genes 0.000 description 6
- 108090000549 Calreticulin Proteins 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 6
- 229940123309 Immune checkpoint modulator Drugs 0.000 description 6
- 101710194995 Interleukin-12 subunit alpha Proteins 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 108700005077 Viral Genes Proteins 0.000 description 6
- 230000005975 antitumor immune response Effects 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 108010054624 red fluorescent protein Proteins 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 5
- 108010067390 Viral Proteins Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000005907 cancer growth Effects 0.000 description 5
- 238000003570 cell viability assay Methods 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 230000009036 growth inhibition Effects 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 4
- 108091029795 Intergenic region Proteins 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 206010041067 Small cell lung cancer Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 210000002798 bone marrow cell Anatomy 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000004611 cancer cell death Effects 0.000 description 4
- 238000012054 celltiter-glo Methods 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 229960004679 doxorubicin Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000015788 innate immune response Effects 0.000 description 4
- 229960005386 ipilimumab Drugs 0.000 description 4
- 238000005304 joining Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003839 Human Proteins Human genes 0.000 description 3
- 108090000144 Human Proteins Proteins 0.000 description 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 3
- 108020004485 Nonsense Codon Proteins 0.000 description 3
- 238000010222 PCR analysis Methods 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 210000005006 adaptive immune system Anatomy 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000005101 cell tropism Effects 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000019734 interleukin-12 production Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 208000037819 metastatic cancer Diseases 0.000 description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 3
- 208000021039 metastatic melanoma Diseases 0.000 description 3
- 108091070501 miRNA Proteins 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 210000004976 peripheral blood cell Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 239000002924 silencing RNA Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012385 systemic delivery Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- 230000006433 tumor necrosis factor production Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000011717 athymic nude mouse Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229950005972 urelumab Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 108091005950 Azurite Proteins 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 229940125565 BMS-986016 Drugs 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108091005944 Cerulean Proteins 0.000 description 1
- 241000579895 Chlorostilbon Species 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 108091005960 Citrine Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108091005942 ECFP Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 101001000216 Mus musculus Decorin Proteins 0.000 description 1
- 101001010586 Mus musculus Interleukin-12 subunit alpha Proteins 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 239000012271 PD-L1 inhibitor Substances 0.000 description 1
- 239000012272 PD-L2 inhibitor Substances 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 229940125566 REGN3767 Drugs 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 241001461517 Sylvilagus bachmani Species 0.000 description 1
- 241000219681 Sylvilagus brasiliensis Species 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 241000545067 Venus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000005735 apoptotic response Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 229950007843 bavituximab Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 102220361483 c.31A>T Human genes 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- 239000011035 citrine Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 239000010976 emerald Substances 0.000 description 1
- 229910052876 emerald Inorganic materials 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229950004270 enoblituzumab Drugs 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000003198 gene knock in Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229940121569 ieramilimab Drugs 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 229950011263 lirilumab Drugs 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000021597 necroptosis Effects 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 1
- 229940121654 pd-l2 inhibitor Drugs 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- VYXXMAGSIYIYGD-NWAYQTQBSA-N propan-2-yl 2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(pyrimidine-4-carbonylamino)phosphoryl]amino]-2-methylpropanoate Chemical compound CC(C)OC(=O)C(C)(C)NP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)NC(=O)c1ccncn1 VYXXMAGSIYIYGD-NWAYQTQBSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 229950007213 spartalizumab Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- GWBUNZLLLLDXMD-UHFFFAOYSA-H tricopper;dicarbonate;dihydroxide Chemical compound [OH-].[OH-].[Cu+2].[Cu+2].[Cu+2].[O-]C([O-])=O.[O-]C([O-])=O GWBUNZLLLLDXMD-UHFFFAOYSA-H 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000010304 tumor cell viability Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000000316 virotherapy Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24071—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- MYXVs recombinant myxoma viruses
- nucleic acid constructs encoding recombinant MYXVs and methods of use thereof.
- MYXV myxoma virus having enhanced anti-cancer activity
- the myxoma virus is genetically engineered to attenuate an activity or expression level of its M153 protein.
- the activity or the expression level of the M153 protein is attenuated at least 80%.
- MYXV is engineered to introduce a mutation in a nucleic acid encoding the M153 protein, wherein the mutation comprises an insertion, deletion, or substitution mutation.
- the mutation enhances cell immune response activity in relation to a wild-type M153 protein.
- at least a portion of a nucleic acid encoding the M153 protein in MYXV genome is knocked out.
- the MYXV comprises an inhibitory molecule targeting M153 transcript that thereby attenuates the M153 protein expression.
- the inhibitory molecule is an inhibitory RNA.
- the inhibitory RNA comprises dsRNA, siRNA, antisense RNA, or miRNA.
- the MYXV further comprises a nucleic acid encoding a non-viral molecule.
- the non-viral molecule is tumor necrosis factor alpha (TNF ⁇ ).
- TNF ⁇ is human TNF ⁇ .
- the TNF ⁇ is a soluble peptide.
- the TNF ⁇ is a membrane- or surface-bound peptide.
- the TNF ⁇ further enhances the anti-cancer activity of the MYXV by activating anti-tumor immune cells or inducing cancer cell death.
- the non-viral molecule is interleukin-12 (IL-12).
- the IL-12 is human IL 12.
- the IL-12 is a soluble peptide.
- the IL-12 is a membrane- or surface-bound peptide.
- the IL-12 further enhances the anti-cancer activity of the MYXV by promoting immune cell differentiation or eliciting immune cell cytotoxicity.
- the IL-12 comprises an IL-12 ⁇ subunit and an IL-12 ⁇ subunit.
- the IL-12 ⁇ subunit and the IL-12 ⁇ subunit are joined by a polypeptide linker.
- the polypeptide linker is an elastin linker.
- the non-viral molecule is decorin.
- the decorin is human decorin.
- the decorin is a soluble peptide.
- the decorin is a membrane- or surface-bound peptide.
- the decorin further enhances the anti-cancer activity of the MYXV by blocking or decreasing TGF- ⁇ signaling.
- the nucleic acid encodes at least two molecules selected from a group consisting of TNF ⁇ , IL-12, and decorin.
- the nucleic acid encodes TNF ⁇ , IL-12, and decorin.
- the MYXV is derived from a Lausanne strain.
- composition comprising a MYXV of any of the above embodiments, and a pharmaceutically acceptable carrier or excipient.
- the composition is formulated for systemic administration. In some embodiments, the composition is formulated for local administration. In some embodiments, the composition is formulated for parenteral administration.
- composition comprising a plurality of cells treated ex vivo by the MYXV of any of the above embodiments, wherein the plurality of cells comprises peripheral blood mononuclear cells (PBMCs), bone marrow (BM) cells, or a combination thereof.
- PBMCs peripheral blood mononuclear cells
- BM bone marrow
- Disclosed herein in some aspects is a method of inhibiting, alleviating, or preventing a cancer in a subject in need thereof, comprising administering to the subject the MYXV or the composition of any one of the above embodiments.
- the subject has, is suspected of having, or is at risk of having the cancer, and wherein the method further comprises selecting the subject.
- the subject is a human.
- the administration is systemic administration.
- the administration reduces cancer cell viability, or activates immunogenic cell death in the cancer.
- the administration improves the subject's survival.
- the cancer comprises a solid tumor.
- the cancer is an osteosarcoma, triple negative breast cancer, or melanoma.
- the cancer has metastasized to a location in the subject.
- the location comprises a lung, a brain, a liver and/or a lymph node of the subject.
- the method further comprises administering to the subject an additional therapeutic agent.
- the additional therapeutic agent is an immune checkpoint modulator.
- the additional therapeutic agent is administered to the subject before administering the composition.
- the additional therapeutic agent is administered to the subject after administering the composition.
- the additional therapeutic agent is administered to the subject as a combination with the composition.
- the composition comprising the plurality of cells is administered to the subject, wherein the plurality of cells comprises cells that are autologous to the subject.
- the composition comprising the plurality of cells is administered to the subject, wherein the plurality of cells comprises cells that are allogenic to the subject.
- a recombinant nucleic acid comprising at least a portion of MYXV genome, wherein the MYXV genome is modified to reduce expression of M153 gene.
- the recombinant nucleic acid comprises DNA.
- the portion of MYXV genome is modified to knock out at least a portion of the M153 gene in the portion of MYXV genome.
- the recombinant MYXV genome comprises a first nucleic acid encoding TNF ⁇ .
- the TNF ⁇ is human TNF ⁇ .
- the first nucleic acid replaces or is adjacent to an M135R gene of the MYXV genome.
- the first nucleic acid is inserted between an M135R gene and an M136R gene of the MYXV genome.
- expression of the first nucleic acid is driven by a poxvirus synthetic early/late (sE/L) promoter.
- the recombinant MYXV genome comprises a second nucleic acid encoding interleukin-12 subunit alpha (IL-12 ⁇ ).
- IL-12 ⁇ is human IL-12 ⁇ .
- expression of IL-12 ⁇ is driven by an internal ribosome entry site (IRES).
- the second nucleic acid IL-12 ⁇ disrupts the expression of the M153 gene of the MYXV genome.
- the recombinant MYXV genome comprises a third nucleic acid encoding an interleukin-12 subunit beta (IL-12 ⁇ ).
- the IL-12 ⁇ is human IL-12 ⁇ .
- expression of the third nucleic acid is driven by an sE/L promoter.
- the third nucleic acid disrupts the expression of the M153 gene of the MYXV genome.
- the recombinant MYXV genome comprises a fourth nucleic acid encoding decorin.
- the decorin is human decorin.
- expression of the fourth nucleic acid is driven by an sE/L promoter.
- the fourth nucleic acid disrupts expression of the M153 gene of the MYXV genome.
- the recombinant MYXV genome further comprises a fifth nucleic acid encoding a reporter tag.
- the reporter tag comprises a green fluorescent protein (GFP).
- GFP green fluorescent protein
- expression of the fifth nucleic acid is driven by an sE/L promoter.
- the recombinant nucleic acid further comprises a sixth nucleic acid encoding a second reporter tag.
- the second reporter tag comprises a red fluorescent protein (RFP).
- expression of the sixth nucleic acid is driven by a poxvirus P11 late promoter.
- the recombinant nucleic acid comprises a vMyx-hTNFa cassette, optionally comprising GFP. In some embodiments, the recombinant nucleic acid comprises an hDecorin-hIL-12 cassette, optionally comprising dsRed. In some embodiments, the recombinant nucleic acid comprises or consists of a vMyx-hTNFa-hDecorin-hIL-12-M153KO (vMyx-Triple) cassette, optionally comprising dsRed and/or GFP.
- a recombinant MYXV comprising the recombinant nucleic acid of any of the above embodiments.
- Disclosed herein is a method of inhibiting, alleviating, or preventing a cancer in a subject in need thereof, comprising administering to the subject the recombinant nucleic acid or the recombinant MYXV of any one of the preceding embodiments.
- the subject has, is suspected of having, or is at risk of having the cancer, and wherein the method further comprises selecting the subject.
- the subject is a human.
- the administration is systemic administration.
- the administration reduces cell viability, or activates immunogenic cell death in the cancer.
- the administration is performed in a dose and a schedule effective to increase expression of at least two cytokines in PBMCs of the subject.
- the administration is performed in a dose and a schedule effective to increase expression of at least two cytokines in cancer cells in the subject.
- the at least two cytokines comprise IFN- ⁇ , IL-2, IL-6, IL-10, IL-12, or TNF- ⁇ .
- the administration is performed in a dose and a schedule effective to reduce volume of the cancer by at least 10%. In some embodiments, wherein the administration is performed in a dose and a schedule effective to reduce growth of the cancer by at least 10%.
- MYXV myxoma virus
- the activity or the expression level of the M153 protein is attenuated at least 80%.
- the MYXV is engineered to introduce a mutation in a nucleic acid encoding the M153 protein, wherein the mutation comprises an insertion, deletion, or substitution mutation. In some embodiments, at least a portion of a nucleic acid encoding the M153 protein in MYXV genome is knocked out.
- the MYXV comprises an inhibitory molecule targeting M153 transcript that thereby attenuates the M153 protein expression, wherein the inhibitory molecule comprises dsRNA, siRNA, antisense RNA, or miRNA.
- the MYXV is further genetically engineered to express a non-viral molecule.
- the non-viral molecule is a cytokine or a cell matrix protein.
- the non-viral molecule is tumor necrosis factor alpha (TNF ⁇ ), interleukin-12 subunit alpha (IL-12 ⁇ ), interleukin-12 subunit beta (IL-12 ⁇ ), or decorin.
- the non-viral molecule is a human protein.
- the MYXV expresses at least two non-viral molecules selected from a group consisting of TNF ⁇ , IL 12a, IL-12 ⁇ , and decorin.
- composition comprising a plurality of cells treated ex vivo by a MYXV, wherein the MYXV is genetically engineered to attenuate an activity or expression level of its M153 protein, and to express a non-viral molecule.
- the plurality of cells comprises peripheral blood mononuclear cells (PBMCs), bone marrow (BM) cells, or a combination thereof.
- PBMCs peripheral blood mononuclear cells
- BM bone marrow
- recombinant nucleic acid comprising at least a portion of MYXV genome, wherein the portion of the MYXV genome is modified to reduce expression of M153 gene.
- the portion of MYXV genome is modified to knock out at least a portion of the M153 gene in the portion of MYXV genome.
- the recombinant nucleic acid comprises a nucleic acid encoding a non-viral molecule.
- the non-viral molecule is human TNF ⁇ , human IL-12 ⁇ (hTNF ⁇ ), human IL-12 ⁇ , or human decorin.
- the nucleic acid encoding the non-viral molecule comprises a vMyx-hTNF ⁇ cassette, and the nucleic acid encoding the non-viral molecule replaces or is adjacent to an M135R gene of the MYXV genome.
- the nucleic acid encoding the non-viral molecule comprises a vMyx-hTNF ⁇ cassette, and the nucleic acid encoding the non-viral molecule is inserted between an M135R gene and an M136R gene of the MYXV genome.
- the nucleic acid encoding the non-viral molecule comprises an hDecorin-hIL-12 cassette, and the nucleic acid encoding the non-viral molecule replaces at least a portion of the M153 gene of the MYXV genome.
- the nucleic acid encoding the non-viral molecule comprises a vMyx-hTNF ⁇ -hDecorin-hIL-12-M153KO (vMyx-Triple) cassette.
- a method of inhibiting, alleviating, or preventing a cancer in a subject in need thereof comprising administering to the subject a MYXV or a plurality of cells treated with the MYXV, wherein the MYXV is genetically engineered to attenuate an activity or expression level of its M153 protein.
- the MYXV is further genetically engineered to express a non-viral molecule.
- the non-viral molecule is tumor necrosis factor alpha (TNF ⁇ ), interleukin-12 subunit alpha (IL-12 ⁇ ), interleukin-12 subunit beta (IL-12 ⁇ ), or decorin.
- the MYXV or the plurality of cells is administered by systemic administration.
- the administration reduces tumor cell viability, or activates immunogenic cell death in the cancer.
- the cancer is a solid tumor, an osteosarcoma, triple negative breast cancer, or melanoma.
- the cancer has metastasized to a lung, a brain, a liver or a lymph node in the subject.
- the method further comprises administering to the subject an immune checkpoint modulator.
- the administration is performed in a dose and a schedule effective to increase expression of at least two cytokines in PBMC or cancer cells of the subject, wherein the at least two cytokines comprise IFN- ⁇ , IL-2, IL-6, IL-10, IL-12, or TNF- ⁇ .
- the administration is performed in a dose and a schedule effective to reduce volume of the cancer at least 10%.
- MYXV myxoma virus having enhanced anti-cancer activity
- the myxoma virus is genetically engineered to attenuate an activity or expression level of its M153 protein.
- the activity or the expression level of the M153 protein is attenuated at least 80%.
- the MYXV is engineered to introduce a mutation to in a nucleic acid encoding the M153 protein, wherein the mutation comprises an insertion, deletion, or substitution mutation.
- the mutation comprises an insertion, deletion, or substitution mutation.
- at least a portion of a nucleic acid encoding the M153 protein in MYXV genome is knocked out.
- the MYXV comprises an inhibitory molecule targeting M153 transcript that thereby attenuates the M153 protein expression, wherein the inhibitory molecule comprises dsRNA, siRNA, antisense RNA, or miRNA.
- the MYXV further comprises a nucleic acid encoding a non-viral molecule.
- the non-viral molecule is tumor necrosis factor alpha (TNF ⁇ ), interleukin-12 subunit alpha (IL-12 ⁇ ), interleukin-12 subunit beta (IL-12 ⁇ ), or decorin.
- the non-viral molecule is a human protein.
- the nucleic acid encodes at least two non-viral molecules selected from a group consisting of TNF ⁇ , IL 12a, IL-12 ⁇ , and decorin.
- composition comprising a plurality of cells treated ex vivo by a MYXV, wherein the MYXV is genetically engineered to attenuate an activity or expression level of its M153 protein, and wherein the plurality of cells comprises peripheral blood mononuclear cells (PBMCs), bone marrow (BM) cells, or a combination thereof.
- PBMCs peripheral blood mononuclear cells
- BM bone marrow
- the composition is for use in inhibiting, alleviating, or preventing a cancer in a subject in need thereof, wherein the plurality of cells comprises cells that are autologous to the subject. In some embodiments, the composition is for use in inhibiting, alleviating, or preventing a cancer in a subject in need thereof, wherein the plurality of cells comprises cells that are allogeneic to the subject.
- MYXV for use in inhibiting, alleviating, or preventing a cancer in a subject in need thereof, wherein the MYXV is genetically engineered to attenuate an activity or expression level of its M153 protein.
- the MYXV is administered to the subject by systemic administration. In some embodiments, the MYXV reduces cancer cell viability, or activates immunogenic cell death in the cancer. In some embodiments, the cancer is a solid tumor, an osteosarcoma, triple negative breast cancer, or melanoma. In some embodiments, the cancer has metastasized to a lung, a brain, a liver or a lymph node in the subject. In some embodiments, the MYXV is administered to the subject with an immune checkpoint modulator.
- the MYXV is administered in a dose and a schedule effective to increase expression of at least two cytokines in PBMC or cancer cells of the subject, wherein the at least two cytokines comprise IFN- ⁇ , IL-2, IL-6, IL-10, IL-12, or TNF- ⁇ . In some embodiments, the MYXV is administered in a dose and a schedule effective to reduce volume of the cancer at least 10%.
- a recombinant nucleic acid comprising at least a portion of MYXV genome, wherein the portion of the MYXV genome is modified to reduce expression of M153.
- the portion of MYXV genome is modified to knock out at least a portion of the M153 gene in the portion of MYXV genome.
- the recombinant nucleic acid comprises a nucleic acid encoding a non-viral molecule.
- the non-viral molecule is tumor necrosis factor alpha (TNF ⁇ ), interleukin-12 subunit alpha (IL-12 ⁇ ), interleukin-12 subunit beta (IL-12 ⁇ ), or decorin.
- the non-viral molecule is a human protein.
- the nucleic acid encoding the non-viral molecule is inserted between an M135R gene and an M136R gene of the MYXV genome.
- the nucleic acid encoding the non-viral molecule is inserted to replace at least a portion of the M153 gene of the MYXV genome.
- the nucleic acid encoding the non-viral molecule comprises a vMyx-hTNFa cassette, optionally comprising GFP, and the nucleic acid encoding the non-viral molecule replaces or is adjacent to an M135R gene of the MYXV genome.
- the nucleic acid encoding the non-viral molecule comprises a vMyx-hTNFa cassette, and the nucleic acid encoding the non-viral molecule is inserted between an M135R gene and an M136R gene of the MYXV genome.
- the nucleic acid encoding the non-viral molecule comprises an hDecorin-hIL-12 cassette, optionally comprising dsRed, and the nucleic acid encoding the non-viral molecule replaces at least a portion of the M153 gene of the MYXV genome.
- the nucleic acid encoding the non-viral molecule comprises a vMyx-hTNFa-hDecorin-hIL-12-M153KO (vMyx-Triple) cassette, optionally comprising dsRed.
- FIG. 1A is a schematic diagram showing construction of recombinant nucleic acids that can be used to generate myxoma viruses (MYXV) disclosed herein.
- the top image depicts a recombinant nucleic acid that comprises a vMyx-hTNFa-GFP cassette, and an M153 locus.
- the recombinant nucleic acid can be present in the genome of a MYXV of the disclosure, for example, a vMyx-hTNFa-GFP virus.
- the middle image shows a recombinant nucleic acid comprising the hDecorin-hIL-12-dsRed cassette with flanking sequences that correspond to sequences that flank the M153 gene in the MYXV genome (M152 and M154).
- This recombinant nucleic acid can be present in a recombination plasmid that can be introduced into MYXV to generate a modified recombinant virus.
- the bottom image shows a modified vMyx-Triple recombinant nucleic acid.
- the recombinant nucleic acid can be present in the genome of a MYXV of the disclosure.
- the recombination plasmid depicted in the middle image can be introduced into a MYXV (e.g., by infecting RK13 cells with vMyx-hTNFa-GFP virus, and transfecting the cells with the recombination plasmid). Recombination can occur to generate the vMyx-Triple recombinant nucleic acid. Recombinant viruses that comprise the vMyx-Triple recombinant nucleic acid can be identified and purified based on a selection marker, for example, dsRed.
- a selection marker for example, dsRed.
- FIG. 1B is a schematic of the M153 locus in recombinant nucleic acids, which can be modified with a mutation or a transgene insertion.
- Recombinant nucleic acids with a modified M153 locus can be introduced into a MYXV genome using methods disclosed herein.
- FIGS. 2A-2D are images of agarose gels showing genetic control of recombinant MYXV constructs.
- FIG. 2A shows genomic viral DNA from vMyx-Triple construct clones using primers to confirm presence of hDecorin-hIL-12.
- FIG. 2B shows the presence of hTNFa.
- FIG. 2C shows the modification at locus M153 and purity of the vMyx-Triple construct.
- FIG. 2D shows the absence of M153 and purity of recombinant vMyx-Triple constructs.
- Lane 1 includes DNA from MYXV-Lau or the expression plasmid for hDec-Hil12 and hTNF.
- MM represents known size DNA ladder.
- FIGS. 3A-3C are images of western blots showing protein expression of the transgenes in vMyx-Triple viruses.
- the western blot analysis was performed on cell lysates and supernatants from vMyx-Triple virus-infected cells, using specific antibodies to confirm protein expression of the three transgenes hTNF ( FIG. 3A ), hDecorin ( FIG. 3B ), and hIL-12 ( FIG. 3C ).
- FIG. 4 is a chart showing a single-step growth analysis of recombinant vMyx-Triple viruses.
- FIGS. 5A and 5B are graphs showing results of a cell viability assay.
- FIG. 6 is a chart showing cell death induced by viral infection with a wild type MYXV or a M153KO MYXV, and showing cell death in untreated B16F10 cells (mock).
- FIGS. 7A and 7B are graphs showing immunogenic cell death induced by M153KO MYXV in B16F10 murine cells in vitro.
- FIG. 7A shows ATP release caused by Doxorubicin (positive control), a wt MYXV, and a M153KO MYXV at different hours post infection (p.i.). When no bar is present, the level of ATP was below the limit of detection for the assay.
- FIG. 7B shows a quantitative representation of calreticulin ecto-expression for untreated (mock), doxorubicin-treated (positive control), a M135KO MYXV-infected, and a M153KO MYXV-infected cells. The data quantify ecto-expression per cell based on confocal images taken 36 hrs post-treatment, with signal normalized to a nuclear stain (DAPI) that represents each cell.
- DAPI nuclear stain
- FIGS. 9A-9D show the concentration of cytokines in the supernatants of Vero cells infected with MYXV of the disclosure.
- FIG. 9A shows TNF concentration.
- FIG. 9B shows Decorin concentration.
- FIG. 9C shows human IL-12 concentration.
- FIG. 9D shows murine IL-12 concentration. When no bar is present, the level of the analyte was below the limit of detection for the assay.
- FIG. 10A shows the viability of L929 cells after exposure to supernatants of Vero cells infected with MYXV of the disclosure, which is indicative of TNF biological activity.
- FIG. 10B shows the expression of a reporter gene after exposure of HEK Blue IL-12 cells to supernatants of Vero cells infected with MYXV of the disclosure. When no bar is present, the level of the analyte was below the limit of detection for the assay.
- FIG. 11A shows viability of cells from human acute myeloid leukemia patients after incubation with vMyx-GFP for 6 days.
- FIG. 11B shows viability of cells from human acute myeloid leukemia patients after incubation with vMyx-Triple for 6 days.
- FIG. 12A shows the concentrations of cytokines in the supernatants of human PBMCs infected with the indicated MYXV at an MOI of 10, at 4 hours post-infection. Mean+/ ⁇ SD is plotted. When no bar is present, the level of the analyte was below the limit of detection for the assay.
- FIG. 12B shows the concentrations of cytokines in the supernatants of human PBMCs infected with the indicated MYXV at an MOI of 10, at 16 hours post-infection. Mean+/ ⁇ SD is plotted. When no bar is present, the level of the analyte was below the limit of detection for the assay.
- FIG. 13A plots the volume of NCI-H1971 (lung cancer) xenograft tumors over time in immunodeficient mice that were treated with the indicated doses of vMyx-Triple once per week (QW).
- FIG. 13B plots the volume of A673 (sarcoma) xenograft tumors over time in immunodeficient mice that were treated with the indicated doses of vMyx-Triple once per week (QW), every 4 days (Q4D), or every 2 days (Q2D).
- FIG. 13C plots the volume of SJSA (sarcoma) xenograft tumors over time in immunodeficient mice that were treated with the indicated doses of vMyx-Triple once per week (QW, every 4 days (Q4D), or every 2 days (Q2D).
- FIG. 14A shows the concentrations of IL-12 and TNF- ⁇ detected in serum and tumor tissue from immunodeficient mice bearing SJSA-1 tumors.
- the mice were treated with vMyx-Triple via the intravenous (IV) or intra-tumoral (IT) routes, and samples collected at 4 hours (4H) or 24 hours (24H) post-treatment. Mean ⁇ SD is plotted. When no bar is present, the level of the analyte was below the limit of detection for the assay.
- FIG. 14B shows the concentrations of IL-12 and TNF- ⁇ detected in serum and tumor tissue from immunodeficient mice bearing A673 tumors.
- the mice were treated with vMyx Triple via the intravenous (IV) or intra-tumoral (IT) routes, and samples collected at 4 hours (4H) or 24 hours (24H) post-treatment. Mean ⁇ SD is plotted. When no bar is present, the level of the analyte was below the limit of detection for the assay.
- FIG. 15 plots tumor volume over time for C57BL/6 mice implanted with B16-F10 mouse melanoma cells, and treated with TNF-expressing MYXV that had M153 and M135 knocked out (TNF135/153 KO) or TNF-expressing MYXV with wild type copies of both genes (TNF135/153 WT).
- FIG. 16A and FIG. 16B plot tumor volume and survival over time for C57BL/6 mice implanted with MC38 mouse colorectal cancer cells.
- Animals were treated via intratumoral (IT) injection of 2 ⁇ 10 7 FFU/dose once every 4 days for four doses with the indicated myxoma virus.
- msTriple low refers to a vMyx-Triple that expresses murine rather than human IL-12, at a relatively low level.
- msTriple high refers to a vMyx-Triple that expresses murine IL-12 at a relatively higher level.
- the msTriple viruses also express human Decorin and TNF, and have the M153 gene knocked out.
- GFP refers to vMyx-GFP, which does not encode any of the cytokines, and contains an intact M153 gene. Tumor volume measurements were recorded three times per week, and are plotted in FIG. 16A . Survival is plotted in FIG. 16B .
- FIG. 17A and FIG. 17B plot tumor volume and survival over time for C57BL/6 mice implanted with B16-F10 mouse melanoma cells. Animals were treated via intratumoral injection of 2 ⁇ 10 7 FFU/dose on Day 1 and Day 8 with the indicated myxoma virus.
- msTriple low refers to a vMyx-Triple that expresses murine rather than human IL-12, at a relatively low level.
- msTriple high refers to a vMyx-Triple that expresses murine IL-12 at a relatively higher level.
- the msTriple viruses also express human Decorin and TNF, and have the M153 gene knocked out.
- GFP refers to vMyx-GFP, which does not encode any of the cytokines, and contains an intact M153 gene. Tumor volume measurements were recorded three times per week, and are plotted in FIG. 17A . Survival is plotted in FIG. 17B .
- FIG. 18A plots tumor volume over time for C57BL/6 mice implanted with B16-F10 mouse melanoma cells, and treated with the indicated doses of msTriple high, a MYXV that expresses a relatively high level of murine IL-12, also expresses human Decorin and human TNF, and has the M153 gene knocked out.
- the virus was administered intratumorally (IT) or intravenously (IV).
- FIG. 18B plots tumor volume over time for Balb/c mice implanted with CT26 mouse colorectal cancer cells, and treated with the indicated doses of msTriple high.
- the virus was administered intratumorally (IT) or intravenously (IV).
- FIG. 19 displays survival curves of Balb/c mice implanted with K7M2 sarcoma cells. Groups of mice were treated via injection into the retro-orbital sinus of 2 ⁇ 10 7 FFU/dose of the vMyx-mouse Triple (low IL-12), and/or with intraperitoneal injections of anti-PD-1 or anti-PD-L1 antibodies at 10 mg/kg.
- FIG. 20A plots tumor volume over time of C57BL/6 mice implanted with MC38 mouse colorectal cancer cells.
- Groups of animals were treated via intratumoral injection of 2 ⁇ 10 7 FFU/dose of vMyx-mouse Triple (low IL-12) on day 1 and day 8 post-randomization, and/or with anti-PD-1 antibody at 10 mg/kg, once every four days for four doses.
- FIG. 20B plots survival of the groups in FIG. 20A .
- MYXV oncolytic poxviruses
- vMyx oncolytic myxoma viruses
- MYXV oncolytic poxviruses
- vMyx oncolytic myxoma viruses
- the MYXV is genetically engineered to attenuate an activity or expression level engineered to inactivate, disrupt, or attenuate expression of an M153 gene or protein, for example, genetically engineered to attenuate an activity or expression level of the M153 gene or protein.
- the modification to the myxoma virus as described herein has unexpectedly improved the oncolytic activity of the MYXV when compared with unmodified MYXV, MYXV that contain an intact wild type M153 gene, or MYXV with modification at another gene locus.
- the MYXV can also include one or more transgenes that encode non-viral molecules, such as a TNF ⁇ , IL-12, and/or decorin to further enhance the oncolytic activity, increase an anti-tumor immune response, or decrease adverse side effects of the MYXV.
- Some embodiments relate to triple transgene-armed oncolytic viruses such as MYXVs, and methods of their use for treatment of cancers, such as metastatic cancers.
- Some embodiments include a recombinant MYXV construct that expresses 3 human transgenes: a human cytokine (hTNF) that improves the efficacy of the treatment of cancers that metastasize to the lung or other parts of the body, an hIL-12 that can amplify anti-tumor immune responses, and a human Decorin (hDecorin) that blocks TGF-beta signaling within tumor beds.
- hTNF human cytokine
- hDecorin human Decorin
- the viruses disclosed here have a knockout (e.g., deletion or disruption) of the myxoma virus M153 gene or at least a portion thereof, which in some embodiments also improves the anti-tumor immune responses following therapy with these virus constructs.
- Some embodiments relate to nucleic acid constructs such as virus triple-transgene constructs that encode the MYXVs.
- the transgenes and other modifications to the MYXV improve cancer therapy efficacy.
- one or more or at least one can mean one, two, three, four, five, six, seven, eight, nine, ten or more, up to any number.
- an “effective amount” or “therapeutically effective amount” refers to an amount of a compound or composition of this invention that is sufficient to produce a desired effect, which can be a therapeutic and/or beneficial effect.
- a “subject in need thereof” or “a subject in need of” is a subject known to have, or is suspected of having a disease, or condition, such as a cancer.
- the term “inhibiting” or “treating” a disease refers to inhibiting the full development of a disease or condition. “Treatment” refers to a therapeutic intervention that ameliorates a sign or symptom of a disease or pathological condition after it has begun to develop.
- the term “ameliorating,” with reference to a disease or pathological condition, refers to any observable beneficial effect of the treatment.
- the beneficial effect can be evidenced, for example, by a delayed onset of clinical symptoms of the disease in a susceptible subject, a reduction in severity of some or all clinical symptoms of the disease, a slower progression of the disease, such a metastasis, an improvement in the overall health or well-being of the subject, or by other parameters well known in the art that are specific to the particular disease.
- a “prophylactic” treatment is a treatment administered to a subject who does not exhibit signs of a disease or exhibits only early signs for the purpose of decreasing the risk of developing pathology, for example metastatic cancer.
- MYXV may infect cells that have a deficient innate anti-viral response.
- a deficient innate anti-viral response refers to a cell that, when exposed to a virus or when invaded by a virus, does not induce anti-viral defense mechanisms, which can include inhibition of viral replication, production of interferon, induction of the interferon response pathway, and apoptosis.
- the term includes a cell, such as a cancer cell, that has a reduced or defective innate anti-viral response upon exposure to or infection by a virus as compared to a normal cell, for example, a non-infected, or non-cancer cell.
- the deficiency may be due to various causes, including infection, genetic defect, or environmental stress. It will however be understood that when the deficiency is caused by a pre-existing infection, superinfection by MYXV may be excluded and a skilled person can readily identify such instances. A skilled person can readily determine without undue experimentation whether any given cell type has a deficient innate anti-viral response and therefore is susceptible to infection by MYXV. Thus, in certain embodiments, the MYXV is capable of infecting cells that have a deficient innate anti-viral response.
- the cells are non-responsive to interferon.
- the cell is a mammalian cancer cell.
- the cell is a human cancer cell including a human solid tumor cell.
- the cells that have a deficient innate anti-viral response comprise cancer cells.
- MYXVs myxoma viruses
- the MYXV may comprise a wild-type strain of MYXV or it may comprise a genetically modified strain of MYXV.
- the MYXV comprises a Lausanne strain.
- the Lausanne strain of MYXV comprises GenBank Accession Number AF170726.2, published on Jul. 11, 2019.
- the MYXV comprises a South American MYXV strain that circulates in Sylvilagus brasiliensis . In some instances, the MYXV comprises a Californian MYXV strain that circulates in Sylvilagus bachmani . In some instances, the MYXV comprises 6918, an attenuated Spanish field strain that comprises modifications in genes M009L, M036L, M135R, and M148R (for example, GenBank Accession number EU552530, published on Jul. 11, 2019). In some instances, the MYXV comprises 6918VP60-T2 (GenBank Accession Number EU552531, published on Jul. 11, 2019). In some instances, the MYXV comprises a Standard laboratory Strain (SLS). In some embodiments, the MYXV comprises a nucleic acid construct or MYXV genome as described herein.
- SLS Standard laboratory Strain
- the MYXV comprises at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, such as between 95% and 98%, 95% and 99%, including 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% nucleic acid sequence identity to a sequence disclosed in Cameron, et al., “The complete DNA sequence of Myxoma Virus,” Virology 264: 298-318 (1999), which is incorporated by reference for such disclosure.
- the MYXV comprises the sequence disclosed in Cameron, et al., “The complete DNA sequence of Myxoma Virus,” Virology 264: 298-318 (1999).
- the MYXVs are engineered to inactivate or attenuate an activity or expression level of a viral gene or protein.
- the viral gene or protein is M153.
- the inactivated or attenuated activity or expression level of the viral gene or protein results in the MYXV exhibiting enhanced anti-cancer activity in relation to a wild-type MYXV, or in relation to a MYXV not having the inactivated or attenuated activity or expression level of the viral gene or protein, for example, a MYXV that comprises a wild type M153 gene and/or expresses a wild type M153 protein.
- the MYXV is engineered to inactivate or attenuate an activity or expression level of more than one viral gene or protein.
- the MYXV comprises a nucleic acid that encodes a non-viral molecule, for example, a transgene that encodes a cytokine.
- the MYXV includes a transgene such as a transgene described herein.
- the transgene encodes a tumor necrosis factor (TNF, e.g., TNF ⁇ ), an interleukin-12 (IL-12), or a decorin.
- TNF tumor necrosis factor
- IL-12 interleukin-12
- the MYXV includes one, two, three, or more transgenes.
- one or more transgenes are knocked in to a MYXV genome.
- a transgene disrupts a gene in the MYXV genome, for example, a transgene inserted within or replaces part of the gene in the MYXV genome, thereby disrupting expression of the gene and/or the protein it encodes.
- a disruption can be referred to as a knockout (KO).
- the MYXV may be modified to produce any non-viral molecule (e.g., modified to carry any transgene) that enhances the anticancer effect of the MYXV.
- a non-viral molecule can be involved in triggering apoptosis, or in targeting the infected cell for immune destruction, such as a non-viral molecule that stimulates a response to interferon (e.g., repairs a lack of response to interferon), or that results in the expression of a cell surface marker that stimulates an antibody response, such as a pathogen-associated molecular pattern, for example, a bacterial cell surface antigen.
- the MYXV can also be modified to produce a non-viral molecule involved in shutting off the neoplastic or cancer cell's proliferation and growth, thereby preventing the cells from dividing.
- the MYXV is modified to produce therapeutic non-viral molecules, such as molecules involved in the synthesis of chemotherapeutic agents, or it can be modified to have increased replication levels in cells of the particular species from which the cells to be inhibited or killed are derived, for example, human cells.
- the MYXV includes a recombinant construct that encodes or expresses one, two, or three separate non-viral molecules, for example, human transgenes (e.g., human TNF, human Decorin and human IL-12).
- the recombinant construct further encodes or expresses one or more reporter tags, for example, fluorescent proteins such as eGFP and dsRed.
- the MYXV is genetically engineered to attenuate an activity or expression level of its M153 gene or protein, for example, comprises a disruption of the viral M153 gene (M153-knockout: M153K0).
- attenuating the activity or expression level of M153 improves the MHC-dependent anti-tumor immune responses to virus-infected cancer cells.
- the MYXVs comprise oncolytic viruses for use in treating cancer. Some embodiments combine a M153KO backbone with the immune-enhancing properties of transgenes disclosed herein to enhance the oncolytic properties of the MYXV.
- the MYXV encodes a TNF (e.g., TNF ⁇ ) transgene, an IL-12 transgene, a decorin transgene, or any combination of two or more of those.
- the MYXV includes a TNF (e.g., TNF ⁇ ) transgene, an IL-12 transgene, and a decorin transgene.
- TNF e.g., TNF ⁇
- the TNF upon administration of such an MYXV to a subject, the TNF activates and jump-starts the innate and acquired arms of the anti-tumor immune system and promotes cancer cell death in a by-stander paracrine-like manner.
- the IL-12 amplifies the resulting anti-cancer innate and adaptive immune responses.
- the decorin interrupts local immunosuppressive actions mediated by TGF- ⁇ , thus enhancing the actions of both TNF and IL-12 and promoting the anti-cancer immune response.
- the synergistic actions of the three transgenes plus the effects of MYXV in the tumor microenvironment (TME) increase the immunotherapeutic potential of oncolytic MYXV vectors.
- the addition of the human transgenes that encode non-viral molecules (hTNF, hIL-12, and/or hDecorin) to the MYXV genome improves the MYXV's capacity to trigger robust anti-tumor immune responses in the tumor microenvironment (TME).
- TEE tumor microenvironment
- the MYXV is modified to enhance the ease of detection of infection state.
- the MYXV may be genetically modified to express a marker that can be readily detected by phase contrast microscopy, fluorescence microscopy or by radioimaging.
- the marker can be an expressed fluorescent protein or an expressed enzyme that is involved in a colorimetric or radiolabeling reaction.
- the marker includes a gene product that interrupts or inhibits a particular function of the cells being tested.
- the engineered MYXV comprises a fluorescent protein.
- fluorescent proteins include blue/UV proteins such as TagBFP, Azurite, Sirus, or Sapphire; cyan proteins such as ECFP, cerulean, or mTurquoise; green proteins such as green fluorescent protein (GFP), Emerald, mUKG, mWasabi, or Clover; yellow proteins such as EYFP, citrine, venus, or SYFP2; orange proteins such as monomeric Kusabira-Orange, mKO2, or mOrange; red proteins such as dsRed, mRaspberrym mCherry, mStrawberry, mTangerine, tdTomato, mApple, or mRuby; photoactivatible proteins such as PA-GFP, PAmCherry1, or PATagRFP; and photoswitchable proteins such as Dropna.
- the MYXV includes more than one fluorescent protein.
- the engineered MYXV includes more than one fluorescent protein
- the MYXV comprises a vMyx-hTNFa-GFP-hDecorin-hIL-12-dsRed-M153KO (vMyx-Triple or vMyx-Triple-red) construct, and is a vMyx-Triple virus.
- the MYXV comprises a vMyx-hTNFa-GFP-hDecorin-hIL-12-M153KO (vMyx-Triple-white) construct, and is a vMyx-Triple-white virus.
- the MYXV comprises a modification at or adjacent to one or more genes associated with rabbit cell tropism.
- the one or more genes associated with rabbit cell tropism comprises M11L, M063, M135R, M136R, M-T2, M-T4, M-T5, or M-T7.
- the one or more genes associated with rabbit cell tropism comprise M135R, M136R, or a combination thereof.
- the MYXV may be prepared using standard techniques known in the art.
- the virus may be prepared by infecting cultured rabbit cells, or immortalized permissive human or primate cells, with the MYXV strain that is to be used, allowing the infection to progress such that the virus replicates in the cultured cells and can be released by standard methods known in the art for disrupting the cell surface and thereby releasing the virus particles for harvesting. Once harvested, the virus titer may be determined by infecting a confluent lawn of rabbit cells and performing a plaque assay.
- the M153 gene product is an E3-Ubiquitin ligase that may participate in the down regulation of diverse cellular receptors and proteins, for example, degradation of MHC Class I and CD4 in human cells.
- a MYXV of the disclosure has an attenuated activity and/or expression level of M153 protein.
- an attenuated activity and/or expression level of M153 protein can enhance presentation of immune epitopes, for example, MHC-dependent presentation of viral and/or cancer immune peptides. Enhanced presentation of immune epitopes by infected cancer cells can elicit stronger immune responses, including anti-cancer T cell responses, such as anti-cancer CD8+ T cell responses.
- an attenuated activity and/or expression level of M153 protein increases direct antigen presentation from M153KO virus-infected tumor cells by MHC-I, and enhances immune activation mediated by the MYXV.
- the MYXV comprises a modification of an M153 gene.
- the modification is a mutation that attenuates an activity or expression level of a protein encoded by the M153 gene (e.g., impairs the function of the protein encoded by the M153 gene).
- the mutation is a deletion, for example, a deletion that attenuates an activity or expression level of a protein encoded by the M153 gene.
- the mutation is a deletion of at least about 1%, at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99%, of the nucleic acid sequence of the M153 gene.
- the mutation is a deletion of the entire M153 gene.
- the modification is a partial deletion, for example, a deletion of about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 95% of the nucleic acid sequence of the M153 gene.
- the deletion is a deletion of at least 1, at least 2, at least 3, at least 4, at least 5, at least 7, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 100, at least 200, or at least 300 nucleic acids.
- the deletion disrupts a promoter (e.g., a promoter that drives expression of M153 in a wild type MYXV).
- the deletion introduces a stop codon into the M153 gene sequence, for example, a premature stop codon that prevents expression of a full length M153 transcript and/or protein.
- the mutation is an insertion, for example, an insertion that attenuates an activity or expression level of a protein encoded by the M153 gene.
- the insertion comprises a transgene that encodes a non-viral molecule, for example, a transgene that encodes TNF, decorin, IL-12, or a combination thereof.
- the insertion comprises two transgenes.
- the insertion comprises three transgenes. The transgene(s) can disrupt (e.g., interrupt) the viral M153 gene and attenuate an activity or expression level of a M153 transcript and/or protein.
- the insertion comprises a transgene that encodes TNF.
- the insertion comprises a transgene that encodes IL-12. In some embodiments, the insertion comprises a transgene that encodes decorin. In some embodiments, the insertion comprises a transgene that encodes TNF and a transgene that encodes IL-12. In some embodiments, the insertion comprises a transgene that encodes TNF and a transgene that encodes decorin. In some embodiments, the insertion comprises a transgene that encodes IL-12 and a transgene that encodes decorin. In some embodiments, the insertion comprises a transgene that encodes TNF, a transgene that encodes IL-12, and a transgene that encodes decorin.
- the insertion comprises one or more promoters.
- the insertion disrupts a promoter (e.g., a promoter that drives expression of M153 in a wild type MYXV).
- a promoter e.g., a promoter that drives expression of M153 in a wild type MYXV.
- combining M153 gene disruption with transgene expression improves the anti-tumor properties of the resulting recombinant virus.
- the insertion is an insertion of at least 1, at least 2, at least 3, at least 4, at least 5, at least 7, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 100, at least 200, at least 300, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1500, or at least 2000 nucleic acids.
- the insertion introduces a stop codon into the M153 gene sequence, for example, a premature stop codon that prevents expression of a full length M153 transcript and/or protein. In some embodiments, the insertion alters the reading frame of the M153 gene sequence, thereby disrupting expression of the M153 transcript and/or protein.
- the mutation is a substitution, for example, a substitution that attenuates an activity or expression level of a protein encoded by the M153 gene. In some embodiments, at least 1, at least 2, at least 3, at least 4, at least 5, at least 7, at least 10, at least 20, at least 30 nucleic acids are substituted.
- the substitution introduces a stop codon into the M153 gene sequence, for example, a premature stop codon that prevents expression of a full length M153 transcript and/or protein.
- the substitution disrupts a promoter (e.g., a promoter that drives expression of M153 in a wild type MYXV).
- a modification or mutation disclosed herein attenuates the activity level of the M153 gene and/or protein by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% relative to a wild type MYXV, or a MYXV that encodes a functional wild type M153.
- a modification or mutation disclosed herein attenuates the expression level of the M153 gene and/or protein by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% relative to a wild type MYXV, or a MYXV that encodes a functional wild type M153.
- a MYXV disclosed herein has an activity level of the M153 protein that is attenuated by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% relative to a wild type MYXV, or a MYXV that encodes a functional wild type M153.
- a MYXV disclosed herein has an expression level of the M153 gene and/or protein that is attenuated by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% relative to a wild type MYXV, or a MYXV that encodes a functional wild type M153.
- the MYXV comprises (e.g., encodes) a non-viral molecule, for example, comprises a transgene that encodes tumor necrosis factor (TNF) protein.
- TNF tumor necrosis factor
- the TNF protein is a TNF ⁇ protein.
- the TNF ⁇ protein is a human TNF ⁇ protein.
- the TNF ⁇ protein is soluble.
- the TNF ⁇ protein is membrane- or surface-bound.
- the TNF ⁇ protein enhances the anti-cancer activity of the MYXV by activating anti-tumor immune cells or inducing cancer cell death.
- the TNF ⁇ is encoded by a gene that replaces or is adjacent to an M135R gene of the MYXV genome. In some embodiments, the TNF ⁇ gene is inserted between an M135R gene and an M136R gene of the MYXV genome. In some embodiments, the TNF ⁇ gene is inserted in the intergenic region between an M135R gene and an M136R gene of the MYXV genome. In some embodiments, the TNF ⁇ is encoded by a gene that replaces or disrupts an M153 gene of the MYXV genome. In some embodiments, the TNF ⁇ gene replaces or disrupts an M153 gene of the MYXV genome.
- expression of the TNF ⁇ gene is driven by a promoter such as a poxvirus synthetic early/late (sE/L) promoter.
- expression of the TNF ⁇ gene is driven by an internal ribosome entry site (IRES).
- TNF is a cytokine that is part of the innate inflammatory immune response.
- TNF participates in amplifying the acquired (e.g., adaptive) immune responses.
- TNF can be expressed as a cell surface immune ligand and it can also be secreted as a cleaved soluble trimeric cytokine when produced in specific cells that express the converting proteolytic enzymes (such as TACE) that catalyze cleavage and release of the soluble ligand, for example that are expressed at high levels in cells of the myeloid lineage.
- TNF effector pathway is the induction of cellular death through the TNF Receptor-1 (TNFR1) pathway.
- TNFR1 TNF Receptor-1
- TNF activates the innate and adaptive immune responses, for example, by activating anti-tumor CD8 + T cells and NK cells.
- TNF soluble TNF
- a virally derived expression of TNF may improve local cancer cell death by eliciting a greater degree of bystander cell killing in the tumor microenvironment, and also stimulate various classes of immune cells residing within the same tumor beds, while minimizing systemic TNF-mediated adverse toxic effects.
- the TNF protein comprises at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the sequence illustrated in UniProtKB-P01375, published on Jul. 3, 2019 (Entry version 247). In some instances, the TNF protein comprises between 95% and 98%, or 95% and 99% sequence identity to the sequence illustrated in UniProtKB-P01375, published on Jul. 3, 2019 (Entry version 247). In some instances, the TNF protein comprises about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity to the sequence illustrated in UniProtKB-P01375, published on Jul. 3, 2019 (Entry version 247). In some embodiments, the TNF protein comprises the sequence illustrated in UniProtKB-P01375, published on Jul. 3, 2019 (Entry version 247).
- the TNF protein comprises at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to residues 77-233 of UniProtKB-P01375. In some instances, the TNF protein comprises between 95% and 98%, or 95% and 99% sequence identity to residues 77-233 of UniProtKB-P01375. In some instances, the TNF protein comprises about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity to residues 77-233 of UniProtKB-P01375. In some embodiments, the TNF protein comprises residues 77-233 of UniProtKB-P01375.
- the TNF protein is encoded by a gene comprising at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 12 or SEQ ID NO: 24. In some instances, the TNF protein is encoded by a gene comprising between 95% and 98%, or 95% and 99% sequence identity SEQ ID NO: 12 or SEQ ID NO: 24. In some instances, the TNF protein is encoded by a gene comprising about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity to SEQ ID NO: 12 or SEQ ID NO: 24.
- the TNF protein is encoded by a gene comprising or consisting of SEQ ID NO: 12 or SEQ ID NO: 24.
- the TNF is encoded by a gene comprising the sequence of SEQ ID NO: 12 or SEQ ID NO: 24.
- the gene encoding the TNF comprises a sequence that is 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, or a range of percentages defined by any two of the aforementioned percentages, identical to that of SEQ ID NO: 12 or SEQ ID NO: 24.
- the TNF protein comprises at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 31 or residues 77-233 of SEQ ID NO: 31. In some instances, the TNF protein comprises between 95% and 98%, or 95% and 99% sequence identity to SEQ ID NO: 31 or residues 77-233 of SEQ ID NO: 31. In some instances, the TNF protein comprises about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity to SEQ ID NO: 31 or residues 77-233 of SEQ ID NO: 31. In some embodiments, the TNF protein comprises SEQ ID NO: 31 or residues 77-233 of SEQ ID NO: 31.
- the MYXV comprises (e.g., encodes) a non-viral molecule, for example, comprises a transgene that encodes interleukin-12 (IL-12) protein.
- the IL-12 protein is a human IL-12 protein.
- the IL-12 protein is soluble.
- the IL-12 protein is membrane- or surface-bound.
- the IL-12 protein further enhances the anti-cancer activity of the MYXV by promoting immune cell differentiation or eliciting immune cell cytotoxicity.
- IL-12 comprises an IL12a subunit (p35 subunit).
- the IL-12 ⁇ subunit is encoded by an IL-12 ⁇ gene.
- the IL-12a gene is a human IL-12 ⁇ gene.
- the IL-12 ⁇ gene is driven by an IRES.
- the IL-12 ⁇ gene is driven by a promoter such as an sE/L promoter.
- IL-12 ⁇ gene replaces or disrupts the M153 gene.
- IL-12 ⁇ gene is inserted in the intergenic region between an M135R gene and an M136R gene of the MYXV genome.
- IL-12 comprises an IL12 ⁇ (p40) subunit.
- the IL-12 ⁇ subunit is encoded by an IL-12 ⁇ gene.
- the IL-12 ⁇ gene is a human IL-12 ⁇ gene.
- the IL-12 ⁇ gene is driven by an IRES.
- the IL-12 ⁇ gene is driven by a promoter such as an sE/L promoter.
- IL-12 ⁇ gene replaces or disrupts an MYXV M153 gene.
- IL-12 ⁇ gene is inserted in the intergenic region between an M135R gene and an M136R gene of the MYXV genome.
- IL-12 comprises an IL12a subunit and an IL-12 ⁇ subunit. In some embodiments the IL12a subunit and the IL-12 ⁇ subunit are covalently linked. In some embodiments the IL12a subunit and the IL-12 ⁇ subunit are not covalently linked. In some embodiments the IL12 ⁇ subunit and the IL-12 ⁇ subunit are expressed as one transcript. In some embodiments the IL12 ⁇ subunit and the IL-12 ⁇ subunit are expressed as one polypeptide, for example, with a peptide linker joining the two subunits.
- a linker sequence can be, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acid residues in length.
- a linker can be at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 amino acid residues in length.
- a linker can be at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, at most 10, at most 15, at most 20, at most 25, at most 30, at most 40, or at most 50 amino acid residues in length.
- a flexible linker can have a sequence containing stretches of glycine and serine residues.
- the small size of the glycine and serine residues provides flexibility, and allows for mobility of the connected functional domains.
- the incorporation of serine or threonine can maintain the stability of the linker in aqueous solutions by forming hydrogen bonds with the water molecules, thereby reducing unfavorable interactions between the linker and protein moieties.
- Flexible linkers can also contain additional amino acids such as threonine and alanine to maintain flexibility, as well as polar amino acids such as lysine and glutamine to improve solubility.
- a rigid linker can have, for example, an alpha helix-structure.
- An alpha-helical rigid linker can act as a spacer between protein domains.
- a linker can comprise any of the sequences of SEQ ID NOs: 33-43, or repeats thereof.
- SEQ ID NOs: 33-38 and 43 provide examples flexible linker sequences.
- SEQ ID NOs: 39-42 provide examples of rigid linker sequences.
- the MYXV expresses a relatively low level of IL-12. Relatively lower expression of IL-12 can be achieved, for example, by use of an IRES sequence between the sequences that encode the IL-12 subunits. In some embodiments, the MYXV expresses a relatively high level of IL-12. Relatively higher expression of IL-12 can be achieved, for example, by use of a suitable linker that joins the subunits of IL-12 in a single polypeptide, for example, an elastin linker, such as the linker of SEQ ID NO: 43.
- a level of IL-12 expression can be as determined by the assay of example 6.
- vero cells can be infected with a MYXV of the disclosure at an MOI of 1, supernatant can be harvested at 24 hours post-infection, and the amount of IL-12 can be measured by ELISA.
- a low level of IL-12 expression can be less than 50, less than 40, less than 30, less than 20, less than 10, or less than 5 ng/mL of IL-12 as determined by the assay of example 6.
- a high level of IL-12 expression can be more than 20, more than 30, more than 40, more than 50, more than 60, more than 70, more than 80, more than 90, more than 100, or more than 150 ng/mL of IL-12 as determined by the assay of example 6. In some embodiments, a high level of IL-12 expression can be more than 20 ng/mL of IL-12, and a low level of IL-12 expression can be less than 20 ng/mL of IL-12.
- one or both of the IL-12 subunits can be truncated.
- An example of an IL-12 with a truncated subunit is provided in SEQ ID NO: 50, which comprises mouse IL-12 B (SEQ ID NO: 51), an elastin linker (SEQ ID NO: 43), and a truncated mouse IL-12 A (SEQ ID NO: 52).
- IL-12 is a cytokine.
- IL-12 promotes T helper type 1 (Th1) differentiation, and enhances the cytotoxicity of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs).
- Th1 T helper type 1
- NK natural killer
- CTLs cytotoxic T lymphocytes
- the actions of this IL-12 create an improved interconnection between the elements of innate and adaptive immunity to promote an anti-cancer immune response.
- IL-12 enhances the anti-tumor effects of the MYXV.
- IL-112 potently stimulates production of IFN- ⁇ (a cytokine that coordinates mechanisms of anticancer defense), thereby enhancing the anti-tumor effects of the MYXV.
- the IL12 ⁇ subunit comprises at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 28, residues 35-253 of SEQ ID NO: 28, or residues 57-253 of SEQ ID NO: 28. In some instances, the IL12 ⁇ subunit comprises between 95% and 98%, or 95% and 99% sequence identity to SEQ ID NO: 28, residues 35-253 of SEQ ID NO: 28, or residues 57-253 of SEQ ID NO: 28.
- the IL12 ⁇ subunit comprises about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity to SEQ ID NO: 28, residues 35-253 of SEQ ID NO: 28, or residues 57-253 of SEQ ID NO: 28. In some embodiments, the IL12 ⁇ subunit comprises SEQ ID NO: 28, residues 35-253 of SEQ ID NO: 28, or residues 57-253 of SEQ ID NO: 28.
- the IL-12 ⁇ subunit comprises at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 29 or residues 23-328 of SEQ ID NO: 29. In some instances, the IL-12 ⁇ subunit comprises between 95% and 98%, or 95% and 99% sequence identity to SEQ ID NO: 29 or residues 23-328 of SEQ ID NO: 29. In some instances, the IL-12 ⁇ subunit comprises about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity to SEQ ID NO: 29 or residues 23-328 of SEQ ID NO: 29. In some embodiments, the IL-120 subunit comprises SEQ ID NO: 29 or residues 23-328 of SEQ ID NO: 29.
- the MYXV comprises (e.g., encodes) a non-viral molecule, for example, comprises a transgene that encodes decorin.
- the decorin protein is a human decorin protein.
- the decorin protein is soluble.
- the decorin protein is membrane- or surface-bound.
- the decorin protein enhances the anti-cancer activity of the MYXV by blocking or decreasing TGF- ⁇ signaling.
- the decorin protein is encoded by a decorin gene.
- the decorin gene is a human decorin gene.
- the decorin gene is driven by an IRES.
- the decorin gene is driven by a promoter such as an sE/L promoter.
- the decorin gene replaces or disrupts an M153 gene.
- the decorin gene is inserted in the intergenic region between an M135R gene and an M136R gene of the MYXV genome.
- Decorin is a member of the extracellular matrix proteoglycans family that exists and functions within stromal tissues and epithelial cells.
- decorin affects the biology of different types of cancer by directly or indirectly targeting signaling molecules involved in cell growth, survival, metastasis and/or angiogenesis.
- decorin blocks TGF- ⁇ -induced signaling.
- TGF- ⁇ is a cytokine that contributes to immune suppression in some tumor microenvironments (TMEs).
- TGF- ⁇ converts effector T-cells, which may otherwise recognize and attack cancer cells, into regulatory (suppressor) T-cells, which instead turn off the innate inflammatory reactions and acquired immune pathways needed to recognize and eliminate the cancer cells.
- an oncolytic MYXV vector expressing decorin blocks TGF- ⁇ directly within the TME and thereby induces a stronger anti-tumor immune response than a MYXV not expressing the decorin.
- decorin can inhibit tumor cell growth and proliferation. Viral delivery of decorin into various solid tumors may directly counteract tumorigenesis.
- decorin is used as an anti-cancer target for at least some types of cancer that are protected by the local over-expression of TGF- ⁇ .
- the decorin is encoded by a gene comprising the sequence of SEQ ID NO: 25.
- the gene encoding the decorin comprises a sequence that is 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, or a range of percentages defined by any two of the aforementioned percentages, identical to that of SEQ ID NO: 25.
- the decorin is encoded by a gene comprising at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 25.
- the decorin is encoded by a gene comprising between 95% and 98%, or 95% and 99% sequence identity to SEQ ID NO: 25. In some instances, the decorin is encoded by a gene comprising about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity to SEQ ID NO: 25.
- the decorin protein comprises at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to residues 31-359 of SEQ ID NO: 14, or any one of SEQ ID NOs: 14-19. In some instances, the decorin protein comprises between 95% and 98%, or 95% and 99% sequence identity to residues 31-359 of SEQ ID NO: 14, or any one of SEQ ID NOs: 14-19. In some instances, the decorin protein comprises about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity to residues 31-359 of SEQ ID NO: 14, or any one of SEQ ID NOs: 14-19. In some embodiments, the decorin protein comprises residues 31-359 of SEQ ID NO: 14, or any one of SEQ ID NOs: 14-19.
- recombinant nucleic acids are recombinant nucleic acids. Some embodiments relate to a recombinant nucleic acid comprising at least a portion of a MYXV genome. In some embodiments, the recombinant nucleic acid comprises DNA. In some embodiments, the MYXV genome or the portion of the MYXV genome is modified to reduce expression of M153 gene. In some embodiments, the M153 gene is modified to knock out at least a portion of the M153 gene in the MYXV genome.
- the recombinant nucleic acid is engineered to introduce a mutation to the M153 gene.
- the mutation can comprise, for example, an insertion, deletion, substation, or a combination thereof.
- the recombinant nucleic acid comprises a gene knock-in where the M153 gene is disrupted.
- the recombinant nucleic acid comprises a nucleic acid that encodes a non-viral molecule. In some embodiments, the recombinant nucleic acid comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more nucleic acid that encode non-viral molecule, for example, transgenes that encode proteins.
- the recombinant nucleic acid comprises a nucleic acid that encodes tumor necrosis factor alpha (TNF ⁇ ).
- TNF ⁇ is a human TNF ⁇ .
- the nucleic acid that encodes the TNF ⁇ replaces or is adjacent to an M135R gene of the MYXV genome.
- the nucleic acid that encodes the TNF ⁇ is inserted between an M135R gene and an M136R gene of the MYXV genome.
- expression of TNF ⁇ is driven by a poxvirus synthetic early/late (sE/L) promoter.
- the nucleic acid that encodes the TNF ⁇ replaces or is adjacent to an M153 gene of the MYXV genome.
- the recombinant nucleic acid comprises a nucleic acid that encodes an interleukin-12 subunit alpha (IL-12 ⁇ ).
- IL-12 ⁇ is a human IL-12 ⁇ .
- expression of the IL-12 ⁇ is driven by an internal ribosome entry site (IRES).
- IRS internal ribosome entry site
- the nucleic acid that encodes IL-12 ⁇ disrupts expression of an M153 gene of the MYXV genome.
- the recombinant nucleic acid comprises a nucleic acid that encodes an interleukin-12 subunit beta (IL-12 ⁇ ).
- the IL-12 ⁇ is a human IL-12 ⁇ gene.
- expression of the IL-12 ⁇ is driven by an sE/L promoter.
- the nucleic acid that encodes IL-12 ⁇ disrupts expression of an M153 gene of the MYXV genome.
- the nucleic acid that encodes IL-12 ⁇ and the nucleic acid that encodes IL-12 ⁇ both disrupt expression of an M153 gene of the MYXV genome.
- the recombinant nucleic acid comprises a nucleic acid that encodes decorin.
- the decorin is a human decorin.
- expression of the decorin is driven by an sE/L promoter.
- the recombinant nucleic acid comprises a nucleic acid that encodes decorin disrupts expression of an M153 gene of the MYXV genome.
- the recombinant nucleic acid comprises a nucleic acid that encodes a reporter tag, for example, a fluorescent protein.
- the reporter tag comprises a green fluorescent protein (GFP).
- GFP green fluorescent protein
- expression of the reporter tag is driven by an sE/L promoter.
- the recombinant nucleic acid further comprises a nucleic acid that encodes a second reporter tag.
- the second reporter tag comprises a red fluorescent protein (RFP), e.g., dsRed.
- expression of the second reporter tag is driven by a poxvirus P11 late promoter.
- the nucleic acid that encodes the second reporter tag disrupts expression of an M153 gene of the MYXV genome.
- the recombinant nucleic acid comprises a vMyx-hTNFa cassette, optionally comprising GFP. In some embodiments, the recombinant nucleic acid comprises an hDecorin-hIL-12 cassette, optionally comprising dsRed. In some embodiments, the recombinant nucleic acid comprises or consists of a vMyx-hTNFa-hDecorin-hIL-12-M153KO (vMyx-Triple) cassette, optionally comprising GFP and/or dsRed.
- compositions comprising a MYXV as described herein.
- the composition comprises a pharmaceutical composition.
- the composition comprises a pharmaceutically acceptable carrier or excipient.
- the pharmaceutically acceptable carrier comprises an injectable fluid such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like.
- the composition comprises a solid composition such as a powder, pill, tablet, or capsule.
- the pharmaceutically acceptable carrier comprises mannitol, lactose, starch, or magnesium stearate.
- the pharmaceutically acceptable carrier comprises a biologically-neutral carrier.
- the composition comprises wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
- the identity or proportion of the pharmaceutically acceptable carrier or excipient is determined based on a route of administration, compatibility with a live virus, or standard pharmaceutical practice.
- the pharmaceutical composition is formulated with components that do not significantly impair the biological properties of the MYXV.
- the pharmaceutical composition can be prepared by known methods for the preparation of pharmaceutically acceptable compositions suitable for administration to subjects, such that an effective quantity of the active substance or substances is combined in a mixture with a pharmaceutically acceptable vehicle.
- the composition includes solutions of the MYXV in association with one or more pharmaceutically acceptable excipient, vehicles, or diluents, and contained in buffer solutions with a suitable pH and iso-osmotic with physiological fluids.
- the pharmaceutical composition is formulated for administration to a subject.
- the pharmaceutical composition may be administered to a subject in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art.
- the pharmaceutical composition is administered systemically, or formulated for systemic administration.
- the pharmaceutical composition is administered locally, or formulated for local administration.
- the pharmaceutical composition is administered parenterally, or formulated for parenteral administration.
- parenteral administration include intravenous, intratumoral, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, rectal and topical modes of administration.
- Parenteral administration may be by continuous infusion over a selected period of time.
- the pharmaceutical composition is administered orally, or formulated for oral administration.
- the pharmaceutical composition may be administered orally, for example, with an inert diluent or with a carrier, or it may be enclosed in hard or soft shell gelatin capsules, or it may be compressed into tablets.
- the MYXV may be incorporated with an excipient and be used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers and the like.
- Solutions of MYXV may be prepared in a physiologically suitable buffer.
- these preparations contain a preservative to prevent the growth of microorganisms, but that will not inactivate the live virus.
- a dose of the pharmaceutical composition to be used depends on the particular condition being treated, the severity of the condition, the individual subject parameters including age, physical condition, size and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and other similar factors that are within the knowledge and expertise of the health practitioner.
- the therapeutic virus may be freeze dried for storage at room temperature.
- compositions may additionally contain additional therapeutic agents, such as additional anti-cancer agents.
- additional therapeutic agents such as additional anti-cancer agents.
- the compositions include a chemotherapeutic agent.
- the chemotherapeutic agent may be substantially any agent, which exhibits an oncolytic effect against cancer cells or neoplastic cells of the subject and that does not inhibit or diminish the tumor killing effect of the MYXV.
- the chemotherapeutic agent may be, without limitation, an anthracycline, an alkylating agent, an alkyl sulfonate, an aziridine, an ethylenimine, a methylmelamine, a nitrogen mustard, a nitrosourea, an antibiotic, an antimetabolite, a folic acid analogue, a purine analogue, a pyrimidine analogue, an enzyme, a podophyllotoxin, a platinum-containing agent or a cytokine.
- the chemotherapeutic agent is one that is known to be effective against the particular cell type that is cancerous or neoplastic.
- the additional therapeutic agent comprises an immune checkpoint modulator.
- the composition comprises peripheral blood mononuclear cells (PBMCs), bone marrow (BM) cells, or a combination thereof treated ex vivo by an MYXV as described herein.
- PBMCs, BM cells, or a combination thereof comprise autologous cells.
- the PBMCs, BM cells, or a combination thereof are obtained from an allogeneic donor.
- the PBMCs, BM cells, or a combination thereof are obtained from heterologous donors.
- a subject in need thereof comprising administering to the subject a composition or pharmaceutical composition as described herein.
- the method includes administering to a subject, such as a human subject, a MYXV as described herein, thereby treating and/or inhibiting the cancer in the subject in need thereof.
- Some embodiments include prophylactic treatment with the MYXV.
- the subject has, is suspected of having, or is at risk of having the cancer.
- Some embodiments include selecting the subject suspected of having.
- Some embodiments include selecting the subject at risk of having the cancer.
- the subject has the cancer.
- the methods include selecting the subject with the cancer.
- the subject is a human. In some embodiments, the subject is a patient. In some embodiments, the subject is an animal or nonhuman animal. Examples of nonhuman animals include vertebrates such as mammals and non-mammals. Some examples of mammals include nonhuman primates, sheep, dog, cat, horse, cow, and rodents such as mice and rats.
- the cancer is a solid tumor.
- solid tumors such as sarcomas and carcinomas include but are not limited to fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, osteogenic sarcoma, and other sarcomas, synovioma, mesothelioma, Ewing's sarcoma, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, lymphoid malignancy, pancreatic cancer, breast cancer, lung cancers, non-small cell lung cancer, ovarian cancer, prostate cancer, hepatocellular carcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma,
- the cancer has metastasized to a location in the subject.
- the location comprises a lung, a brain, a liver and/or a lymph node of the subject.
- the cancer comprises a hematologic cancer such as Hodgkin's lymphoma or non-Hodgkin's lymphoma.
- the hematologic cancers include B-cell or T-cell hematologic cancer.
- the composition reduces cancer cell viability, or activates immunogenic cell death in the cancer.
- the cancer is inhibited, alleviated, or prevented upon administration of the composition.
- the administration improves the subject's survival.
- MYXV or the composition comprising the MYXV can be administered to the subject using standard methods of administration.
- the virus or the composition comprising the virus is administered systemically (e.g., IV injection).
- the virus or the composition comprising the virus is administered by injection at the disease site (e.g., intratumorally).
- the virus or the composition comprising the virus is administered orally or parenterally, or by any standard method known in the art.
- the MYXV or the composition comprising the MYXV is administered at a site of a tumor and/or metastasis.
- the MYXV can be administered initially in a suitable amount that may be adjusted as required, depending on the clinical response of the subject.
- the effective amount of virus can be determined empirically and depends on the maximal amount of the MYXV that can be administered safely, and the minimal amount of the virus that produces the desired result.
- the concentration of virus to be administered may vary depending on the virulence of the particular strain of MYXV that is to be administered and on the nature of the cells that are being targeted.
- a dose of less than about 3 ⁇ 10 10 focus forming units (“ffu”) is administered to a human subject, in various embodiments, between about 10 2 to about 10 9 pfu, between about 10 2 to about 10 7 pfu, between about 10 3 to about 10 6 pfu, or between about 10 4 to about 10 5 pfu may be administered in a single dose.
- the MYXV is administered at a dose and schedule effective to increase expression of a cytokine by immune cells (e.g., PBMCs) in the subject.
- a cytokine by immune cells e.g., PBMCs
- the expression of a cytokine by immune cells can be increased, for example, by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 50-fold, at least about 100-fold, at least about 1000-fold, or at least about 1000-fold.
- the MYXV is administered at a dose and schedule effective to increase expression of two, three, four, five, six, or more cytokines by immune cells in the subject. In some embodiments, the MYXV is administered at a dose and schedule effective to increase expression of at least one, at least two, at least three, at least four, at least five, at least six, or more cytokines by immune cells in the subject.
- the cytokines can comprise, for example, IFN- ⁇ , IL-2, IL-6, IL-10, IL-12, TNF- ⁇ , or any combination thereof.
- expression of TNF- ⁇ is increased.
- expression of IL-12 is increased.
- expression of decorin is increased.
- expression of IFN- ⁇ is increased.
- the MYXV is administered at a dose and schedule effective to increase expression of a cytokine by cancer cells in the subject.
- the expression of a cytokine by cancer cells can be increased, for example, by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 50-fold, at least about 100-fold, at least about 1000-fold, or at least about 1000-fold.
- the MYXV is administered at a dose and schedule effective to increase expression of two, three, four, five, six, or more cytokines by cancer cells in the subject. In some embodiments, the MYXV is administered at a dose and schedule effective to increase expression of at least one, at least two, at least three, at least four, at least five, at least six, or more cytokines by cancer cells in the subject.
- the cytokines can comprise, for example, IFN- ⁇ , IL-2, IL-6, IL-10, IL-12, TNF- ⁇ , or any combination thereof.
- expression of TNF- ⁇ is increased.
- expression of IL-12 is increased.
- expression of decorin is increased.
- expression of IFN- ⁇ is increased.
- the MYXV is administered at a dose and schedule effective to reduce the volume of a tumor in the subject.
- the volume of the tumor can be reduced, for example, by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%.
- the MYXV is administered at a dose and schedule effective to reduce the rate of tumor or cancer cell growth in the subject.
- the rate of tumor or cancer cell growth can be reduced, for example, by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%.
- the MYXV can be administered as a sole therapy or may be administered in combination with other therapies, including chemotherapy, immunotherapy and/or radiation therapy.
- the MYXV can be administered either prior to or following surgical removal of a primary tumor or prior to, concurrently with or following treatment such as administration of radiotherapy or conventional chemotherapeutic drugs.
- the MYXV can be administered at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 1.5 weeks, 2 weeks, or 3 weeks before the other therapy.
- the MYXV can be administered at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 1.5 weeks, 2 weeks, or 3 weeks after the other therapy.
- the MYXV can be administered within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days of the other therapy.
- the MYXV can be administered concurrently with the other therapy.
- Some embodiments further comprise administering to the subject an additional therapeutic agent.
- the additional therapeutic agent is an immune checkpoint modulator.
- the additional therapeutic agent is administered to the subject before administering the composition.
- the additional therapeutic agent is administered to the subject after administering the composition.
- the additional therapeutic agent is administered to the subject as a combination with the composition.
- the additional therapeutic agent comprises an immune modulator, for example, an immune checkpoint modulator or inhibitor.
- immune checkpoint modulators include, but are not limited to, PD-L1 inhibitors such as durvalumab (Imfinzi) from AstraZeneca, atezolizumab (MPDL3280A) from Genentech, avelumab from EMD Serono/Pfizer, CX-072 from CytomX Therapeutics, FAZ053 from Novartis Pharmaceuticals, KNO35 from 3D Medicine/Alphamab, LY3300054 from Eli Lilly, or M7824 (anti-PD-L1/TGFbeta trap) from EMD Serono; PD-L2 inhibitors such as GlaxoSmithKline's AMP-224 (Amplimmune), and rHIgM12B7; PD-1 inhibitors such as nivolumab (Opdivo) from Bristol-Myers Squibb, pembrolizumab (Keytrud
- MYXV can be delivered to metastatic cancer sites via migration of leukocytes pre-infected with virus ex vivo.
- This systemic delivery method is sometimes called “ex vivo virotherapy”, or EVV (aka EV2), because the virus is first delivered to isolated leukocytes prior to infusion into the patient.
- EVV aka EV2
- the MYXV construct and this delivery strategy may significantly reduce tumor burden and increase survival in a subject in need thereof.
- the BM or PBMC cells are adsorbed with MYXV constructs for one hour ex vivo, and then the MYXV-loaded leukocytes are infused back into the recipient.
- the mononuclear peripheral blood cells and/or bone marrow cells are obtained from the subject, for example as autologous cells.
- the mononuclear peripheral blood cells and/or bone marrow cells are obtained from one or more allogeneic donors, for example, a donor that is matched to the recipient for at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8 HLA alleles (such as one or both copies of HLA-A, HLA-B, HLA-A, and/or HLA-DR alleles).
- HLA alleles can be types, for example, using DNA-based methods.
- the mononuclear peripheral blood cells and/or bone marrow cells are obtained from one or more heterologous donors.
- Recombinant plasmids were designed for insertion of hDecorin, and hIL12 nucleic acid sequences at the myxoma virus M153 locus, with or without a dsRed nucleic acid sequence.
- a human Decorin gene was PCR amplified from a cDNA ORF clone from OHu16408 (GenScript). Human subunits IL-12 p35 and p40 were obtained from vMyx-huIL-12-GFP described in Journal of Virology, November 2007, P. 12704-12708, the disclosure of which is incorporated herein by reference.
- dsRed red fluorescent protein gene
- vMyx-Triple A red fluorescent protein (dsRed) gene was inserted immediately downstream of a hDecorin-hIL-12 expression cassette, and its expression was driven by a poxvirus P11 late promoter.
- This recombinant nucleic acid is referred to as vMyx-Triple or vMyx-Triple-red.
- the dsRed served as a fluorescent marker for MYXV replication in vitro and in vivo, as MYXV infection could be monitored by live imaging of dsRed expression.
- a second version of this recombinant nucleic acid was made that lacked the dsRed marker (referred to as vMyx-Triple-white).
- FIG. 1A diagrams construction of a vMyx-Triple recombinant nucleic acid.
- the top image depicts a vMyx-hTNFa-GFP genome and the insertion site (M153 locus) of the expressing hDecorin-hIL-12-dsRed cassette.
- the middle image shows the hDecorin-hIL-12-dsRed cassette, and the bottom image shows a vMyx-Triple construct.
- Decorin and IL-12 transgenes in the hDecorin-hIL-12-dsRed cassette were expressed under the control of a poxvirus synthetic early/late promoter (sE/L), while expression of dsRed was controlled by the poxvirus late promoter, P11.
- the vMyx-Triple-white construct is identical to vMyx-Triple-red but lacks the dsRed cassette.
- a recombinant plasmid was first constructed using Gateway System (ThermoFisher Scientific). Upstream and downstream hybridizing sequences were amplified by PCR to generate entry clones by Gateway BP recombination with appropriate pDONR vectors. The final recombinant plasmid was constructed by recombining three entry clones with a destination vector in a sequential manner.
- the hDecorin-hIL12-dsRed expression cassette was inserted into the MYXV genome by infecting RK13 cells with vMyx-hTNFa-GFP virus and then transfecting with an appropriate recombination plasmid.
- FIGS. 2A and 2B Multiple rounds of foci purification were conducted to obtain pure stocks of recombinant virus, using the fluorescent dsRed protein as a selection marker.
- Table 1 includes primer sequences used in generating the constructs.
- Antibodies used to detect transgene expression were as follows: human TNF- ⁇ : Monoclonal Mouse IgG1 Clone #28401 (MAB610-100, R&D Systems); human Decorin: Rabbit polyclonal antibody (ab175404, Abcam); human IL-12: Rabbit polyclonal to IL-12 p70 antibody (ab25105, Abcam).
- Recombinant MYXV that expresses mouse IL-12 rather than human IL-12 were generated using the same Gateway System (ThermoFisher Scientific) as used for the viruses expressing human IL-12.
- a virus that expresses relatively lower levels of mouse IL-12 was generated using a synthetic early/late promoter with an IRES sequence between the subunits of IL-12 (msTriple IL-12 low), and a vMyxv-msTriple that expresses relatively higher levels of mouse IL-12 was generated using a synthetic early/late promoter with mouse IL-12 that contained an Elastin linker between the subunits of IL-12 (msTriple IL-12 high).
- the replication capacity of the vMyx-Triple virus prepared in Example 1 was tested in RK13 cells.
- the replication capacity of vMyx-Triple virus was similar to the parental vMyx-hTNFa-GFP virus ( FIG. 4 ).
- a recombinant MYXV expressing transgenic human TNF ⁇ , decorin, and IL-12, and lacking M153 effectively replicated in host cells.
- CT26 colon carcinoma
- HELA human cervical cancer
- vMyx-Triple virus induced similar levels of cell death in both cell lines, as compared with the parental virus vMyx-hTNFa, and also as compared with vMyx-GFP. There was a trend towards increased cancer cell killing by the vMyx-Triple virus compared to the other viruses.
- a recombinant MYXV expressing transgenic human TNF ⁇ , decorin, and IL-12, and lacking M153 was cytotoxic to cancer cells.
- FIG. 1B diagrams the M153 locus, which can be modified in recombinant nucleic acids and MYXV of the disclosure.
- the modification can include a mutation in the M153 sequence, for example, an insertion, a deletion, a substitution, or a combination thereof.
- the modification can attenuate an activity or expression level of M153.
- the modification can include deletion of M153 gene and/or replacement of M153 gene with one or more transgenes.
- the replacement gene can be selected from hTNFa, hDecorin, IL-12, or another transgene that help enhance the oncolytic activity or decrease adverse side effects of the MYXV.
- a recombinant plasmid can be first constructed using Gateway System (ThermoFisher Scientific). Upstream and downstream hybridizing sequences are amplified by PCR to generate entry clones by Gateway BP recombination with appropriate pDONR vectors. The final recombinant plasmid is constructed by recombining one or more entry clones with a destination vector in a sequential manner. The recombinant plasmid is inserted into the MYXV genome by infecting RK13 cells with vMyx and then transfecting with an appropriate recombination plasmid. Multiple rounds of foci purification are conducted to obtain pure stocks of recombinant virus. A selection marker can be used, such as a fluorescent protein, for example, dsRed. The presence of the transgenes can be confirmed by PCR and/or sequencing.
- An M153 knockout virus can be constructed in this manner.
- the recombinant plasmid can be designed to contain sequences that flank the sequence of the M153 gene, without the M153 gene sequence.
- an expression cassette for a fluorescent protein can be included.
- the M153 knockout can be generated by infecting RK13 cells with MYXV, and transfecting the cells with the recombination plasmid. Multiple rounds of foci purification are conducted to obtain pure stocks of M153KO virus, optionally using the fluorescent protein as a selection marker. The M153 knockout and purity of the virus is confirmed via PCR analysis using suitable primers.
- the replication capacity of the modified vMyx virus can be tested in RK13 cells.
- the replication capacity of a modified vMyx virus can be similar to the parental vMyx virus.
- the cell killing capacity of the modified vMyx virus is tested in two different cancer cell lines.
- the modified vMyx virus can induce similar levels of cell death in both cell lines, or higher levels of cell death, as compared with the parental virus vMyx, and also as compared with vMyx-GFP.
- Therapeutic transgenes can be added to MYXV at two types of genomic loci: as a disruption construct within protein coding genes, such that the recombinant virus is a genetic “knockout” of that virus gene, or else at “innocuous” intergenic locus that is predicted to not affect the biology or oncolytic potential of the recombinant virus.
- a disruption construct within protein coding genes such that the recombinant virus is a genetic “knockout” of that virus gene, or else at “innocuous” intergenic locus that is predicted to not affect the biology or oncolytic potential of the recombinant virus.
- endogenous virus genes When endogenous virus genes are knocked out, it is possible that the new knockout construct will differ from the parental virus in terms of its oncolytic capacity against cancer cells, independent of which transgenes are inserted into the locus.
- the M153 gene of MYXV encodes an immunoregulatory protein from a family of E3-Ubiquitin ligases that participates in the down-regulation of diverse cellular receptors, including MHC class-I and CD4 proteins.
- inactivation or knockdown of M153 can result in enhanced expression of MHC-I dependent immune epitopes, for example, increased direct presentation of viral and/or tumor antigens, thereby increasing recognition of virally infected cells (e.g., cancer cells) by host T cells. This allows a myxoma virus with an inactivated M153 gene to be used as an oncolytic vector.
- M153 knockout myxoma virus M153KO MYXV
- M153KO MYXV M153 knockout myxoma virus
- a M153KO MYXV without a transgene exhibited a greater oncolytic activity than the parental MYXV or wt MYXV.
- M153KO MYXV with one or more transgenes can also exhibit an enhanced oncolytic activity than the parental MYXV or wt MYXV.
- a murine melanoma cell line a M153KO MYXV was tested for induction of cell killing compared to a wild-type myxoma vim that contains an intact wild type M153 (wt MYXV).
- This M153KO MYXV did not include hTNFa, hDecorin, hIL-12A, or hIL-12B transgenes.
- the M153KO MYXV reduced cell viability in the B16F10 cells to a greater extent than the wt MYXV at early time points post-infection, up to approximately 36 hours post-infection ( FIG. 6 ).
- ICD Immunogenic Cell Death
- the release of ATP from dying cells can indicate ICD. ATP release observed after infection with the wt MYXV was not significantly different from negative controls. On the other hand, the amount of ATP released after infection with the M153KO MYXV was higher than in untreated cells, and up to about four-fold higher than for cells infected by wt MYXV (see, FIG. 7A , for example, the peak value at 10 hours post-infection). The peak result from M153KO MYXV infection was similar to the peak values obtained with a drug-induced positive control (Doxorubicin), but at a later time ( FIG. 7A , see results at 640 hrs post-infection).
- Doxorubicin drug-induced positive control
- a MYXV with an inactivation or knockdown of M153 has superior oncolytic properties compared to a wt MYXV or compared to a MYXV without the M153 inactivation or knockdown.
- a MYXV with the M153 inactivation or knockdown induces immunogenic cell death to a greater extent than a MYXV without the M153 inactivation or knockdown or a WT MYXV.
- Calreticulin is usually expressed within the endoplasmic reticulum, but where ICD is occurring, it can be expressed on the cell surface (ecto-expression). Ecto-expression of calreticulin was evaluated using confocal microscopy and quantified using a ratio of the signal of the calreticulin observed per signal of a nuclear stain (DAPI) that represents each cell. In this case, the M135KO MYXV was used as a representation of an unarmed virus with a genetic knockout lesion in an unrelated viral gene (M135) that does not alter cell killing caused by the parental MYXV and behaves similarly to wt MYXV in this regard. The induction of ecto-expression of calreticulin higher in M153KO MYXV-infected cells than in M135KO MYXV-infected or Doxorubicin-treated cells ( FIG. 7B ).
- M153KO MYXV can induce hallmarks of ICD in B16F10 cells in vitro, and may induce the immune system (e.g., the adaptive immune system) when used in vivo.
- a MYXV with a M153 inactivation or knockdown induces ICD in melanoma or cancer cells.
- a MYXV with a M153 inactivation or knockdown can also stimulate the immune system (e.g., the adaptive immune system).
- mice were seeded via intravenous injections in the tail vein with B16F10 cells to induce dispersed metastatic melanoma lesions in the lungs.
- mice were treated with 2 ⁇ 10 7 ffu of M153KO MYXV or a saline control via intravenous injections in the retro-orbital area. Mice treated with one dose of the M153KO virus showed fewer signs of metastatic disease, and survived longer than the control mice ( FIG. 8 ).
- the M135KO MYXV contains a gene knockout in an unrelated virus gene involved in rabbit pathogenesis, and is used as a control here to measure any oncolytic effects caused by the virus in the absence of M153KO.
- M153KO virus provided significantly longer term survival compared to untreated control mice, but the M135KO virus did not.
- M153KO MYXV can be used as an oncolytic vector platform with superior anti-cancer effects compared to a parental MYXV with an intact M153 gene or compared to a wt MYXV.
- a MYXV with a M153 inactivation or knockdown prolongs survival in a subject with cancer (for example, melanoma).
- the cancer or melanoma can be metastatic.
- the mice treated with M153 knockout showed significant improvement in survival rate and survival length than the control group
- This example demonstrates that cells infected with myxoma viruses of the disclosure secrete TNF, Decorin, and IL-12, and further demonstrates that the secreted TNF and IL-12 have biological activity.
- Vero cells were infected with vMyx-Triple (huTriple red and huTriple white), msTriple IL12 low, msTriple IL-12 hi, each at an MOI of 1.
- vMyx-Triple huTriple red and huTriple white
- vMyx-GFP which does not encode any of the cytokines, and contains an intact M153 gene.
- supernatant was harvested and ELISA assays conducted to determine the concentration of each of the cytokines in supernatant ( FIGS. 9A-9D ).
- the results demonstrate that cells infected with the various vMyx-Triple viruses secrete TNF ( FIG. 9A ), Decorin ( FIG. 9B ), and IL-12 ( FIG.
- FIG. 9C human IL-12
- FIG. 9D murine IL-12
- the cytokines were not detected in mock-infected cells, or cells infected with vMyx-GFP.
- Infection with msTriple IL-12 hi was shown to elicit higher expression of mouse IL-12 than infection with msTriple IL-12 low.
- L929 cells which are sensitive TNF, and lose viability upon sufficient exposure to biologically active TNF.
- L292 cells were exposed to supernatants from Vero cells that had been infected with the indicated viruses.
- FIG. 10A cells infected with the various vMyx-Triple viruses generate biologically-active TNF, while cells infected with vMyx-GFP do not.
- a HEK Blue IL-12 reporter assay was conducted.
- the HEK Blue IL-12 cells express a reporter gene in response to biologically active IL-12, and the reporter gene can be detected using a colorimetric assay.
- FIG. 10B supernatants from Vero cells infected with the vMyx-Triple viruses elicited reporter gene expression, while controls, including supernatants from cells infected with vMyx-GFP, did not.
- vMyx-Triple The ability of vMyx-Triple to inhibit growth of multiple cancer cell lines was evaluated in vitro.
- Cells were infected at multiplicities of infection (MOI) of 0.1, 1, or 10 focus forming units (FFU) per cell. After incubation for 72 hours, cell viability was tested using a CellTiter-Glo Cell Viability Assay, and mean growth inhibition was determined. The results showed that vMyx-Triple could inhibit growth of a range of human and mouse cancer cell lines derived from different tissues. Results are provided in Table 2.
- vMyx-Triple demonstrated inhibition of a number of the human lung cancer tumor cell lines, with EC50s shown in Table 3.
- vMyx-Triple To further characterize the ability of vMyx-Triple to inhibit growth of cancer cell lines in vitro, 8 human sarcoma cell lines were infected at 9 different multiplicities of infection ranging from 0.01 FFU/cell to 100 FFU/cell. After incubation for 72 hours, cell viability was assessed using a CellTiter-Glo Cell Viability Assay. EC 50 was calculated for each cell line, as the MOI that achieved 50% of maximum growth inhibition, as determined by curve fit using non-linear regression analysis via GraphPad Prism software. The vMyx-Triple demonstrated inhibition of a number of the human sarcoma cell lines, with EC50s shown in Table 4.
- vMyx-Triple The ability of vMyx-Triple to kill human cancer cells from patients was tested.
- AML Acute myeloid leukemia
- MOI multiplicities of infection
- IC 50 was calculated for each sample, as the MOT that achieved 50% of maximum growth inhibition, as determined by curve fit using non-linear regression analysis via GraphPad Prism software.
- vMyx-Triple exhibited superior inhibition of human AML samples, with the IC 50 s calculated at 4.203, 6.524, and 10.25. The results show that vMyx-Triple can inhibit the growth of cancer cells from human cancer patients, and exhibits superior anti-cancer effects compared to the parental virus which lacks TNF, Decorin and IL-12, and which contains an intact wild type M153 gene.
- vMyx-Triple The ability of vMyx-Triple to elicit cytokine production by human peripheral blood mononuclear cells (PBMCs) was tested.
- Human PBMCs were infected with MYXV, each at an MOT of 10.
- the MYXV used were vMyx-Triple (“Human triple”), parental virus vMyx-GFP (“Parental MYXV”), vMyx-hTNFa-GFP (“TNF single”), and a MYXV that expresses TNF on the cell surface (“Membrane bound TNF”).
- the MYXV that expresses TNF on the cell surface encodes the TNF ⁇ of SEQ ID NO: 45, which contains an altered TNF ⁇ sequence that will remain membrane bound.
- FIG. 12A illustrates the mean (+/ ⁇ SD) concentrations of the cytokines in supernatant at 4 hours post-infection
- FIG. 12B illustrates the mean (+/ ⁇ SD) concentrations of the cytokines in supernatant at 16 hours post-infection. Where no bar is present, this indicates the cytokine level was below the limit of detection for the assay.
- vMyx-Triple virus elicits production of cytokines by human PBMCs, including IL-12 and TNF ⁇ .
- the levels of IL-12 observed in response to infection with vMyx-Triple were higher than levels observed for any of the other viruses. Additionally, higher levels of IFN- ⁇ were observed in response to the vMyx-Triple virus, particularly at 4 hours post-infection.
- vMYX Triple The ability of vMYX Triple to inhibit growth of human tumors in vivo was tested in xenograft models.
- the human cancer cell lines NCI-H1971 (lung cancer), A673 (sarcoma), and SJSA-1 (sarcoma) were implanted with 5 million tumor cells per mouse subcutaneously into the flanks of immunodeficient mice (athymic nude mice for NCI-H1975 and SJSA-1, CD17.SCID mice for A673).
- Tumor bearing animals were randomized into treatment groups of 7-8 animals per group with an average tumor volume of 100-150 mm 3 .
- Animals were treated with intratumoral injection of vMyx-Triple at doses of 1 ⁇ 10 7 focus forming units (FFU) or 2 ⁇ 10 7 FFU. Doses were administered once per week (QW), once every 4 days (Q4D), or once every two days (Q2D). Tumor volume and body weight were measured three times per week.
- FIG. 13A plots the volume of NCI-H1971 (lung cancer) xenograft tumors over time, showing that intra-tumoral injection of vMYX Triple inhibits tumor growth in a dose-dependent manner in this model.
- FIG. 13B plots the volume of A673 (sarcoma) xenograft tumors over time, showing that administering vMYX Triple more frequently results in greater inhibition of tumor growth in this model.
- FIG. 13C plots the volume of SJSA-1 (sarcoma) xenograft tumors over time, showing that administering vMYX Triple more frequently results in greater inhibition of tumor growth in this model.
- vMYX Triple The ability of vMYX Triple to elicit IL-12 and TNF ⁇ production in vivo was tested in xenograft models.
- MSD MesoScale Discovery
- FIG. 14A shows the concentrations of IL-12 and TNF ⁇ detected in serum at 4 and 24 hours post-treatment, and in tumors at 24 hours post-treatment, in animals bearing SJSA-1 tumors. Mean ⁇ SD is plotted. When no bar is present, the level of the analyte was below the limit of detection for the assay.
- FIG. 14B shows the concentrations of IL-12 and TNF ⁇ detected in serum at 4 and 24 hours post-treatment, and in tumors at 24 hours post-treatment, in animals bearing A673 tumors. Mean ⁇ SD is plotted. When no bar is present, the level of the analyte was below the limit of detection for the assay.
- This example compared the degree of tumor growth inhibition achieved by a MYXV with the M153 gene knocked out versus a MYXV that expresses a wild type M153.
- Both MYXV viruses contained transgenes for expression of TNF inserted in between the M135 and M136 region.
- B16-F10 mouse melanoma cells were implanted into C57BL/6 mice. Tumor bearing animals were randomized into treatment groups of 8 animals per group with an average tumor volume of 75-100 mm 3 . Animals were treated via intratumoral injection of the indicated myxoma virus at 2 ⁇ 10 7 FFU/dose on day 1 and day 8 post-randomization.
- FIG. 15 plots tumor volume over time, and shows that the virus with M153 knocked out inhibited tumor growth to a greater extent than the virus that expresses wild type M153.
- vMyx-Triple The anti-cancer efficacy of vMyx-Triple was evaluated in an MC38 mouse model.
- C57BL/6 mice were implanted with MC38 mouse colorectal cancer cells.
- Tumor-bearing animals were randomized into treatment groups of 8 animals per group with an average tumor volume of 75-100 mm 3 .
- Animals were treated via intratumoral (IT) injection of 2 ⁇ 10 7 FFU/dose once every 4 days for four doses with the indicated myxoma virus.
- msTriple low refers to a vMyx-Triple that expresses murine rather than human IL-12, at a relatively low level.
- msTriple high refers to a vMyx-Triple that expresses murine rather than human IL-12, at a relatively higher level (as a single polypeptide with an elastin linker joining the IL-12 subunits).
- the msTriple viruses also express human Decorin and TNF, and have the M153 gene knocked out.
- GFP refers to vMyx-GFP, which does not encode any of the cytokines, and contains an intact wild type M153 gene.
- Tumor volume measurements were recorded three times per week, and are plotted in FIG. 16A . Survival is plotted in FIG. 16B . Survival endpoints were met when tumor volume was ⁇ 1500 mm 3 (for an individual animal), or when the animal met IACUC guidelines for terminal sacrifice.
- vMyx-Triple that expresses mouse IL-12 was evaluated in a B16-F10 mouse model.
- C57BL/6 mice were implanted with B16-F10 mouse melanoma cells.
- Tumor bearing animals were randomized into treatment groups of 8 animals per group with an average tumor volume of 75-100 mm 3 . Animals were treated via intratumoral injection of 2 ⁇ 10 7 FFU/dose on Day 1 and Day 8 with the indicated myxoma virus.
- msTriple low refers to a vMyx-Triple that expresses murine rather than human IL-12, at a relatively low level.
- msTriple high refers to a vMyx-Triple that expresses murine rather than human IL-12, at a relatively higher level (as a single polypeptide with an elastin linker joining the IL-12 subunits).
- the msTriple viruses also express human Decorin and TNF, and have the M153 gene knocked out.
- GFP refers to vMyx-GFP, which does not encode any of the cytokines, and contains an intact M153 gene.
- Tumor volume measurements were recorded three times per week, and are plotted in 17A. Survival is plotted in FIG. 17B . Survival endpoints were met when tumor volume was ⁇ 1500 mm 3 (for an individual animal), or when the animal met IACUC guidelines for terminal sacrifice.
- MYXV can inhibit tumor growth in vivo and enhance survival.
- vMyx mouse Triple The anti-tumor efficacy of vMyx mouse Triple was evaluated in mouse syngeneic cancer models, with comparison of intravenous and intratumoral routes of administration.
- C57BL/6 mice were implanted subcutaneously with B16-F10 melanoma cells, and Balb/c mice were implanted subcutaneously with CT26 colorectal cancer cells.
- Tumor bearing animals were randomized into treatment groups of 8 animals per group with an average tumor volume of 75-100 mm 3 . Animals were treated via intratumoral (IT) or intravenous (IV) injection msTriple high, a MYXV that expresses a relatively high level of murine IL-12 (as a single polypeptide with an elastin linker joining the IL-12 subunits).
- msTriple high also express human Decorin and TNF, and has the M153 gene knocked out.
- Four doses of 2 ⁇ 10 7 focus forming units (FFU) or 1 ⁇ 10 8 FFU were administered to each mouse, with doses administered every four days. Tumor volume measurements were recorded three times per week.
- FIG. 18A shows tumor volumes of the C57BL/6 mice with B16-F10 tumors.
- FIG. 18B shows tumor volumes of the Balb/c mice with CT26 tumors.
- msTriple high inhibited tumor growth at all doses and routes of administration tested compared to vehicle control.
- intra-tumoral injection of 2 ⁇ 10 7 FFU per dose exhibited greater inhibition of tumor growth than intravenous administration at either 1 ⁇ 10 8 or 2 ⁇ 10 7 FFU per dose.
- FIG. 19 displays survival curves the groups. All animals in the untreated control group had succumbed to infection by approximately day 80 post-implant. At day 130 post-implant, approximately 30-40% of animals that received anti-PD-1 or anti-PD-L1 had survived, over 50% of animals treated with vMyx-mouse Triple (low IL-12) had survived, and animals treated with a combination of vMyx-mouse Triple (low IL-12) and either anti-PD-1 or anti-PD-L1 exhibited the highest survival, with more than about 80% alive.
- vMyx-mouse Triple low IL-12
- C57BL/6 mice were implanted with MC38 mouse colorectal cancer cells subcutaneously on the flank. Tumor bearing animals were randomized into treatment groups of 8 animals per group with an average tumor volume of 75-100 mm 3 .
- Animals were treated via intratumoral injection of 2 ⁇ 10 7 FFU/dose on day 1 and day 8 post-randomization with vMyx-mouse Triple (low IL-12). Some groups were injected intraperitoneally with anti-PD-1 antibody at 10 mg/kg, once every four days for four doses. Tumor volume and body weight was measured three times per week.
- FIG. 20A plots tumor volume over time. Tumor volume for vehicle-treated control mice is shown by circles connected by solid lines. Mice treated with vMyx-mouse Triple alone (squares) exhibited reduced tumor volume and delayed tumor growth compared to vehicle-treated controls, as did mice treated with anti-PD-1 alone (circles with dashed line). The greatest inhibition of tumor growth was observed in the group that received both vMyx-mouse Triple and anti-PD-1 (triangles).
- FIG. 20B shows survival curves for the groups. Similar to tumor volume, the group that received both vMyx-mouse Triple and anti-PD-1 exhibited the best survival profile.
- myxoma viruses of the disclosure can inhibit tumor growth and enhance survival of subjects with cancer, and that combination therapy with an immune checkpoint inhibitors can have a synergistic effect.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This application is a continuation of U.S. application Ser. No. 17/010,711, filed Sep. 2, 2020, which claims priority to U.S. provisional application No. 62/894,925, filed Sep. 2, 2019, and U.S. provisional application No. 62/944,233, filed Dec. 5, 2019, each of which is incorporated herein by reference in its entirety.
- This invention was made with government support under P50 CA186781 awarded by the National Institutes of Health. The government has certain rights in the invention.
- The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jun. 24, 2021, is named 42206-721_301_SL.txt and is 72,974 bytes in size.
- Disclosed herein are recombinant myxoma viruses (MYXVs), nucleic acid constructs encoding recombinant MYXVs, and methods of use thereof.
- Current treatments used to treat various types of cancer tend to work by poisoning or killing the cancerous cell, but treatments that are toxic to cancer cells typically tend to be toxic to healthy cells as well. Moreover, the heterogenous nature of tumors is one of the primary reasons that effective treatments for cancer remain elusive. Current mainstream therapies such as chemotherapy and radiotherapy tend to be used within a narrow therapeutic window of toxicity. These types of therapies have limited applicability due to the varying types of tumor cells and the limited window in which these treatments can be administered.
- Disclosed herein in some aspects is a myxoma virus (MYXV) having enhanced anti-cancer activity, wherein the myxoma virus is genetically engineered to attenuate an activity or expression level of its M153 protein.
- In certain embodiments, the activity or the expression level of the M153 protein is attenuated at least 80%. Alternatively and/or additionally, MYXV is engineered to introduce a mutation in a nucleic acid encoding the M153 protein, wherein the mutation comprises an insertion, deletion, or substitution mutation. In some embodiments, the mutation enhances cell immune response activity in relation to a wild-type M153 protein. In certain embodiments, at least a portion of a nucleic acid encoding the M153 protein in MYXV genome is knocked out. In some embodiments, the MYXV comprises an inhibitory molecule targeting M153 transcript that thereby attenuates the M153 protein expression. In some embodiments, the inhibitory molecule is an inhibitory RNA. In some embodiments, the inhibitory RNA comprises dsRNA, siRNA, antisense RNA, or miRNA. In some embodiments, the MYXV further comprises a nucleic acid encoding a non-viral molecule. In some embodiments, the non-viral molecule is tumor necrosis factor alpha (TNFα). In some embodiments, the TNFα is human TNFα. In some embodiments, the TNFα is a soluble peptide. In some embodiments, the TNFα is a membrane- or surface-bound peptide. In some embodiments, the TNFα further enhances the anti-cancer activity of the MYXV by activating anti-tumor immune cells or inducing cancer cell death. In some embodiments, the non-viral molecule is interleukin-12 (IL-12). In some embodiments, the IL-12 is
human IL 12. In some embodiments, the IL-12 is a soluble peptide. In some embodiments, the IL-12 is a membrane- or surface-bound peptide. In some embodiments, the IL-12 further enhances the anti-cancer activity of the MYXV by promoting immune cell differentiation or eliciting immune cell cytotoxicity. In some embodiments, the IL-12 comprises an IL-12α subunit and an IL-12β subunit. In some embodiments, the IL-12α subunit and the IL-12β subunit are joined by a polypeptide linker. In some embodiments, the polypeptide linker is an elastin linker. In some embodiments, the non-viral molecule is decorin. In some embodiments, the decorin is human decorin. In some embodiments, the decorin is a soluble peptide. In some embodiments, the decorin is a membrane- or surface-bound peptide. In some embodiments, the decorin further enhances the anti-cancer activity of the MYXV by blocking or decreasing TGF-β signaling. In some embodiments, the nucleic acid encodes at least two molecules selected from a group consisting of TNFα, IL-12, and decorin. In some embodiments, the nucleic acid encodes TNFα, IL-12, and decorin. In some embodiments, the MYXV is derived from a Lausanne strain. - Disclosed herein, in some aspects, is a composition comprising a MYXV of any of the above embodiments, and a pharmaceutically acceptable carrier or excipient.
- In some embodiments, the composition is formulated for systemic administration. In some embodiments, the composition is formulated for local administration. In some embodiments, the composition is formulated for parenteral administration.
- Disclosed herein, in some aspects is a composition comprising a plurality of cells treated ex vivo by the MYXV of any of the above embodiments, wherein the plurality of cells comprises peripheral blood mononuclear cells (PBMCs), bone marrow (BM) cells, or a combination thereof.
- Disclosed herein, in some aspects is a method of inhibiting, alleviating, or preventing a cancer in a subject in need thereof, comprising administering to the subject the MYXV or the composition of any one of the above embodiments.
- In some embodiments, the subject has, is suspected of having, or is at risk of having the cancer, and wherein the method further comprises selecting the subject. In some embodiments, the subject is a human. In some embodiments, the administration is systemic administration. In some embodiments, the administration reduces cancer cell viability, or activates immunogenic cell death in the cancer. In some embodiments, the administration improves the subject's survival. In some embodiments, the cancer comprises a solid tumor. In some embodiments, the cancer is an osteosarcoma, triple negative breast cancer, or melanoma. In some embodiments, the cancer has metastasized to a location in the subject. In some embodiments, the location comprises a lung, a brain, a liver and/or a lymph node of the subject. In some embodiments, the method further comprises administering to the subject an additional therapeutic agent. In some embodiments, the additional therapeutic agent is an immune checkpoint modulator. In some embodiments, the additional therapeutic agent is administered to the subject before administering the composition. In some embodiments, the additional therapeutic agent is administered to the subject after administering the composition. In some embodiments, the additional therapeutic agent is administered to the subject as a combination with the composition. In some embodiments, the composition comprising the plurality of cells is administered to the subject, wherein the plurality of cells comprises cells that are autologous to the subject. In some embodiments, the composition comprising the plurality of cells is administered to the subject, wherein the plurality of cells comprises cells that are allogenic to the subject.
- Disclosed herein, in some aspects is a recombinant nucleic acid comprising at least a portion of MYXV genome, wherein the MYXV genome is modified to reduce expression of M153 gene. In some embodiments, the recombinant nucleic acid comprises DNA. In some embodiments, the portion of MYXV genome is modified to knock out at least a portion of the M153 gene in the portion of MYXV genome. In some embodiments, the recombinant MYXV genome comprises a first nucleic acid encoding TNFα. In some embodiments, the TNFα is human TNFα. In some embodiments, the first nucleic acid replaces or is adjacent to an M135R gene of the MYXV genome. In some embodiments, the first nucleic acid is inserted between an M135R gene and an M136R gene of the MYXV genome. In some embodiments, expression of the first nucleic acid is driven by a poxvirus synthetic early/late (sE/L) promoter. In some embodiments, the recombinant MYXV genome comprises a second nucleic acid encoding interleukin-12 subunit alpha (IL-12α). In some embodiments, the IL-12α is human IL-12α. In some embodiments, expression of IL-12α is driven by an internal ribosome entry site (IRES). In some embodiments, the second nucleic acid IL-12α disrupts the expression of the M153 gene of the MYXV genome. In some embodiments, the recombinant MYXV genome comprises a third nucleic acid encoding an interleukin-12 subunit beta (IL-12β). In some embodiments, the IL-12β is human IL-12β. In some embodiments, expression of the third nucleic acid is driven by an sE/L promoter. In some embodiments, the third nucleic acid disrupts the expression of the M153 gene of the MYXV genome. In some embodiments, the recombinant MYXV genome comprises a fourth nucleic acid encoding decorin. In some embodiments, the decorin is human decorin. In some embodiments, expression of the fourth nucleic acid is driven by an sE/L promoter. In some embodiments, the fourth nucleic acid disrupts expression of the M153 gene of the MYXV genome. In some embodiments, the recombinant MYXV genome further comprises a fifth nucleic acid encoding a reporter tag. In some embodiments, the reporter tag comprises a green fluorescent protein (GFP). In some embodiments, expression of the fifth nucleic acid is driven by an sE/L promoter. In some embodiments, the recombinant nucleic acid further comprises a sixth nucleic acid encoding a second reporter tag. In some embodiments, the second reporter tag comprises a red fluorescent protein (RFP). In some embodiments, expression of the sixth nucleic acid is driven by a poxvirus P11 late promoter. In some embodiments, the recombinant nucleic acid comprises a vMyx-hTNFa cassette, optionally comprising GFP. In some embodiments, the recombinant nucleic acid comprises an hDecorin-hIL-12 cassette, optionally comprising dsRed. In some embodiments, the recombinant nucleic acid comprises or consists of a vMyx-hTNFa-hDecorin-hIL-12-M153KO (vMyx-Triple) cassette, optionally comprising dsRed and/or GFP.
- Disclosed herein, in some aspects, is a recombinant MYXV comprising the recombinant nucleic acid of any of the above embodiments.
- Disclosed herein, in some aspects, is a method of inhibiting, alleviating, or preventing a cancer in a subject in need thereof, comprising administering to the subject the recombinant nucleic acid or the recombinant MYXV of any one of the preceding embodiments.
- In some embodiments, the subject has, is suspected of having, or is at risk of having the cancer, and wherein the method further comprises selecting the subject. In some embodiments, the subject is a human. In some embodiments, the administration is systemic administration. In some embodiments, the administration reduces cell viability, or activates immunogenic cell death in the cancer. In some embodiments, the administration is performed in a dose and a schedule effective to increase expression of at least two cytokines in PBMCs of the subject. In some embodiments, the administration is performed in a dose and a schedule effective to increase expression of at least two cytokines in cancer cells in the subject. In some embodiments, the at least two cytokines comprise IFN-γ, IL-2, IL-6, IL-10, IL-12, or TNF-α. In some embodiments, the administration is performed in a dose and a schedule effective to reduce volume of the cancer by at least 10%. In some embodiments, wherein the administration is performed in a dose and a schedule effective to reduce growth of the cancer by at least 10%.
- Disclosed herein, in some aspects, is a myxoma virus (MYXV) having enhanced anti-cancer activity, wherein the MYXV is genetically engineered to attenuate an activity or expression level of its M153 protein.
- In some embodiments, the activity or the expression level of the M153 protein is attenuated at least 80%. In some embodiments, the MYXV is engineered to introduce a mutation in a nucleic acid encoding the M153 protein, wherein the mutation comprises an insertion, deletion, or substitution mutation. In some embodiments, at least a portion of a nucleic acid encoding the M153 protein in MYXV genome is knocked out. In some embodiments, the MYXV comprises an inhibitory molecule targeting M153 transcript that thereby attenuates the M153 protein expression, wherein the inhibitory molecule comprises dsRNA, siRNA, antisense RNA, or miRNA. In some embodiments, the MYXV is further genetically engineered to express a non-viral molecule. In some embodiments, the non-viral molecule is a cytokine or a cell matrix protein. In some embodiments, the non-viral molecule is tumor necrosis factor alpha (TNFα), interleukin-12 subunit alpha (IL-12α), interleukin-12 subunit beta (IL-12β), or decorin. In some embodiments, the non-viral molecule is a human protein. In some embodiments, the MYXV expresses at least two non-viral molecules selected from a group consisting of TNFα, IL 12a, IL-12β, and decorin.
- Disclosed herein, in some aspects is a composition comprising a plurality of cells treated ex vivo by a MYXV, wherein the MYXV is genetically engineered to attenuate an activity or expression level of its M153 protein, and to express a non-viral molecule.
- In some embodiments, the plurality of cells comprises peripheral blood mononuclear cells (PBMCs), bone marrow (BM) cells, or a combination thereof.
- Disclosed herein, in some aspects, is recombinant nucleic acid comprising at least a portion of MYXV genome, wherein the portion of the MYXV genome is modified to reduce expression of M153 gene.
- In some embodiments, the portion of MYXV genome is modified to knock out at least a portion of the M153 gene in the portion of MYXV genome. In some embodiments, the recombinant nucleic acid comprises a nucleic acid encoding a non-viral molecule. In some embodiments, the non-viral molecule is human TNFα, human IL-12α (hTNFα), human IL-12β, or human decorin. In some embodiments, the nucleic acid encoding the non-viral molecule comprises a vMyx-hTNFα cassette, and the nucleic acid encoding the non-viral molecule replaces or is adjacent to an M135R gene of the MYXV genome. In some embodiments, the nucleic acid encoding the non-viral molecule comprises a vMyx-hTNFα cassette, and the nucleic acid encoding the non-viral molecule is inserted between an M135R gene and an M136R gene of the MYXV genome. In some embodiments, the nucleic acid encoding the non-viral molecule comprises an hDecorin-hIL-12 cassette, and the nucleic acid encoding the non-viral molecule replaces at least a portion of the M153 gene of the MYXV genome. In some embodiments, the nucleic acid encoding the non-viral molecule comprises a vMyx-hTNFα-hDecorin-hIL-12-M153KO (vMyx-Triple) cassette.
- Disclosed herein, in some aspects is a method of inhibiting, alleviating, or preventing a cancer in a subject in need thereof, comprising administering to the subject a MYXV or a plurality of cells treated with the MYXV, wherein the MYXV is genetically engineered to attenuate an activity or expression level of its M153 protein.
- In some embodiments, the MYXV is further genetically engineered to express a non-viral molecule. In some embodiments, the non-viral molecule is tumor necrosis factor alpha (TNFα), interleukin-12 subunit alpha (IL-12α), interleukin-12 subunit beta (IL-12β), or decorin. In some embodiments, the MYXV or the plurality of cells is administered by systemic administration. In some embodiments, the administration reduces tumor cell viability, or activates immunogenic cell death in the cancer. In some embodiments, the cancer is a solid tumor, an osteosarcoma, triple negative breast cancer, or melanoma. In some embodiments, the cancer has metastasized to a lung, a brain, a liver or a lymph node in the subject. In some embodiments, the method further comprises administering to the subject an immune checkpoint modulator. In some embodiments, the administration is performed in a dose and a schedule effective to increase expression of at least two cytokines in PBMC or cancer cells of the subject, wherein the at least two cytokines comprise IFN-γ, IL-2, IL-6, IL-10, IL-12, or TNF-α. In some embodiments, the administration is performed in a dose and a schedule effective to reduce volume of the cancer at least 10%.
- Disclosed herein, in some aspects, is a myxoma virus (MYXV) having enhanced anti-cancer activity, wherein the myxoma virus is genetically engineered to attenuate an activity or expression level of its M153 protein.
- In some embodiments, the activity or the expression level of the M153 protein is attenuated at least 80%. In some embodiments, the MYXV is engineered to introduce a mutation to in a nucleic acid encoding the M153 protein, wherein the mutation comprises an insertion, deletion, or substitution mutation. In some embodiments, at least a portion of a nucleic acid encoding the M153 protein in MYXV genome is knocked out. In some embodiments, the MYXV comprises an inhibitory molecule targeting M153 transcript that thereby attenuates the M153 protein expression, wherein the inhibitory molecule comprises dsRNA, siRNA, antisense RNA, or miRNA. In some embodiments, the MYXV further comprises a nucleic acid encoding a non-viral molecule. In some embodiments, the non-viral molecule is tumor necrosis factor alpha (TNFα), interleukin-12 subunit alpha (IL-12α), interleukin-12 subunit beta (IL-12β), or decorin. In some embodiments, the non-viral molecule is a human protein. In some embodiments, the nucleic acid encodes at least two non-viral molecules selected from a group consisting of TNFα, IL 12a, IL-12β, and decorin.
- Disclosed herein, in some aspects, is a composition comprising a plurality of cells treated ex vivo by a MYXV, wherein the MYXV is genetically engineered to attenuate an activity or expression level of its M153 protein, and wherein the plurality of cells comprises peripheral blood mononuclear cells (PBMCs), bone marrow (BM) cells, or a combination thereof.
- In some embodiments, the composition is for use in inhibiting, alleviating, or preventing a cancer in a subject in need thereof, wherein the plurality of cells comprises cells that are autologous to the subject. In some embodiments, the composition is for use in inhibiting, alleviating, or preventing a cancer in a subject in need thereof, wherein the plurality of cells comprises cells that are allogeneic to the subject.
- Disclosed herein, in some aspects, is a MYXV for use in inhibiting, alleviating, or preventing a cancer in a subject in need thereof, wherein the MYXV is genetically engineered to attenuate an activity or expression level of its M153 protein.
- In some embodiments, the MYXV is administered to the subject by systemic administration. In some embodiments, the MYXV reduces cancer cell viability, or activates immunogenic cell death in the cancer. In some embodiments, the cancer is a solid tumor, an osteosarcoma, triple negative breast cancer, or melanoma. In some embodiments, the cancer has metastasized to a lung, a brain, a liver or a lymph node in the subject. In some embodiments, the MYXV is administered to the subject with an immune checkpoint modulator. In some embodiments, the MYXV is administered in a dose and a schedule effective to increase expression of at least two cytokines in PBMC or cancer cells of the subject, wherein the at least two cytokines comprise IFN-γ, IL-2, IL-6, IL-10, IL-12, or TNF-α. In some embodiments, the MYXV is administered in a dose and a schedule effective to reduce volume of the cancer at least 10%.
- Disclosed herein, in some aspects is a recombinant nucleic acid comprising at least a portion of MYXV genome, wherein the portion of the MYXV genome is modified to reduce expression of M153.
- In some embodiments, the portion of MYXV genome is modified to knock out at least a portion of the M153 gene in the portion of MYXV genome. In some embodiments, the recombinant nucleic acid comprises a nucleic acid encoding a non-viral molecule. In some embodiments, the non-viral molecule is tumor necrosis factor alpha (TNFα), interleukin-12 subunit alpha (IL-12α), interleukin-12 subunit beta (IL-12β), or decorin. In some embodiments, the non-viral molecule is a human protein. In some embodiments, the nucleic acid encoding the non-viral molecule is inserted between an M135R gene and an M136R gene of the MYXV genome. In some embodiments, the nucleic acid encoding the non-viral molecule is inserted to replace at least a portion of the M153 gene of the MYXV genome. In some embodiments, the nucleic acid encoding the non-viral molecule comprises a vMyx-hTNFa cassette, optionally comprising GFP, and the nucleic acid encoding the non-viral molecule replaces or is adjacent to an M135R gene of the MYXV genome. In some embodiments, the nucleic acid encoding the non-viral molecule comprises a vMyx-hTNFa cassette, and the nucleic acid encoding the non-viral molecule is inserted between an M135R gene and an M136R gene of the MYXV genome. In some embodiments, the nucleic acid encoding the non-viral molecule comprises an hDecorin-hIL-12 cassette, optionally comprising dsRed, and the nucleic acid encoding the non-viral molecule replaces at least a portion of the M153 gene of the MYXV genome. In some embodiments, the nucleic acid encoding the non-viral molecule comprises a vMyx-hTNFa-hDecorin-hIL-12-M153KO (vMyx-Triple) cassette, optionally comprising dsRed.
- The novel features of certain embodiments of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
-
FIG. 1A is a schematic diagram showing construction of recombinant nucleic acids that can be used to generate myxoma viruses (MYXV) disclosed herein. The top image depicts a recombinant nucleic acid that comprises a vMyx-hTNFa-GFP cassette, and an M153 locus. The recombinant nucleic acid can be present in the genome of a MYXV of the disclosure, for example, a vMyx-hTNFa-GFP virus. The middle image shows a recombinant nucleic acid comprising the hDecorin-hIL-12-dsRed cassette with flanking sequences that correspond to sequences that flank the M153 gene in the MYXV genome (M152 and M154). This recombinant nucleic acid can be present in a recombination plasmid that can be introduced into MYXV to generate a modified recombinant virus. The bottom image shows a modified vMyx-Triple recombinant nucleic acid. The recombinant nucleic acid can be present in the genome of a MYXV of the disclosure. For example, the recombination plasmid depicted in the middle image can be introduced into a MYXV (e.g., by infecting RK13 cells with vMyx-hTNFa-GFP virus, and transfecting the cells with the recombination plasmid). Recombination can occur to generate the vMyx-Triple recombinant nucleic acid. Recombinant viruses that comprise the vMyx-Triple recombinant nucleic acid can be identified and purified based on a selection marker, for example, dsRed. -
FIG. 1B is a schematic of the M153 locus in recombinant nucleic acids, which can be modified with a mutation or a transgene insertion. Recombinant nucleic acids with a modified M153 locus can be introduced into a MYXV genome using methods disclosed herein. -
FIGS. 2A-2D are images of agarose gels showing genetic control of recombinant MYXV constructs.FIG. 2A shows genomic viral DNA from vMyx-Triple construct clones using primers to confirm presence of hDecorin-hIL-12.FIG. 2B shows the presence of hTNFa.FIG. 2C shows the modification at locus M153 and purity of the vMyx-Triple construct.FIG. 2D shows the absence of M153 and purity of recombinant vMyx-Triple constructs.Lane 1 includes DNA from MYXV-Lau or the expression plasmid for hDec-Hil12 and hTNF. MM represents known size DNA ladder. -
FIGS. 3A-3C are images of western blots showing protein expression of the transgenes in vMyx-Triple viruses. The western blot analysis was performed on cell lysates and supernatants from vMyx-Triple virus-infected cells, using specific antibodies to confirm protein expression of the three transgenes hTNF (FIG. 3A ), hDecorin (FIG. 3B ), and hIL-12 (FIG. 3C ). -
FIG. 4 is a chart showing a single-step growth analysis of recombinant vMyx-Triple viruses. The replication capacities in RK13 cells of vMyx-Triple viruses was similar to the parental virus vMyx-TNF-GFP. MOI=1. -
FIGS. 5A and 5B are graphs showing results of a cell viability assay. The cell killing capacity of a vMyx-Triple virus was tested in two different cell lines: CT26 (murine colon carcinoma) and HELA (human cervical cancer). Cells were infected at MOI=10 for 48 hrs, and then the MTS assay was performed. -
FIG. 6 is a chart showing cell death induced by viral infection with a wild type MYXV or a M153KO MYXV, and showing cell death in untreated B16F10 cells (mock). -
FIGS. 7A and 7B are graphs showing immunogenic cell death induced by M153KO MYXV in B16F10 murine cells in vitro.FIG. 7A shows ATP release caused by Doxorubicin (positive control), a wt MYXV, and a M153KO MYXV at different hours post infection (p.i.). When no bar is present, the level of ATP was below the limit of detection for the assay.FIG. 7B shows a quantitative representation of calreticulin ecto-expression for untreated (mock), doxorubicin-treated (positive control), a M135KO MYXV-infected, and a M153KO MYXV-infected cells. The data quantify ecto-expression per cell based on confocal images taken 36 hrs post-treatment, with signal normalized to a nuclear stain (DAPI) that represents each cell. -
FIG. 8 is a chart showing a survival curve in a metastatic melanoma mouse model (B16F10) when mice were left untreated (control; middle line), treated with a M153KO MYXV (153KO; line extending to the right) or treated with a M135KO MYXV as a second control (M135KO; left line). Days p.i.=days post implantation. -
FIGS. 9A-9D show the concentration of cytokines in the supernatants of Vero cells infected with MYXV of the disclosure.FIG. 9A shows TNF concentration.FIG. 9B shows Decorin concentration.FIG. 9C shows human IL-12 concentration.FIG. 9D shows murine IL-12 concentration. When no bar is present, the level of the analyte was below the limit of detection for the assay. -
FIG. 10A shows the viability of L929 cells after exposure to supernatants of Vero cells infected with MYXV of the disclosure, which is indicative of TNF biological activity. -
FIG. 10B shows the expression of a reporter gene after exposure of HEK Blue IL-12 cells to supernatants of Vero cells infected with MYXV of the disclosure. When no bar is present, the level of the analyte was below the limit of detection for the assay. -
FIG. 11A shows viability of cells from human acute myeloid leukemia patients after incubation with vMyx-GFP for 6 days. -
FIG. 11B shows viability of cells from human acute myeloid leukemia patients after incubation with vMyx-Triple for 6 days. -
FIG. 12A shows the concentrations of cytokines in the supernatants of human PBMCs infected with the indicated MYXV at an MOI of 10, at 4 hours post-infection. Mean+/−SD is plotted. When no bar is present, the level of the analyte was below the limit of detection for the assay. -
FIG. 12B shows the concentrations of cytokines in the supernatants of human PBMCs infected with the indicated MYXV at an MOI of 10, at 16 hours post-infection. Mean+/−SD is plotted. When no bar is present, the level of the analyte was below the limit of detection for the assay. -
FIG. 13A plots the volume of NCI-H1971 (lung cancer) xenograft tumors over time in immunodeficient mice that were treated with the indicated doses of vMyx-Triple once per week (QW). -
FIG. 13B plots the volume of A673 (sarcoma) xenograft tumors over time in immunodeficient mice that were treated with the indicated doses of vMyx-Triple once per week (QW), every 4 days (Q4D), or every 2 days (Q2D). -
FIG. 13C plots the volume of SJSA (sarcoma) xenograft tumors over time in immunodeficient mice that were treated with the indicated doses of vMyx-Triple once per week (QW, every 4 days (Q4D), or every 2 days (Q2D). -
FIG. 14A shows the concentrations of IL-12 and TNF-α detected in serum and tumor tissue from immunodeficient mice bearing SJSA-1 tumors. The mice were treated with vMyx-Triple via the intravenous (IV) or intra-tumoral (IT) routes, and samples collected at 4 hours (4H) or 24 hours (24H) post-treatment. Mean±SD is plotted. When no bar is present, the level of the analyte was below the limit of detection for the assay. -
FIG. 14B shows the concentrations of IL-12 and TNF-α detected in serum and tumor tissue from immunodeficient mice bearing A673 tumors. The mice were treated with vMyx Triple via the intravenous (IV) or intra-tumoral (IT) routes, and samples collected at 4 hours (4H) or 24 hours (24H) post-treatment. Mean±SD is plotted. When no bar is present, the level of the analyte was below the limit of detection for the assay. -
FIG. 15 plots tumor volume over time for C57BL/6 mice implanted with B16-F10 mouse melanoma cells, and treated with TNF-expressing MYXV that had M153 and M135 knocked out (TNF135/153 KO) or TNF-expressing MYXV with wild type copies of both genes (TNF135/153 WT). -
FIG. 16A andFIG. 16B plot tumor volume and survival over time for C57BL/6 mice implanted with MC38 mouse colorectal cancer cells. Animals were treated via intratumoral (IT) injection of 2×107 FFU/dose once every 4 days for four doses with the indicated myxoma virus. msTriple low refers to a vMyx-Triple that expresses murine rather than human IL-12, at a relatively low level. msTriple high refers to a vMyx-Triple that expresses murine IL-12 at a relatively higher level. The msTriple viruses also express human Decorin and TNF, and have the M153 gene knocked out. GFP refers to vMyx-GFP, which does not encode any of the cytokines, and contains an intact M153 gene. Tumor volume measurements were recorded three times per week, and are plotted inFIG. 16A . Survival is plotted inFIG. 16B . -
FIG. 17A andFIG. 17B plot tumor volume and survival over time for C57BL/6 mice implanted with B16-F10 mouse melanoma cells. Animals were treated via intratumoral injection of 2×107 FFU/dose onDay 1 andDay 8 with the indicated myxoma virus. msTriple low refers to a vMyx-Triple that expresses murine rather than human IL-12, at a relatively low level. msTriple high refers to a vMyx-Triple that expresses murine IL-12 at a relatively higher level. The msTriple viruses also express human Decorin and TNF, and have the M153 gene knocked out. GFP refers to vMyx-GFP, which does not encode any of the cytokines, and contains an intact M153 gene. Tumor volume measurements were recorded three times per week, and are plotted inFIG. 17A . Survival is plotted inFIG. 17B . -
FIG. 18A plots tumor volume over time for C57BL/6 mice implanted with B16-F10 mouse melanoma cells, and treated with the indicated doses of msTriple high, a MYXV that expresses a relatively high level of murine IL-12, also expresses human Decorin and human TNF, and has the M153 gene knocked out. The virus was administered intratumorally (IT) or intravenously (IV). -
FIG. 18B plots tumor volume over time for Balb/c mice implanted with CT26 mouse colorectal cancer cells, and treated with the indicated doses of msTriple high. The virus was administered intratumorally (IT) or intravenously (IV). -
FIG. 19 displays survival curves of Balb/c mice implanted with K7M2 sarcoma cells. Groups of mice were treated via injection into the retro-orbital sinus of 2×107 FFU/dose of the vMyx-mouse Triple (low IL-12), and/or with intraperitoneal injections of anti-PD-1 or anti-PD-L1 antibodies at 10 mg/kg. -
FIG. 20A plots tumor volume over time of C57BL/6 mice implanted with MC38 mouse colorectal cancer cells. Groups of animals were treated via intratumoral injection of 2×107 FFU/dose of vMyx-mouse Triple (low IL-12) onday 1 andday 8 post-randomization, and/or with anti-PD-1 antibody at 10 mg/kg, once every four days for four doses. Circles connected by solid lines: vehicle-treated; squares: vMyx-mouse Triple alone; circles with dashed line; anti-PD-1; triangles: combination of vMyx-mouse Triple and anti-PD-1. -
FIG. 20B plots survival of the groups inFIG. 20A . - Described herein are oncolytic viruses, specifically oncolytic poxviruses such as oncolytic myxoma viruses. Myxoma viruses can be referred to herein as MYXV or vMyx. In some embodiments, the MYXV is genetically engineered to attenuate an activity or expression level engineered to inactivate, disrupt, or attenuate expression of an M153 gene or protein, for example, genetically engineered to attenuate an activity or expression level of the M153 gene or protein. The modification to the myxoma virus as described herein has unexpectedly improved the oncolytic activity of the MYXV when compared with unmodified MYXV, MYXV that contain an intact wild type M153 gene, or MYXV with modification at another gene locus. In addition to modification at the M153 locus, the MYXV can also include one or more transgenes that encode non-viral molecules, such as a TNFα, IL-12, and/or decorin to further enhance the oncolytic activity, increase an anti-tumor immune response, or decrease adverse side effects of the MYXV.
- Some embodiments relate to triple transgene-armed oncolytic viruses such as MYXVs, and methods of their use for treatment of cancers, such as metastatic cancers. Some embodiments include a recombinant MYXV construct that expresses 3 human transgenes: a human cytokine (hTNF) that improves the efficacy of the treatment of cancers that metastasize to the lung or other parts of the body, an hIL-12 that can amplify anti-tumor immune responses, and a human Decorin (hDecorin) that blocks TGF-beta signaling within tumor beds. In some embodiments, the viruses disclosed here have a knockout (e.g., deletion or disruption) of the myxoma virus M153 gene or at least a portion thereof, which in some embodiments also improves the anti-tumor immune responses following therapy with these virus constructs. Some embodiments relate to nucleic acid constructs such as virus triple-transgene constructs that encode the MYXVs. In some embodiments, the transgenes and other modifications to the MYXV improve cancer therapy efficacy.
- The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
- The following explanations of terms are provided for the purpose of describing particular embodiments and examples only and is not intended to be limiting.
- As used herein, the singular forms “a,” “an,” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.
- As used herein, the term “and/or” refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative (“or”).
- As used herein, “one or more” or at least one can mean one, two, three, four, five, six, seven, eight, nine, ten or more, up to any number.
- An “effective amount” or “therapeutically effective amount” refers to an amount of a compound or composition of this invention that is sufficient to produce a desired effect, which can be a therapeutic and/or beneficial effect.
- A “subject in need thereof” or “a subject in need of” is a subject known to have, or is suspected of having a disease, or condition, such as a cancer.
- As used herein, the term “inhibiting” or “treating” a disease refers to inhibiting the full development of a disease or condition. “Treatment” refers to a therapeutic intervention that ameliorates a sign or symptom of a disease or pathological condition after it has begun to develop. The term “ameliorating,” with reference to a disease or pathological condition, refers to any observable beneficial effect of the treatment. The beneficial effect can be evidenced, for example, by a delayed onset of clinical symptoms of the disease in a susceptible subject, a reduction in severity of some or all clinical symptoms of the disease, a slower progression of the disease, such a metastasis, an improvement in the overall health or well-being of the subject, or by other parameters well known in the art that are specific to the particular disease. A “prophylactic” treatment is a treatment administered to a subject who does not exhibit signs of a disease or exhibits only early signs for the purpose of decreasing the risk of developing pathology, for example metastatic cancer.
- MYXV may infect cells that have a deficient innate anti-viral response. Having “a deficient innate anti-viral response” as used herein refers to a cell that, when exposed to a virus or when invaded by a virus, does not induce anti-viral defense mechanisms, which can include inhibition of viral replication, production of interferon, induction of the interferon response pathway, and apoptosis. The term includes a cell, such as a cancer cell, that has a reduced or defective innate anti-viral response upon exposure to or infection by a virus as compared to a normal cell, for example, a non-infected, or non-cancer cell. This includes a cell that is non-responsive to interferon and a cell that has a reduced or defective apoptotic response or induction of the apoptotic pathway. The deficiency may be due to various causes, including infection, genetic defect, or environmental stress. It will however be understood that when the deficiency is caused by a pre-existing infection, superinfection by MYXV may be excluded and a skilled person can readily identify such instances. A skilled person can readily determine without undue experimentation whether any given cell type has a deficient innate anti-viral response and therefore is susceptible to infection by MYXV. Thus, in certain embodiments, the MYXV is capable of infecting cells that have a deficient innate anti-viral response. In certain embodiments, the cells are non-responsive to interferon. In specific embodiments, the cell is a mammalian cancer cell. In certain embodiments, the cell is a human cancer cell including a human solid tumor cell. In certain embodiments, the cells that have a deficient innate anti-viral response comprise cancer cells.
- Disclosed herein, in certain embodiments, are myxoma viruses (MYXVs). The MYXV may comprise a wild-type strain of MYXV or it may comprise a genetically modified strain of MYXV. In some embodiments, the MYXV comprises a Lausanne strain. In some embodiments, the Lausanne strain of MYXV comprises GenBank Accession Number AF170726.2, published on Jul. 11, 2019.
- In some instances, the MYXV comprises a South American MYXV strain that circulates in Sylvilagus brasiliensis. In some instances, the MYXV comprises a Californian MYXV strain that circulates in Sylvilagus bachmani. In some instances, the MYXV comprises 6918, an attenuated Spanish field strain that comprises modifications in genes M009L, M036L, M135R, and M148R (for example, GenBank Accession number EU552530, published on Jul. 11, 2019). In some instances, the MYXV comprises 6918VP60-T2 (GenBank Accession Number EU552531, published on Jul. 11, 2019). In some instances, the MYXV comprises a Standard laboratory Strain (SLS). In some embodiments, the MYXV comprises a nucleic acid construct or MYXV genome as described herein.
- In some instances, the MYXV comprises at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, such as between 95% and 98%, 95% and 99%, including 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% nucleic acid sequence identity to a sequence disclosed in Cameron, et al., “The complete DNA sequence of Myxoma Virus,” Virology 264: 298-318 (1999), which is incorporated by reference for such disclosure. In some cases, the MYXV comprises the sequence disclosed in Cameron, et al., “The complete DNA sequence of Myxoma Virus,” Virology 264: 298-318 (1999).
- In some embodiments, the MYXVs are engineered to inactivate or attenuate an activity or expression level of a viral gene or protein. In some embodiments, the viral gene or protein is M153. In some embodiments, the inactivated or attenuated activity or expression level of the viral gene or protein results in the MYXV exhibiting enhanced anti-cancer activity in relation to a wild-type MYXV, or in relation to a MYXV not having the inactivated or attenuated activity or expression level of the viral gene or protein, for example, a MYXV that comprises a wild type M153 gene and/or expresses a wild type M153 protein. In some embodiments, the MYXV is engineered to inactivate or attenuate an activity or expression level of more than one viral gene or protein.
- In some embodiments, the MYXV comprises a nucleic acid that encodes a non-viral molecule, for example, a transgene that encodes a cytokine. In some embodiments, the MYXV includes a transgene such as a transgene described herein. In some embodiments, the transgene encodes a tumor necrosis factor (TNF, e.g., TNFα), an interleukin-12 (IL-12), or a decorin. In some embodiments, the MYXV includes one, two, three, or more transgenes. In some embodiments, one or more transgenes are knocked in to a MYXV genome. In some embodiments, a transgene disrupts a gene in the MYXV genome, for example, a transgene inserted within or replaces part of the gene in the MYXV genome, thereby disrupting expression of the gene and/or the protein it encodes. Such a disruption can be referred to as a knockout (KO).
- The MYXV may be modified to produce any non-viral molecule (e.g., modified to carry any transgene) that enhances the anticancer effect of the MYXV. Such a non-viral molecule can be involved in triggering apoptosis, or in targeting the infected cell for immune destruction, such as a non-viral molecule that stimulates a response to interferon (e.g., repairs a lack of response to interferon), or that results in the expression of a cell surface marker that stimulates an antibody response, such as a pathogen-associated molecular pattern, for example, a bacterial cell surface antigen. The MYXV can also be modified to produce a non-viral molecule involved in shutting off the neoplastic or cancer cell's proliferation and growth, thereby preventing the cells from dividing. In some embodiments, the MYXV is modified to produce therapeutic non-viral molecules, such as molecules involved in the synthesis of chemotherapeutic agents, or it can be modified to have increased replication levels in cells of the particular species from which the cells to be inhibited or killed are derived, for example, human cells.
- In some embodiments, the MYXV includes a recombinant construct that encodes or expresses one, two, or three separate non-viral molecules, for example, human transgenes (e.g., human TNF, human Decorin and human IL-12). In some embodiments, the recombinant construct further encodes or expresses one or more reporter tags, for example, fluorescent proteins such as eGFP and dsRed.
- In some embodiments, the MYXV is genetically engineered to attenuate an activity or expression level of its M153 gene or protein, for example, comprises a disruption of the viral M153 gene (M153-knockout: M153K0). In some embodiments, attenuating the activity or expression level of M153 improves the MHC-dependent anti-tumor immune responses to virus-infected cancer cells. In some embodiments, the MYXVs comprise oncolytic viruses for use in treating cancer. Some embodiments combine a M153KO backbone with the immune-enhancing properties of transgenes disclosed herein to enhance the oncolytic properties of the MYXV.
- In some embodiments, the MYXV encodes a TNF (e.g., TNFα) transgene, an IL-12 transgene, a decorin transgene, or any combination of two or more of those. In some embodiments, the MYXV includes a TNF (e.g., TNFα) transgene, an IL-12 transgene, and a decorin transgene. In some such embodiments, upon administration of such an MYXV to a subject, the TNF activates and jump-starts the innate and acquired arms of the anti-tumor immune system and promotes cancer cell death in a by-stander paracrine-like manner. In some embodiments, the IL-12 amplifies the resulting anti-cancer innate and adaptive immune responses. In some embodiments, the decorin interrupts local immunosuppressive actions mediated by TGF-β, thus enhancing the actions of both TNF and IL-12 and promoting the anti-cancer immune response. In some embodiments, the synergistic actions of the three transgenes plus the effects of MYXV in the tumor microenvironment (TME) increase the immunotherapeutic potential of oncolytic MYXV vectors. In some embodiments, the addition of the human transgenes that encode non-viral molecules (hTNF, hIL-12, and/or hDecorin) to the MYXV genome improves the MYXV's capacity to trigger robust anti-tumor immune responses in the tumor microenvironment (TME).
- In some embodiments, the MYXV is modified to enhance the ease of detection of infection state. For example, the MYXV may be genetically modified to express a marker that can be readily detected by phase contrast microscopy, fluorescence microscopy or by radioimaging. The marker can be an expressed fluorescent protein or an expressed enzyme that is involved in a colorimetric or radiolabeling reaction. In some embodiments, the marker includes a gene product that interrupts or inhibits a particular function of the cells being tested.
- In some embodiments, the engineered MYXV comprises a fluorescent protein. Exemplary fluorescent proteins include blue/UV proteins such as TagBFP, Azurite, Sirus, or Sapphire; cyan proteins such as ECFP, cerulean, or mTurquoise; green proteins such as green fluorescent protein (GFP), Emerald, mUKG, mWasabi, or Clover; yellow proteins such as EYFP, citrine, venus, or SYFP2; orange proteins such as monomeric Kusabira-Orange, mKO2, or mOrange; red proteins such as dsRed, mRaspberrym mCherry, mStrawberry, mTangerine, tdTomato, mApple, or mRuby; photoactivatible proteins such as PA-GFP, PAmCherry1, or PATagRFP; and photoswitchable proteins such as Dropna. In some embodiments, the MYXV includes more than one fluorescent protein. In some embodiments the engineered MYXV does not encode a fluorescent protein.
- In some embodiments, the MYXV comprises a vMyx-hTNFa-GFP-hDecorin-hIL-12-dsRed-M153KO (vMyx-Triple or vMyx-Triple-red) construct, and is a vMyx-Triple virus. In some embodiments, the MYXV comprises a vMyx-hTNFa-GFP-hDecorin-hIL-12-M153KO (vMyx-Triple-white) construct, and is a vMyx-Triple-white virus.
- In some embodiments, the MYXV comprises a modification at or adjacent to one or more genes associated with rabbit cell tropism. In some instances, the one or more genes associated with rabbit cell tropism comprises M11L, M063, M135R, M136R, M-T2, M-T4, M-T5, or M-T7. In some instances, the one or more genes associated with rabbit cell tropism comprise M135R, M136R, or a combination thereof.
- The MYXV may be prepared using standard techniques known in the art. For example, the virus may be prepared by infecting cultured rabbit cells, or immortalized permissive human or primate cells, with the MYXV strain that is to be used, allowing the infection to progress such that the virus replicates in the cultured cells and can be released by standard methods known in the art for disrupting the cell surface and thereby releasing the virus particles for harvesting. Once harvested, the virus titer may be determined by infecting a confluent lawn of rabbit cells and performing a plaque assay.
- The M153 gene product is an E3-Ubiquitin ligase that may participate in the down regulation of diverse cellular receptors and proteins, for example, degradation of MHC Class I and CD4 in human cells. In some embodiments, a MYXV of the disclosure has an attenuated activity and/or expression level of M153 protein. In some embodiments, an attenuated activity and/or expression level of M153 protein can enhance presentation of immune epitopes, for example, MHC-dependent presentation of viral and/or cancer immune peptides. Enhanced presentation of immune epitopes by infected cancer cells can elicit stronger immune responses, including anti-cancer T cell responses, such as anti-cancer CD8+ T cell responses. In some embodiments, an attenuated activity and/or expression level of M153 protein increases direct antigen presentation from M153KO virus-infected tumor cells by MHC-I, and enhances immune activation mediated by the MYXV.
- In some embodiments, the MYXV comprises a modification of an M153 gene. In some instances, the modification is a mutation that attenuates an activity or expression level of a protein encoded by the M153 gene (e.g., impairs the function of the protein encoded by the M153 gene).
- In some instances, the mutation is a deletion, for example, a deletion that attenuates an activity or expression level of a protein encoded by the M153 gene. In some embodiments, the mutation is a deletion of at least about 1%, at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99%, of the nucleic acid sequence of the M153 gene. In some embodiments, the mutation is a deletion of the entire M153 gene. In some cases, the modification is a partial deletion, for example, a deletion of about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 95% of the nucleic acid sequence of the M153 gene. In some embodiments, the deletion is a deletion of at least 1, at least 2, at least 3, at least 4, at least 5, at least 7, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 100, at least 200, or at least 300 nucleic acids. In some embodiments, the deletion disrupts a promoter (e.g., a promoter that drives expression of M153 in a wild type MYXV). In some embodiments, the deletion introduces a stop codon into the M153 gene sequence, for example, a premature stop codon that prevents expression of a full length M153 transcript and/or protein.
- In some instances, the mutation is an insertion, for example, an insertion that attenuates an activity or expression level of a protein encoded by the M153 gene. In some embodiments, the insertion comprises a transgene that encodes a non-viral molecule, for example, a transgene that encodes TNF, decorin, IL-12, or a combination thereof. In some embodiments, the insertion comprises two transgenes. In some embodiments, the insertion comprises three transgenes. The transgene(s) can disrupt (e.g., interrupt) the viral M153 gene and attenuate an activity or expression level of a M153 transcript and/or protein. In some embodiments, the insertion comprises a transgene that encodes TNF. In some embodiments, the insertion comprises a transgene that encodes IL-12. In some embodiments, the insertion comprises a transgene that encodes decorin. In some embodiments, the insertion comprises a transgene that encodes TNF and a transgene that encodes IL-12. In some embodiments, the insertion comprises a transgene that encodes TNF and a transgene that encodes decorin. In some embodiments, the insertion comprises a transgene that encodes IL-12 and a transgene that encodes decorin. In some embodiments, the insertion comprises a transgene that encodes TNF, a transgene that encodes IL-12, and a transgene that encodes decorin. In some embodiments, the insertion comprises one or more promoters. In some embodiments, the insertion disrupts a promoter (e.g., a promoter that drives expression of M153 in a wild type MYXV). In some embodiments, combining M153 gene disruption with transgene expression improves the anti-tumor properties of the resulting recombinant virus.
- In some embodiments, the insertion is an insertion of at least 1, at least 2, at least 3, at least 4, at least 5, at least 7, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 100, at least 200, at least 300, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1500, or at least 2000 nucleic acids.
- In some embodiments, the insertion introduces a stop codon into the M153 gene sequence, for example, a premature stop codon that prevents expression of a full length M153 transcript and/or protein. In some embodiments, the insertion alters the reading frame of the M153 gene sequence, thereby disrupting expression of the M153 transcript and/or protein.
- In some instances, the mutation is a substitution, for example, a substitution that attenuates an activity or expression level of a protein encoded by the M153 gene. In some embodiments, at least 1, at least 2, at least 3, at least 4, at least 5, at least 7, at least 10, at least 20, at least 30 nucleic acids are substituted. In some embodiments, the substitution introduces a stop codon into the M153 gene sequence, for example, a premature stop codon that prevents expression of a full length M153 transcript and/or protein. In some embodiments, the substitution disrupts a promoter (e.g., a promoter that drives expression of M153 in a wild type MYXV).
- In some embodiments, a modification or mutation disclosed herein attenuates the activity level of the M153 gene and/or protein by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% relative to a wild type MYXV, or a MYXV that encodes a functional wild type M153.
- In some embodiments, a modification or mutation disclosed herein attenuates the expression level of the M153 gene and/or protein by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% relative to a wild type MYXV, or a MYXV that encodes a functional wild type M153.
- In some embodiments, a MYXV disclosed herein has an activity level of the M153 protein that is attenuated by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% relative to a wild type MYXV, or a MYXV that encodes a functional wild type M153.
- In some embodiments, a MYXV disclosed herein has an expression level of the M153 gene and/or protein that is attenuated by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% relative to a wild type MYXV, or a MYXV that encodes a functional wild type M153.
- In some embodiments, the MYXV comprises (e.g., encodes) a non-viral molecule, for example, comprises a transgene that encodes tumor necrosis factor (TNF) protein. In some embodiments, the TNF protein is a TNFα protein. In some embodiments, the TNFα protein is a human TNFα protein. In some embodiments, the TNFα protein is soluble. In some embodiments, the TNFα protein is membrane- or surface-bound. In some embodiments, the TNFα protein enhances the anti-cancer activity of the MYXV by activating anti-tumor immune cells or inducing cancer cell death.
- In some embodiments, the TNFα is encoded by a gene that replaces or is adjacent to an M135R gene of the MYXV genome. In some embodiments, the TNFα gene is inserted between an M135R gene and an M136R gene of the MYXV genome. In some embodiments, the TNFα gene is inserted in the intergenic region between an M135R gene and an M136R gene of the MYXV genome. In some embodiments, the TNFα is encoded by a gene that replaces or disrupts an M153 gene of the MYXV genome. In some embodiments, the TNFα gene replaces or disrupts an M153 gene of the MYXV genome.
- In some embodiments, expression of the TNFα gene is driven by a promoter such as a poxvirus synthetic early/late (sE/L) promoter. In some embodiments, expression of the TNFα gene is driven by an internal ribosome entry site (IRES). TNF is a cytokine that is part of the innate inflammatory immune response. In some embodiments, TNF participates in amplifying the acquired (e.g., adaptive) immune responses. TNF can be expressed as a cell surface immune ligand and it can also be secreted as a cleaved soluble trimeric cytokine when produced in specific cells that express the converting proteolytic enzymes (such as TACE) that catalyze cleavage and release of the soluble ligand, for example that are expressed at high levels in cells of the myeloid lineage. One TNF effector pathway is the induction of cellular death through the TNF Receptor-1 (TNFR1) pathway. In some embodiments, induction of the TNFR1 pathway by TNF leads to apoptosis or necroptosis. In some embodiments, TNF activates the innate and adaptive immune responses, for example, by activating anti-tumor CD8+ T cells and NK cells.
- Despite the early hope that systemic administration of soluble TNF may function in humans as a potent anti-tumor drug, some clinical trials showed that the secreted cytokine caused severe systemic toxicities in patients treated systemically with the soluble ligand. Additionally, the systemic TNF treatment did not induce the dramatic anti-tumor effects in patients that was reported preclinically. A virally derived expression of TNF, e.g., the cell surface membrane form of TNF, may improve local cancer cell death by eliciting a greater degree of bystander cell killing in the tumor microenvironment, and also stimulate various classes of immune cells residing within the same tumor beds, while minimizing systemic TNF-mediated adverse toxic effects.
- In some instances, the TNF protein comprises at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the sequence illustrated in UniProtKB-P01375, published on Jul. 3, 2019 (Entry version 247). In some instances, the TNF protein comprises between 95% and 98%, or 95% and 99% sequence identity to the sequence illustrated in UniProtKB-P01375, published on Jul. 3, 2019 (Entry version 247). In some instances, the TNF protein comprises about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity to the sequence illustrated in UniProtKB-P01375, published on Jul. 3, 2019 (Entry version 247). In some embodiments, the TNF protein comprises the sequence illustrated in UniProtKB-P01375, published on Jul. 3, 2019 (Entry version 247).
- In some instances, the TNF protein comprises at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to residues 77-233 of UniProtKB-P01375. In some instances, the TNF protein comprises between 95% and 98%, or 95% and 99% sequence identity to residues 77-233 of UniProtKB-P01375. In some instances, the TNF protein comprises about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity to residues 77-233 of UniProtKB-P01375. In some embodiments, the TNF protein comprises residues 77-233 of UniProtKB-P01375.
- In some instances, the TNF protein is encoded by a gene comprising at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 12 or SEQ ID NO: 24. In some instances, the TNF protein is encoded by a gene comprising between 95% and 98%, or 95% and 99% sequence identity SEQ ID NO: 12 or SEQ ID NO: 24. In some instances, the TNF protein is encoded by a gene comprising about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity to SEQ ID NO: 12 or SEQ ID NO: 24. In some embodiments, the TNF protein is encoded by a gene comprising or consisting of SEQ ID NO: 12 or SEQ ID NO: 24. In some embodiments, the TNF is encoded by a gene comprising the sequence of SEQ ID NO: 12 or SEQ ID NO: 24. In some embodiments, the gene encoding the TNF comprises a sequence that is 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, or a range of percentages defined by any two of the aforementioned percentages, identical to that of SEQ ID NO: 12 or SEQ ID NO: 24.
- In some instances, the TNF protein comprises at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 31 or residues 77-233 of SEQ ID NO: 31. In some instances, the TNF protein comprises between 95% and 98%, or 95% and 99% sequence identity to SEQ ID NO: 31 or residues 77-233 of SEQ ID NO: 31. In some instances, the TNF protein comprises about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity to SEQ ID NO: 31 or residues 77-233 of SEQ ID NO: 31. In some embodiments, the TNF protein comprises SEQ ID NO: 31 or residues 77-233 of SEQ ID NO: 31.
- In some embodiments, the MYXV comprises (e.g., encodes) a non-viral molecule, for example, comprises a transgene that encodes interleukin-12 (IL-12) protein. In some embodiments, the IL-12 protein is a human IL-12 protein. In some embodiments, the IL-12 protein is soluble. In some embodiments, the IL-12 protein is membrane- or surface-bound. In some embodiments, the IL-12 protein further enhances the anti-cancer activity of the MYXV by promoting immune cell differentiation or eliciting immune cell cytotoxicity.
- In some embodiments, IL-12 comprises an IL12a subunit (p35 subunit). In some embodiments, the IL-12α subunit is encoded by an IL-12α gene. In some embodiments, the IL-12a gene is a human IL-12α gene. In some embodiments, the IL-12α gene is driven by an IRES. In some embodiments, the IL-12α gene is driven by a promoter such as an sE/L promoter. In some embodiments, IL-12α gene replaces or disrupts the M153 gene. In some embodiments, IL-12α gene is inserted in the intergenic region between an M135R gene and an M136R gene of the MYXV genome.
- In some embodiments, IL-12 comprises an IL12β (p40) subunit. In some embodiments, the IL-12β subunit is encoded by an IL-12β gene. In some embodiment, the IL-12β gene is a human IL-12β gene. In some embodiments, the IL-12β gene is driven by an IRES. In some embodiments, the IL-12β gene is driven by a promoter such as an sE/L promoter. In some embodiments, IL-12β gene replaces or disrupts an MYXV M153 gene. In some embodiments, IL-12β gene is inserted in the intergenic region between an M135R gene and an M136R gene of the MYXV genome.
- In some embodiments, IL-12 comprises an IL12a subunit and an IL-12β subunit. In some embodiments the IL12a subunit and the IL-12β subunit are covalently linked. In some embodiments the IL12a subunit and the IL-12β subunit are not covalently linked. In some embodiments the IL12α subunit and the IL-12β subunit are expressed as one transcript. In some embodiments the IL12α subunit and the IL-12β subunit are expressed as one polypeptide, for example, with a peptide linker joining the two subunits. A linker sequence can be, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acid residues in length. A linker can be at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 amino acid residues in length. A linker can be at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, at most 10, at most 15, at most 20, at most 25, at most 30, at most 40, or at most 50 amino acid residues in length. A flexible linker can have a sequence containing stretches of glycine and serine residues. The small size of the glycine and serine residues provides flexibility, and allows for mobility of the connected functional domains. The incorporation of serine or threonine can maintain the stability of the linker in aqueous solutions by forming hydrogen bonds with the water molecules, thereby reducing unfavorable interactions between the linker and protein moieties. Flexible linkers can also contain additional amino acids such as threonine and alanine to maintain flexibility, as well as polar amino acids such as lysine and glutamine to improve solubility. A rigid linker can have, for example, an alpha helix-structure. An alpha-helical rigid linker can act as a spacer between protein domains. A linker can comprise any of the sequences of SEQ ID NOs: 33-43, or repeats thereof. SEQ ID NOs: 33-38 and 43 provide examples flexible linker sequences. SEQ ID NOs: 39-42 provide examples of rigid linker sequences.
- In some embodiments, the MYXV expresses a relatively low level of IL-12. Relatively lower expression of IL-12 can be achieved, for example, by use of an IRES sequence between the sequences that encode the IL-12 subunits. In some embodiments, the MYXV expresses a relatively high level of IL-12. Relatively higher expression of IL-12 can be achieved, for example, by use of a suitable linker that joins the subunits of IL-12 in a single polypeptide, for example, an elastin linker, such as the linker of SEQ ID NO: 43.
- In some embodiments, a level of IL-12 expression can be as determined by the assay of example 6. For example, vero cells can be infected with a MYXV of the disclosure at an MOI of 1, supernatant can be harvested at 24 hours post-infection, and the amount of IL-12 can be measured by ELISA. In some embodiments, a low level of IL-12 expression can be less than 50, less than 40, less than 30, less than 20, less than 10, or less than 5 ng/mL of IL-12 as determined by the assay of example 6. In some embodiments, a high level of IL-12 expression can be more than 20, more than 30, more than 40, more than 50, more than 60, more than 70, more than 80, more than 90, more than 100, or more than 150 ng/mL of IL-12 as determined by the assay of example 6. In some embodiments, a high level of IL-12 expression can be more than 20 ng/mL of IL-12, and a low level of IL-12 expression can be less than 20 ng/mL of IL-12.
- In some embodiments, one or both of the IL-12 subunits can be truncated. An example of an IL-12 with a truncated subunit is provided in SEQ ID NO: 50, which comprises mouse IL-12 B (SEQ ID NO: 51), an elastin linker (SEQ ID NO: 43), and a truncated mouse IL-12 A (SEQ ID NO: 52).
- IL-12 is a cytokine. In some embodiments, IL-12 promotes T helper type 1 (Th1) differentiation, and enhances the cytotoxicity of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). In some embodiments, the actions of this IL-12 create an improved interconnection between the elements of innate and adaptive immunity to promote an anti-cancer immune response. In some embodiments, due to this bridging the innate and adaptive immunity, IL-12 enhances the anti-tumor effects of the MYXV. In some embodiments, IL-112 potently stimulates production of IFN-γ (a cytokine that coordinates mechanisms of anticancer defense), thereby enhancing the anti-tumor effects of the MYXV.
- Clinical trials of systemic delivery of recombinant IL-12 cytokine therapy have not induced satisfactory outcomes in cancer patients due to toxicity events, the transient nature of systemically administered IL-12, and tumor-induced immunosuppression. Nevertheless, viruses expressing IL-12 locally within the tumor microenvironment (TME) may result in potent antitumor efficacy. In some embodiments, expression of IL-12 from an oncolytic virus that is restricted to tumor beds, such that the transgenes are expressed locally within the TME, reduces the toxic effects associated with the systemic delivery of this cytokine. Thus, in some embodiments, the co-expression of the two subunits of IL-12 improves the anti-tumor immunity induced by armed-MYXV against different type of cancers.
- In some instances, the IL12α subunit comprises at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 28, residues 35-253 of SEQ ID NO: 28, or residues 57-253 of SEQ ID NO: 28. In some instances, the IL12α subunit comprises between 95% and 98%, or 95% and 99% sequence identity to SEQ ID NO: 28, residues 35-253 of SEQ ID NO: 28, or residues 57-253 of SEQ ID NO: 28. In some instances, the IL12α subunit comprises about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity to SEQ ID NO: 28, residues 35-253 of SEQ ID NO: 28, or residues 57-253 of SEQ ID NO: 28. In some embodiments, the IL12α subunit comprises SEQ ID NO: 28, residues 35-253 of SEQ ID NO: 28, or residues 57-253 of SEQ ID NO: 28.
- In some instances, the IL-12β subunit comprises at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 29 or residues 23-328 of SEQ ID NO: 29. In some instances, the IL-12β subunit comprises between 95% and 98%, or 95% and 99% sequence identity to SEQ ID NO: 29 or residues 23-328 of SEQ ID NO: 29. In some instances, the IL-12β subunit comprises about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity to SEQ ID NO: 29 or residues 23-328 of SEQ ID NO: 29. In some embodiments, the IL-120 subunit comprises SEQ ID NO: 29 or residues 23-328 of SEQ ID NO: 29.
- In some embodiments, the MYXV comprises (e.g., encodes) a non-viral molecule, for example, comprises a transgene that encodes decorin. In some embodiments, the decorin protein is a human decorin protein. In some embodiments, the decorin protein is soluble. In some embodiments, the decorin protein is membrane- or surface-bound. In some embodiments, the decorin protein enhances the anti-cancer activity of the MYXV by blocking or decreasing TGF-β signaling.
- In some embodiments, the decorin protein is encoded by a decorin gene. In some embodiments, the decorin gene is a human decorin gene. In some embodiments, the decorin gene is driven by an IRES. In some embodiments, the decorin gene is driven by a promoter such as an sE/L promoter. In some embodiments, the decorin gene replaces or disrupts an M153 gene. In some embodiments, the decorin gene is inserted in the intergenic region between an M135R gene and an M136R gene of the MYXV genome.
- Decorin is a member of the extracellular matrix proteoglycans family that exists and functions within stromal tissues and epithelial cells. In some embodiments, decorin affects the biology of different types of cancer by directly or indirectly targeting signaling molecules involved in cell growth, survival, metastasis and/or angiogenesis. In some embodiments, decorin blocks TGF-β-induced signaling. In some embodiments, TGF-β is a cytokine that contributes to immune suppression in some tumor microenvironments (TMEs). In some cases, TGF-β converts effector T-cells, which may otherwise recognize and attack cancer cells, into regulatory (suppressor) T-cells, which instead turn off the innate inflammatory reactions and acquired immune pathways needed to recognize and eliminate the cancer cells. In multiple type of cancers, parts of the TGF-β signaling pathways are mutated, and this cytokine no longer controls at least some of the cell targets. These cancer cells may proliferate and increase their endogenous production of TGF-β, which may act on the surrounding stromal cells, immune cells, endothelial and smooth-muscle, causing local immunosuppression within the cancer tissue and tumor bed angiogenesis, which makes the cancer even more invasive. Hence, in some embodiments, an oncolytic MYXV vector expressing decorin blocks TGF-β directly within the TME and thereby induces a stronger anti-tumor immune response than a MYXV not expressing the decorin.
- Additionally, decorin can inhibit tumor cell growth and proliferation. Viral delivery of decorin into various solid tumors may directly counteract tumorigenesis. In some embodiments, decorin is used as an anti-cancer target for at least some types of cancer that are protected by the local over-expression of TGF-β.
- In some embodiments, the decorin is encoded by a gene comprising the sequence of SEQ ID NO: 25. In some embodiments, the gene encoding the decorin comprises a sequence that is 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, or a range of percentages defined by any two of the aforementioned percentages, identical to that of SEQ ID NO: 25. In some instances, the decorin is encoded by a gene comprising at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 25. In some instances, the decorin is encoded by a gene comprising between 95% and 98%, or 95% and 99% sequence identity to SEQ ID NO: 25. In some instances, the decorin is encoded by a gene comprising about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity to SEQ ID NO: 25.
- In some instances, the decorin protein comprises at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to residues 31-359 of SEQ ID NO: 14, or any one of SEQ ID NOs: 14-19. In some instances, the decorin protein comprises between 95% and 98%, or 95% and 99% sequence identity to residues 31-359 of SEQ ID NO: 14, or any one of SEQ ID NOs: 14-19. In some instances, the decorin protein comprises about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity to residues 31-359 of SEQ ID NO: 14, or any one of SEQ ID NOs: 14-19. In some embodiments, the decorin protein comprises residues 31-359 of SEQ ID NO: 14, or any one of SEQ ID NOs: 14-19.
- Disclosed herein, in certain embodiments, are recombinant nucleic acids. Some embodiments relate to a recombinant nucleic acid comprising at least a portion of a MYXV genome. In some embodiments, the recombinant nucleic acid comprises DNA. In some embodiments, the MYXV genome or the portion of the MYXV genome is modified to reduce expression of M153 gene. In some embodiments, the M153 gene is modified to knock out at least a portion of the M153 gene in the MYXV genome.
- In some embodiments, the recombinant nucleic acid is engineered to introduce a mutation to the M153 gene. The mutation can comprise, for example, an insertion, deletion, substation, or a combination thereof. In some embodiments, the recombinant nucleic acid comprises a gene knock-in where the M153 gene is disrupted.
- In some embodiments, the recombinant nucleic acid comprises a nucleic acid that encodes a non-viral molecule. In some embodiments, the recombinant nucleic acid comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more nucleic acid that encode non-viral molecule, for example, transgenes that encode proteins.
- In some embodiments, the recombinant nucleic acid comprises a nucleic acid that encodes tumor necrosis factor alpha (TNFα). In some embodiments, the TNFα is a human TNFα. In some embodiments, the nucleic acid that encodes the TNFα replaces or is adjacent to an M135R gene of the MYXV genome. In some embodiments, the nucleic acid that encodes the TNFα is inserted between an M135R gene and an M136R gene of the MYXV genome. In some embodiments, expression of TNFα is driven by a poxvirus synthetic early/late (sE/L) promoter. In some embodiments, the nucleic acid that encodes the TNFα replaces or is adjacent to an M153 gene of the MYXV genome.
- In some embodiments, the recombinant nucleic acid comprises a nucleic acid that encodes an interleukin-12 subunit alpha (IL-12α). In some embodiments, the IL-12α is a human IL-12α. In some embodiments, expression of the IL-12α is driven by an internal ribosome entry site (IRES). In some embodiments, the nucleic acid that encodes IL-12α disrupts expression of an M153 gene of the MYXV genome.
- In some embodiments, the recombinant nucleic acid comprises a nucleic acid that encodes an interleukin-12 subunit beta (IL-12β). In some embodiments, the IL-12β is a human IL-12β gene. In some embodiments, expression of the IL-12β is driven by an sE/L promoter. In some embodiments, the nucleic acid that encodes IL-12β disrupts expression of an M153 gene of the MYXV genome. In some embodiments, the nucleic acid that encodes IL-12β and the nucleic acid that encodes IL-12α both disrupt expression of an M153 gene of the MYXV genome.
- In some embodiments, the recombinant nucleic acid comprises a nucleic acid that encodes decorin. In some embodiments, the decorin is a human decorin. In some embodiments, expression of the decorin is driven by an sE/L promoter. In some embodiments, the recombinant nucleic acid comprises a nucleic acid that encodes decorin disrupts expression of an M153 gene of the MYXV genome.
- In some embodiments, the recombinant nucleic acid comprises a nucleic acid that encodes a reporter tag, for example, a fluorescent protein. In some embodiments, the reporter tag comprises a green fluorescent protein (GFP). In some embodiments, expression of the reporter tag is driven by an sE/L promoter. In some embodiments, the recombinant nucleic acid further comprises a nucleic acid that encodes a second reporter tag. In some embodiments, the second reporter tag comprises a red fluorescent protein (RFP), e.g., dsRed. In some embodiments, expression of the second reporter tag is driven by a poxvirus P11 late promoter. In some embodiments, the nucleic acid that encodes the second reporter tag disrupts expression of an M153 gene of the MYXV genome.
- In some embodiments, the recombinant nucleic acid comprises a vMyx-hTNFa cassette, optionally comprising GFP. In some embodiments, the recombinant nucleic acid comprises an hDecorin-hIL-12 cassette, optionally comprising dsRed. In some embodiments, the recombinant nucleic acid comprises or consists of a vMyx-hTNFa-hDecorin-hIL-12-M153KO (vMyx-Triple) cassette, optionally comprising GFP and/or dsRed.
- Disclosed herein, in certain embodiments, are compositions comprising a MYXV as described herein. In some embodiments, the composition comprises a pharmaceutical composition. In some embodiments, the composition comprises a pharmaceutically acceptable carrier or excipient.
- In some embodiments, the pharmaceutically acceptable carrier comprises an injectable fluid such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like. In some embodiments, the composition comprises a solid composition such as a powder, pill, tablet, or capsule. In some embodiments such as those including solid compositions, the pharmaceutically acceptable carrier comprises mannitol, lactose, starch, or magnesium stearate. In some embodiments, the pharmaceutically acceptable carrier comprises a biologically-neutral carrier. In some embodiments, the composition comprises wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
- In some embodiments, the identity or proportion of the pharmaceutically acceptable carrier or excipient is determined based on a route of administration, compatibility with a live virus, or standard pharmaceutical practice. In some embodiments, the pharmaceutical composition is formulated with components that do not significantly impair the biological properties of the MYXV. The pharmaceutical composition can be prepared by known methods for the preparation of pharmaceutically acceptable compositions suitable for administration to subjects, such that an effective quantity of the active substance or substances is combined in a mixture with a pharmaceutically acceptable vehicle. In some embodiments, the composition includes solutions of the MYXV in association with one or more pharmaceutically acceptable excipient, vehicles, or diluents, and contained in buffer solutions with a suitable pH and iso-osmotic with physiological fluids.
- In some embodiments, the pharmaceutical composition is formulated for administration to a subject. The pharmaceutical composition may be administered to a subject in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art. In some instances, the pharmaceutical composition is administered systemically, or formulated for systemic administration. In some embodiments, the pharmaceutical composition is administered locally, or formulated for local administration.
- In some embodiments, the pharmaceutical composition is administered parenterally, or formulated for parenteral administration. Examples of parenteral administration include intravenous, intratumoral, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, rectal and topical modes of administration. Parenteral administration may be by continuous infusion over a selected period of time.
- In some embodiments, the pharmaceutical composition is administered orally, or formulated for oral administration. The pharmaceutical composition may be administered orally, for example, with an inert diluent or with a carrier, or it may be enclosed in hard or soft shell gelatin capsules, or it may be compressed into tablets. For oral therapeutic administration, the MYXV may be incorporated with an excipient and be used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers and the like.
- Solutions of MYXV may be prepared in a physiologically suitable buffer. In some embodiments, under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms, but that will not inactivate the live virus. In some embodiments, a dose of the pharmaceutical composition to be used depends on the particular condition being treated, the severity of the condition, the individual subject parameters including age, physical condition, size and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and other similar factors that are within the knowledge and expertise of the health practitioner. In certain embodiments, the therapeutic virus may be freeze dried for storage at room temperature.
- The pharmaceutical compositions may additionally contain additional therapeutic agents, such as additional anti-cancer agents. In some embodiments, the compositions include a chemotherapeutic agent. The chemotherapeutic agent, for example, may be substantially any agent, which exhibits an oncolytic effect against cancer cells or neoplastic cells of the subject and that does not inhibit or diminish the tumor killing effect of the MYXV. For example, the chemotherapeutic agent may be, without limitation, an anthracycline, an alkylating agent, an alkyl sulfonate, an aziridine, an ethylenimine, a methylmelamine, a nitrogen mustard, a nitrosourea, an antibiotic, an antimetabolite, a folic acid analogue, a purine analogue, a pyrimidine analogue, an enzyme, a podophyllotoxin, a platinum-containing agent or a cytokine. Preferably, the chemotherapeutic agent is one that is known to be effective against the particular cell type that is cancerous or neoplastic. In some cases, the additional therapeutic agent comprises an immune checkpoint modulator.
- In some embodiments, the composition comprises peripheral blood mononuclear cells (PBMCs), bone marrow (BM) cells, or a combination thereof treated ex vivo by an MYXV as described herein. In some embodiments, the PBMCs, BM cells, or a combination thereof comprise autologous cells. In some embodiments, the PBMCs, BM cells, or a combination thereof are obtained from an allogeneic donor. In some embodiments, the PBMCs, BM cells, or a combination thereof are obtained from heterologous donors.
- Disclosed herein, in certain embodiments, are methods of inhibiting, alleviating, or preventing a cancer in a subject in need thereof, comprising administering to the subject a composition or pharmaceutical composition as described herein. In certain embodiments, the method includes administering to a subject, such as a human subject, a MYXV as described herein, thereby treating and/or inhibiting the cancer in the subject in need thereof.
- Some embodiments include prophylactic treatment with the MYXV. In some embodiments, the subject has, is suspected of having, or is at risk of having the cancer. Some embodiments include selecting the subject suspected of having. Some embodiments include selecting the subject at risk of having the cancer. In some embodiments, the subject has the cancer. In some embodiments, the methods include selecting the subject with the cancer.
- In some embodiments, the subject is a human. In some embodiments, the subject is a patient. In some embodiments, the subject is an animal or nonhuman animal. Examples of nonhuman animals include vertebrates such as mammals and non-mammals. Some examples of mammals include nonhuman primates, sheep, dog, cat, horse, cow, and rodents such as mice and rats.
- In some embodiments, the cancer is a solid tumor. Examples of solid tumors such as sarcomas and carcinomas include but are not limited to fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, osteogenic sarcoma, and other sarcomas, synovioma, mesothelioma, Ewing's sarcoma, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, lymphoid malignancy, pancreatic cancer, breast cancer, lung cancers, non-small cell lung cancer, ovarian cancer, prostate cancer, hepatocellular carcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, Wilms' tumor, cervical cancer, testicular tumor, bladder carcinoma, and CNS tumors (such as a glioma, astrocytoma, medulloblastoma, craniopharyogioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma and retinoblastoma). In some embodiments, the cancer comprises an osteosarcoma, triple negative breast cancer, or melanoma.
- In some embodiments, the cancer has metastasized to a location in the subject. In some embodiments, the location comprises a lung, a brain, a liver and/or a lymph node of the subject.
- In some embodiments, the cancer comprises a hematologic cancer such as Hodgkin's lymphoma or non-Hodgkin's lymphoma. In some embodiments, the hematologic cancers include B-cell or T-cell hematologic cancer.
- In some embodiments, the composition reduces cancer cell viability, or activates immunogenic cell death in the cancer. In some embodiments, the cancer is inhibited, alleviated, or prevented upon administration of the composition. In some embodiments, the administration improves the subject's survival.
- MYXV or the composition comprising the MYXV can be administered to the subject using standard methods of administration. In some embodiments, the virus or the composition comprising the virus is administered systemically (e.g., IV injection). In some embodiments, the virus or the composition comprising the virus is administered by injection at the disease site (e.g., intratumorally). In some embodiments, the virus or the composition comprising the virus is administered orally or parenterally, or by any standard method known in the art. In certain embodiments, the MYXV or the composition comprising the MYXV is administered at a site of a tumor and/or metastasis.
- The MYXV can be administered initially in a suitable amount that may be adjusted as required, depending on the clinical response of the subject. The effective amount of virus can be determined empirically and depends on the maximal amount of the MYXV that can be administered safely, and the minimal amount of the virus that produces the desired result.
- The concentration of virus to be administered may vary depending on the virulence of the particular strain of MYXV that is to be administered and on the nature of the cells that are being targeted. In one embodiment, a dose of less than about 3×1010 focus forming units (“ffu”), also called “infectious units”, is administered to a human subject, in various embodiments, between about 102 to about 109 pfu, between about 102 to about 107 pfu, between about 103 to about 106 pfu, or between about 104 to about 105 pfu may be administered in a single dose.
- In some embodiments, the MYXV is administered at a dose and schedule effective to increase expression of a cytokine by immune cells (e.g., PBMCs) in the subject. The expression of a cytokine by immune cells can be increased, for example, by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 50-fold, at least about 100-fold, at least about 1000-fold, or at least about 1000-fold. In some embodiments, the MYXV is administered at a dose and schedule effective to increase expression of two, three, four, five, six, or more cytokines by immune cells in the subject. In some embodiments, the MYXV is administered at a dose and schedule effective to increase expression of at least one, at least two, at least three, at least four, at least five, at least six, or more cytokines by immune cells in the subject. The cytokines can comprise, for example, IFN-γ, IL-2, IL-6, IL-10, IL-12, TNF-α, or any combination thereof. In some embodiments, expression of TNF-α is increased. In some embodiments, expression of IL-12 is increased. In some embodiments, expression of decorin is increased. In some embodiments, expression of IFN-γ is increased.
- In some embodiments, the MYXV is administered at a dose and schedule effective to increase expression of a cytokine by cancer cells in the subject. The expression of a cytokine by cancer cells can be increased, for example, by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 50-fold, at least about 100-fold, at least about 1000-fold, or at least about 1000-fold. In some embodiments, the MYXV is administered at a dose and schedule effective to increase expression of two, three, four, five, six, or more cytokines by cancer cells in the subject. In some embodiments, the MYXV is administered at a dose and schedule effective to increase expression of at least one, at least two, at least three, at least four, at least five, at least six, or more cytokines by cancer cells in the subject. The cytokines can comprise, for example, IFN-γ, IL-2, IL-6, IL-10, IL-12, TNF-α, or any combination thereof. In some embodiments, expression of TNF-α is increased. In some embodiments, expression of IL-12 is increased. In some embodiments, expression of decorin is increased. In some embodiments, expression of IFN-γ is increased.
- In some embodiments, the MYXV is administered at a dose and schedule effective to reduce the volume of a tumor in the subject. The volume of the tumor can be reduced, for example, by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%.
- In some embodiments, the MYXV is administered at a dose and schedule effective to reduce the rate of tumor or cancer cell growth in the subject. The rate of tumor or cancer cell growth can be reduced, for example, by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%.
- The MYXV can be administered as a sole therapy or may be administered in combination with other therapies, including chemotherapy, immunotherapy and/or radiation therapy. For example, the MYXV can be administered either prior to or following surgical removal of a primary tumor or prior to, concurrently with or following treatment such as administration of radiotherapy or conventional chemotherapeutic drugs. In some embodiments, the MYXV can be administered at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 1.5 weeks, 2 weeks, or 3 weeks before the other therapy. In some embodiments, the MYXV can be administered at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 1.5 weeks, 2 weeks, or 3 weeks after the other therapy. In some embodiments, the MYXV can be administered within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days of the other therapy. In some embodiments, the MYXV can be administered concurrently with the other therapy.
- Some embodiments further comprise administering to the subject an additional therapeutic agent. In some embodiments, the additional therapeutic agent is an immune checkpoint modulator. In some embodiments, the additional therapeutic agent is administered to the subject before administering the composition. In some embodiments, the additional therapeutic agent is administered to the subject after administering the composition. In some embodiments, the additional therapeutic agent is administered to the subject as a combination with the composition.
- In some embodiments, the additional therapeutic agent comprises an immune modulator, for example, an immune checkpoint modulator or inhibitor. Exemplary immune checkpoint modulators include, but are not limited to, PD-L1 inhibitors such as durvalumab (Imfinzi) from AstraZeneca, atezolizumab (MPDL3280A) from Genentech, avelumab from EMD Serono/Pfizer, CX-072 from CytomX Therapeutics, FAZ053 from Novartis Pharmaceuticals, KNO35 from 3D Medicine/Alphamab, LY3300054 from Eli Lilly, or M7824 (anti-PD-L1/TGFbeta trap) from EMD Serono; PD-L2 inhibitors such as GlaxoSmithKline's AMP-224 (Amplimmune), and rHIgM12B7; PD-1 inhibitors such as nivolumab (Opdivo) from Bristol-Myers Squibb, pembrolizumab (Keytruda) from Merck, AGEN 2034 from Agenus, BGB-A317 from BeiGene, B1-754091 from Boehringer-Ingelheim Pharmaceuticals, CBT-501 (genolimzumab) from CBT Pharmaceuticals, INCSHR1210 from Incyte, JNJ-63723283 from Janssen Research & Development, MEDI0680 from Medlmmune, MGA 012 from MacroGenics, PDR001 from Novartis Pharmaceuticals, PF-06801591 from Pfizer, REGN2810 (SAR439684) from Regeneron Pharmaceuticals/Sanofi, or TSR-042 from TESARO; CTLA-4 inhibitors such as ipilimumab (also known as Yervoy®, MDX-010, BMS-734016 and MDX-101) from Bristol Meyers Squibb, tremelimumab (CP-675,206, ticilimumab) from Pfizer, or AGEN 1884 from Agenus; LAG3 inhibitors such as BMS-986016 from Bristol-Myers Squibb, IMP701 from Novartis Pharmaceuticals, LAG525 from Novartis Pharmaceuticals, or REGN3767 from Regeneron Pharmaceuticals; B7-H3 inhibitors such as enoblituzumab (MGA271) from MacroGenics; MR inhibitors such as Lirilumab (IPH2101; BMS-986015) from Innate Pharma; CD137 inhibitors such as urelumab (BMS-663513, Bristol-Myers Squibb), PF-05082566 (anti-4-1BB, PF-2566, Pfizer), or XmAb-5592 (Xencor); PS inhibitors such as Bavituximab; and inhibitors such as an antibody or fragments (e.g., a monoclonal antibody, a human, humanized, or chimeric antibody) thereof, RNAi molecules, or small molecules to TIM3, CD52, CD30, CD20, CD33, CD27, OX40, GITR, ICOS, BTLA (CD272), CD160, 2B4, LAIR1, TIGHT, LIGHT, DR3, CD226, CD2, or SLAM.
- Further disclosed is a delivery strategy where the therapeutic MYXV virus is first adsorbed ex vivo to mixed leukocytes from either bone marrow or peripheral blood mononuclear cells prior to infusion, such as re-infusion back, into the cancer patient. In this strategy, MYXV can be delivered to metastatic cancer sites via migration of leukocytes pre-infected with virus ex vivo. This systemic delivery method is sometimes called “ex vivo virotherapy”, or EVV (aka EV2), because the virus is first delivered to isolated leukocytes prior to infusion into the patient. The MYXV construct and this delivery strategy may significantly reduce tumor burden and increase survival in a subject in need thereof. In some embodiments, the BM or PBMC cells are adsorbed with MYXV constructs for one hour ex vivo, and then the MYXV-loaded leukocytes are infused back into the recipient.
- In certain embodiments, the mononuclear peripheral blood cells and/or bone marrow cells are obtained from the subject, for example as autologous cells. In some embodiments, the mononuclear peripheral blood cells and/or bone marrow cells are obtained from one or more allogeneic donors, for example, a donor that is matched to the recipient for at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8 HLA alleles (such as one or both copies of HLA-A, HLA-B, HLA-A, and/or HLA-DR alleles). HLA alleles can be types, for example, using DNA-based methods. In some embodiments, the mononuclear peripheral blood cells and/or bone marrow cells are obtained from one or more heterologous donors.
- These examples are provided for illustrative purposes only and not to limit the scope of the claims provided herein.
- Recombinant plasmids were designed for insertion of hDecorin, and hIL12 nucleic acid sequences at the myxoma virus M153 locus, with or without a dsRed nucleic acid sequence. A human Decorin gene was PCR amplified from a cDNA ORF clone from OHu16408 (GenScript). Human subunits IL-12 p35 and p40 were obtained from vMyx-huIL-12-GFP described in Journal of Virology, November 2007, P. 12704-12708, the disclosure of which is incorporated herein by reference. A red fluorescent protein (dsRed) gene was inserted immediately downstream of a hDecorin-hIL-12 expression cassette, and its expression was driven by a poxvirus P11 late promoter. This recombinant nucleic acid is referred to as vMyx-Triple or vMyx-Triple-red. The dsRed served as a fluorescent marker for MYXV replication in vitro and in vivo, as MYXV infection could be monitored by live imaging of dsRed expression. A second version of this recombinant nucleic acid was made that lacked the dsRed marker (referred to as vMyx-Triple-white).
-
FIG. 1A diagrams construction of a vMyx-Triple recombinant nucleic acid. The top image depicts a vMyx-hTNFa-GFP genome and the insertion site (M153 locus) of the expressing hDecorin-hIL-12-dsRed cassette. The middle image shows the hDecorin-hIL-12-dsRed cassette, and the bottom image shows a vMyx-Triple construct. Decorin and IL-12 transgenes in the hDecorin-hIL-12-dsRed cassette were expressed under the control of a poxvirus synthetic early/late promoter (sE/L), while expression of dsRed was controlled by the poxvirus late promoter, P11. The vMyx-Triple-white construct is identical to vMyx-Triple-red but lacks the dsRed cassette. - To create the vMyx-Triple and vMyx-Triple-white viruses, a recombinant plasmid was first constructed using Gateway System (ThermoFisher Scientific). Upstream and downstream hybridizing sequences were amplified by PCR to generate entry clones by Gateway BP recombination with appropriate pDONR vectors. The final recombinant plasmid was constructed by recombining three entry clones with a destination vector in a sequential manner. The hDecorin-hIL12-dsRed expression cassette was inserted into the MYXV genome by infecting RK13 cells with vMyx-hTNFa-GFP virus and then transfecting with an appropriate recombination plasmid. Multiple rounds of foci purification were conducted to obtain pure stocks of recombinant virus, using the fluorescent dsRed protein as a selection marker. The presence of the transgenes was confirmed by PCR (
FIGS. 2A and 2B ) using specific primers for hTNF, hDecorin and hIL-12. This PCR analysis shown in these figures verified that transgenes were present in various vMyx-Triple clones, and the bands shown in the figures were at the expected sizes. Table 1 includes primer sequences used in generating the constructs. -
TABLE 1 SEQ ID NO Name Primer Sequence 1 hTNF_F GGGGACAACTTTTCTATACAAAGTTGCCAAAAATTGA AATTTTATTTTTTTTTTTTGGGA 2 hTNF_R GGGGACACCTTTATTATACAAAGTTGAGGGCAATGAT CCCAAAGT 3 AttB4r_hDCN_F GGGACAACTTTTCTATACAAAGTTGCCAAAATTGAAA TTTTATTTTTTTTTTTTGGAATATAAATAATGAAGGCC ACTATCATCCTCC 4 hDCN_R_Over CTGGATCTATCAACAGGAGTCCAAGCTTACTTATAGTT TCCGAGTTG 5 hIL12_F_Over GCTTGGACTCCTGTTGATAGATCCAGAAAAATTGAAA TTTTATTTTTTTTTTTTGGAATATAAATAATGTGTCACC AGCAGTTGGTCATC 6 AttB3r_hIL12_R GGGGACAACTTTATTATACAAAGTTGTTTAGGAAGCA TTCAGATAGCTCATC 7 attB1_M152_F GGGGACAAGTTTGTACAAAAAAGCAGGCTCGTAGACG CGGTGTTTCTATCC 8 M154-attB2- R GGGGACCACTTTGTACAAGAAAGCTGGGTAAACGTAA CACCGTAACTGCC 9 M153- F ATGGCTACTGTTGTAAACATGG 10 M153-Rev CTAAGCGGGTGACTCCACGACG - The purity of the recombinant vMyx-Triple and vMyx-Triple-white viruses, and the lack of M153, was confirmed by PCR using the appropriate primer sets (
FIGS. 2C and 2D ). The PCR analysis shown inFIG. 2C verified that the clones were clean of wild type virus, by using primers in the flanking regions of 135 and 136 genes. A western blot confirmed protein expression of the three transgenes (FIGS. 3A-3C ). Thus, recombinant MYXVs expressing transgenic human TNFα, decorin, and IL-12, and lacking M153, were generated (vMyx-Triple). Antibodies used to detect transgene expression were as follows: human TNF-α: Monoclonal Mouse IgG1 Clone #28401 (MAB610-100, R&D Systems); human Decorin: Rabbit polyclonal antibody (ab175404, Abcam); human IL-12: Rabbit polyclonal to IL-12 p70 antibody (ab25105, Abcam). - Recombinant MYXV that expresses mouse IL-12 rather than human IL-12 were generated using the same Gateway System (ThermoFisher Scientific) as used for the viruses expressing human IL-12. A virus that expresses relatively lower levels of mouse IL-12 was generated using a synthetic early/late promoter with an IRES sequence between the subunits of IL-12 (msTriple IL-12 low), and a vMyxv-msTriple that expresses relatively higher levels of mouse IL-12 was generated using a synthetic early/late promoter with mouse IL-12 that contained an Elastin linker between the subunits of IL-12 (msTriple IL-12 high).
- The replication capacity of the vMyx-Triple virus prepared in Example 1 was tested in RK13 cells. The replication capacity of vMyx-Triple virus was similar to the parental vMyx-hTNFa-GFP virus (
FIG. 4 ). Thus, a recombinant MYXV expressing transgenic human TNFα, decorin, and IL-12, and lacking M153, effectively replicated in host cells. - Next, the cell killing capacity of the vMyx-Triple virus was tested in two different cell lines: CT26 (colon carcinoma) and HELA (human cervical cancer (
FIGS. 5A and 5B ). To measure cell viability (and thus infer cytotoxicity), a CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) was used (Promega, USA). CT26 and HELA cells were infected with the different viruses for 48 hr at a multiplicity of infection (MOI) of 10. After 48 hours, a tetrazolium substrate (MTS) was added to the CT26 and HELA cells and an A490 formazan product produced in viable cells was measured using a microplate reader after 2 hr of incubation. Each sample was quantified in triplicate and a total of two independent experiments were performed. The vMyx-Triple virus induced similar levels of cell death in both cell lines, as compared with the parental virus vMyx-hTNFa, and also as compared with vMyx-GFP. There was a trend towards increased cancer cell killing by the vMyx-Triple virus compared to the other viruses. Thus, a recombinant MYXV expressing transgenic human TNFα, decorin, and IL-12, and lacking M153, was cytotoxic to cancer cells. -
FIG. 1B diagrams the M153 locus, which can be modified in recombinant nucleic acids and MYXV of the disclosure. The modification can include a mutation in the M153 sequence, for example, an insertion, a deletion, a substitution, or a combination thereof. The modification can attenuate an activity or expression level of M153. The modification can include deletion of M153 gene and/or replacement of M153 gene with one or more transgenes. The replacement gene can be selected from hTNFa, hDecorin, IL-12, or another transgene that help enhance the oncolytic activity or decrease adverse side effects of the MYXV. - To create the vMyx constructs, a recombinant plasmid can be first constructed using Gateway System (ThermoFisher Scientific). Upstream and downstream hybridizing sequences are amplified by PCR to generate entry clones by Gateway BP recombination with appropriate pDONR vectors. The final recombinant plasmid is constructed by recombining one or more entry clones with a destination vector in a sequential manner. The recombinant plasmid is inserted into the MYXV genome by infecting RK13 cells with vMyx and then transfecting with an appropriate recombination plasmid. Multiple rounds of foci purification are conducted to obtain pure stocks of recombinant virus. A selection marker can be used, such as a fluorescent protein, for example, dsRed. The presence of the transgenes can be confirmed by PCR and/or sequencing.
- An M153 knockout virus can be constructed in this manner. The recombinant plasmid can be designed to contain sequences that flank the sequence of the M153 gene, without the M153 gene sequence. Optionally, an expression cassette for a fluorescent protein can be included. The M153 knockout can be generated by infecting RK13 cells with MYXV, and transfecting the cells with the recombination plasmid. Multiple rounds of foci purification are conducted to obtain pure stocks of M153KO virus, optionally using the fluorescent protein as a selection marker. The M153 knockout and purity of the virus is confirmed via PCR analysis using suitable primers.
- The replication capacity of the modified vMyx virus can be tested in RK13 cells. The replication capacity of a modified vMyx virus can be similar to the parental vMyx virus. Next, the cell killing capacity of the modified vMyx virus is tested in two different cancer cell lines. To measure cell viability (and thus infer cytotoxicity), a CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) is used (Promega, USA). Cancer cells are infected with the different viruses for 48 hr at M01=10. After 48 hours, a tetrazolium substrate (MTS) is added to the cells and an A490 formazan product produced in viable cells is measured using a microplate reader after 2 hr of incubation. Each sample is quantified in triplicate and a total of two independent experiments is performed. The modified vMyx virus can induce similar levels of cell death in both cell lines, or higher levels of cell death, as compared with the parental virus vMyx, and also as compared with vMyx-GFP.
- Therapeutic transgenes can be added to MYXV at two types of genomic loci: as a disruption construct within protein coding genes, such that the recombinant virus is a genetic “knockout” of that virus gene, or else at “innocuous” intergenic locus that is predicted to not affect the biology or oncolytic potential of the recombinant virus. When endogenous virus genes are knocked out, it is possible that the new knockout construct will differ from the parental virus in terms of its oncolytic capacity against cancer cells, independent of which transgenes are inserted into the locus.
- The M153 gene of MYXV encodes an immunoregulatory protein from a family of E3-Ubiquitin ligases that participates in the down-regulation of diverse cellular receptors, including MHC class-I and CD4 proteins. Without wishing to be bound by theory, inactivation or knockdown of M153 can result in enhanced expression of MHC-I dependent immune epitopes, for example, increased direct presentation of viral and/or tumor antigens, thereby increasing recognition of virally infected cells (e.g., cancer cells) by host T cells. This allows a myxoma virus with an inactivated M153 gene to be used as an oncolytic vector. The data in this and the following example indicate that a M153 knockout myxoma virus (M153KO MYXV) backbone exhibited higher oncolytic activity in vitro and in vivo than a parental MYXV with an intact M153 gene in an immunocompetent model. As such, a M153KO MYXV without a transgene exhibited a greater oncolytic activity than the parental MYXV or wt MYXV. In addition, M153KO MYXV with one or more transgenes can also exhibit an enhanced oncolytic activity than the parental MYXV or wt MYXV.
- In B16F10 cells, a murine melanoma cell line, a M153KO MYXV was tested for induction of cell killing compared to a wild-type myxoma vim that contains an intact wild type M153 (wt MYXV). This M153KO MYXV did not include hTNFa, hDecorin, hIL-12A, or hIL-12B transgenes. The M153KO MYXV reduced cell viability in the B16F10 cells to a greater extent than the wt MYXV at early time points post-infection, up to approximately 36 hours post-infection (
FIG. 6 ). These results suggest that a MYXV with the M153 inactivation or knockdown induces cell death to a greater extent than a wild type or a MYXV without the M153 inactivation. - Based on this result, the possibility that the M153KO virus may induce a specific type of cell death, called Immunogenic Cell Death (ICD), was evaluated to determine the potential of the M153KO MYXV as an oncolytic vector to induce ICD in cancer cells. There are different hallmarks in vitro that can indicate induction of ICD, which can stimulate the immune system (for example, the adaptive immune system). In this case, two signals were the focus of this investigation: release of ATP to the extracellular environment, and expression of calreticulin on the surface of the cell or ecto-expression.
- The release of ATP from dying cells can indicate ICD. ATP release observed after infection with the wt MYXV was not significantly different from negative controls. On the other hand, the amount of ATP released after infection with the M153KO MYXV was higher than in untreated cells, and up to about four-fold higher than for cells infected by wt MYXV (see,
FIG. 7A , for example, the peak value at 10 hours post-infection). The peak result from M153KO MYXV infection was similar to the peak values obtained with a drug-induced positive control (Doxorubicin), but at a later time (FIG. 7A , see results at 640 hrs post-infection). Thus, a MYXV with an inactivation or knockdown of M153 has superior oncolytic properties compared to a wt MYXV or compared to a MYXV without the M153 inactivation or knockdown. In particular, a MYXV with the M153 inactivation or knockdown induces immunogenic cell death to a greater extent than a MYXV without the M153 inactivation or knockdown or a WT MYXV. - Calreticulin is usually expressed within the endoplasmic reticulum, but where ICD is occurring, it can be expressed on the cell surface (ecto-expression). Ecto-expression of calreticulin was evaluated using confocal microscopy and quantified using a ratio of the signal of the calreticulin observed per signal of a nuclear stain (DAPI) that represents each cell. In this case, the M135KO MYXV was used as a representation of an unarmed virus with a genetic knockout lesion in an unrelated viral gene (M135) that does not alter cell killing caused by the parental MYXV and behaves similarly to wt MYXV in this regard. The induction of ecto-expression of calreticulin higher in M153KO MYXV-infected cells than in M135KO MYXV-infected or Doxorubicin-treated cells (
FIG. 7B ). - Overall, these results showed that the M153KO MYXV can induce hallmarks of ICD in B16F10 cells in vitro, and may induce the immune system (e.g., the adaptive immune system) when used in vivo. Thus, a MYXV with a M153 inactivation or knockdown induces ICD in melanoma or cancer cells. A MYXV with a M153 inactivation or knockdown can also stimulate the immune system (e.g., the adaptive immune system).
- Additionally, studies were performed with a syngeneic metastatic melanoma mouse model, using the same murine cancer cell line, B16F10, as used for the in vitro studies. In this case, C57BL/6 mice were seeded via intravenous injections in the tail vein with B16F10 cells to induce dispersed metastatic melanoma lesions in the lungs. Three days after implantation of the melanoma cells, mice were treated with 2×107 ffu of M153KO MYXV or a saline control via intravenous injections in the retro-orbital area. Mice treated with one dose of the M153KO virus showed fewer signs of metastatic disease, and survived longer than the control mice (
FIG. 8 ). The M135KO MYXV contains a gene knockout in an unrelated virus gene involved in rabbit pathogenesis, and is used as a control here to measure any oncolytic effects caused by the virus in the absence of M153KO. In this model, M153KO virus provided significantly longer term survival compared to untreated control mice, but the M135KO virus did not. - These results show that M153KO MYXV can be used as an oncolytic vector platform with superior anti-cancer effects compared to a parental MYXV with an intact M153 gene or compared to a wt MYXV. Thus, a MYXV with a M153 inactivation or knockdown prolongs survival in a subject with cancer (for example, melanoma). The cancer or melanoma can be metastatic. The mice treated with M153 knockout showed significant improvement in survival rate and survival length than the control group
- This example demonstrates that cells infected with myxoma viruses of the disclosure secrete TNF, Decorin, and IL-12, and further demonstrates that the secreted TNF and IL-12 have biological activity.
- Vero cells were infected with vMyx-Triple (huTriple red and huTriple white), msTriple IL12 low, msTriple IL-12 hi, each at an MOI of 1. As a control, cells were infected with vMyx-GFP, which does not encode any of the cytokines, and contains an intact M153 gene. After 24 hours, supernatant was harvested and ELISA assays conducted to determine the concentration of each of the cytokines in supernatant (
FIGS. 9A-9D ). The results demonstrate that cells infected with the various vMyx-Triple viruses secrete TNF (FIG. 9A ), Decorin (FIG. 9B ), and IL-12 (FIG. 9C —human IL-12;FIG. 9D —murine IL-12). In contrast, the cytokines were not detected in mock-infected cells, or cells infected with vMyx-GFP. Infection with msTriple IL-12 hi was shown to elicit higher expression of mouse IL-12 than infection with msTriple IL-12 low. - To test whether the TNF secreted by infected cells was biologically active, an assay was conducted utilizing L929 cells, which are sensitive TNF, and lose viability upon sufficient exposure to biologically active TNF. L292 cells were exposed to supernatants from Vero cells that had been infected with the indicated viruses. As shown in
FIG. 10A , cells infected with the various vMyx-Triple viruses generate biologically-active TNF, while cells infected with vMyx-GFP do not. These results show that MYXV of the disclosure that encode TNF can elicit expression of biologically active TNF. - To test whether the IL-12 secreted by infected cells was biologically active, a HEK Blue IL-12 reporter assay was conducted. The HEK Blue IL-12 cells express a reporter gene in response to biologically active IL-12, and the reporter gene can be detected using a colorimetric assay. As shown in
FIG. 10B , supernatants from Vero cells infected with the vMyx-Triple viruses elicited reporter gene expression, while controls, including supernatants from cells infected with vMyx-GFP, did not. These results show that MYXV of the disclosure that encode IL-12 can elicit expression of biologically active IL-12. - The ability of vMyx-Triple to inhibit growth of multiple cancer cell lines was evaluated in vitro. Cells were infected at multiplicities of infection (MOI) of 0.1, 1, or 10 focus forming units (FFU) per cell. After incubation for 72 hours, cell viability was tested using a CellTiter-Glo Cell Viability Assay, and mean growth inhibition was determined. The results showed that vMyx-Triple could inhibit growth of a range of human and mouse cancer cell lines derived from different tissues. Results are provided in Table 2.
-
TABLE 2 Mean Growth Inhibition (%) vMyx-Triple Cell Line Tissue Type 0.1 ffu/cell 1 ffu/cell 10 ffu/cell MDA-MB-231 Human Breast 0.40 4.65 47.95 MDA-MB-468 Human Breast 2.35 1.60 45.90 HCT-116 Human Colon 0.80 2.20 5.80 COLO 205 Human Colon 2.95 12.45 71.30 RPMI-8226 Human Myeloma 0.00 13.30 87.35 CCRF-CEM Human Leukemia 24.85 25.35 39.35 SK-MEL-28 Human Melanoma 0.65 4.20 56.90 A375 Human Melanoma 0.00 8.70 62.60 A549 Human NSCLC 4.35 11.10 66.15 H460 Human NSCLC 3.55 4.90 21.50 OVCAR-3 Human Ovarian 5.30 0.70 1.75 SKOV-3 Human Ovarian 6.20 23.15 71.75 ASPC-1 Human Pancreas 16.55 18.75 48.70 Capan-1 Human Pancreas 1.30 1.05 3.25 PC-3 Human Prostate 0.30 2.15 33.15 DU-145 Human Prostate 4.35 5.60 43.00 786-0 Human Renal 1.45 2.00 69.05 RXF-393 Human Renal 1.30 4.95 29.15 Hep3B Human Liver 2.40 3.55 12.00 Hep-G2 Human Liver 4.70 8.45 63.60 MBT-2 Murine Bladder 16.25 32.30 57.90 4T-1 Murine Breast 0.05 0.35 10.75 CT-26 Murine Colon 6.30 25.40 39.75 C-1498 Murine AML 1.50 1.20 1.30 B16-F10 Murine Melanoma 2.15 9.55 18.20 TC-1 Murine Lung 0.95 4.35 41.30 LL/2 Murine Lung 0.95 2.05 6.75 Pan02 Murine Pancreas 0.00 0.00 25.50 Hepa 1-6 Murine Liver 0.85 1.60 46.75 RENCA Murine Renal Cell 1.60 0.20 75.55 MC38 Murine Colon 3.85 20.25 81.85 - To further characterize the ability of vMyx-Triple to inhibit growth of cancer cell lines, in vitro, 17 human lung cancer cell lines were infected at 9 different multiplicities of infection ranging from 0.01 FFU/cell to 100 FFU/cell. After incubation for 72 hours, cell viability was assessed using a CellTiter-Glo Cell Viability Assay. EC50 was calculated for each cell line, as the MOI that achieved 50% of maximum growth inhibition, as determined by curve fit using non-linear regression analysis via GraphPad Prism software. The vMyx-Triple demonstrated inhibition of a number of the human lung cancer tumor cell lines, with EC50s shown in Table 3.
-
TABLE 3 Mean EC50 Cell Line Tissue Type (ffu/cell) H1650 Human NSCLC 17.20 H1975 Human NSCLC 4.73 H358 Human NSCLC 11.18 H441 Human NSCLC 33.37 HCC827 Human NSCLC >100* LK-2 Human Squamous Cell Lung 19.94 NCI-H226 Human Squamous Cell Lung 10.14 SK-MES-1 Human Squamous Cell Lung 5.59 H720 Human Lung Carcinoma >100* H820 Human Lung Adenocarcinoma 5.61 A427 Human Lung Carcinoma 8.13 H209 Human SCLC >100* H69 Human SCLC 12.54 SHP-77 Human SCLC >100* H1963 Human SCLC 94.88{circumflex over ( )} A549 Human NSCLC 5.60 H2228 Human NSCLC 53.76 *Value was averaged using >100 ffu/cell value for both trial results. {circumflex over ( )}Value was averaged using >100 ffu/cell value for one trial result. - To further characterize the ability of vMyx-Triple to inhibit growth of cancer cell lines in vitro, 8 human sarcoma cell lines were infected at 9 different multiplicities of infection ranging from 0.01 FFU/cell to 100 FFU/cell. After incubation for 72 hours, cell viability was assessed using a CellTiter-Glo Cell Viability Assay. EC50 was calculated for each cell line, as the MOI that achieved 50% of maximum growth inhibition, as determined by curve fit using non-linear regression analysis via GraphPad Prism software. The vMyx-Triple demonstrated inhibition of a number of the human sarcoma cell lines, with EC50s shown in Table 4.
-
TABLE 4 Mean EC50 Cell Line Tissue Type (ffu/cell) 143B Human Osteosarcoma 17.76 A204 Human Rhabdomyosarcoma 1.51 A673 Human Ewing's Sarcoma 7.26 HS822T Human Ewing's Sarcoma >100* HT-1080 Human Fibrosarcoma 20.93 KHOS/NP Human Osteosarcoma 30.48 SJSA-1 Human Osteosarcoma 5.41 SK-ES-1 Human Sarcoma 14.40 *Value was averaged using >100 ffu/cell value for both trial results. - The ability of vMyx-Triple to kill human cancer cells from patients was tested. Acute myeloid leukemia (AML) samples from human patients were exposed to vMyx-Triple, or the parental virus vMyx-GFP ex vivo, at 6 different multiplicities of infection (MOI) ranging from 0.01 FFU/cell to 100 FFU/cell. After incubation for 6 days of continuous culture, cell viability was tested using a CellTiter-Glo Cell Viability Assay. IC50 was calculated for each sample, as the MOT that achieved 50% of maximum growth inhibition, as determined by curve fit using non-linear regression analysis via GraphPad Prism software.
- As shown in
FIG. 11A , no IC50 could be calculated for two of three samples exposed to the parental virus, while an IC50 of 19660 was calculated for the other sample. As shown inFIG. 11B , vMyx-Triple exhibited superior inhibition of human AML samples, with the IC50s calculated at 4.203, 6.524, and 10.25. The results show that vMyx-Triple can inhibit the growth of cancer cells from human cancer patients, and exhibits superior anti-cancer effects compared to the parental virus which lacks TNF, Decorin and IL-12, and which contains an intact wild type M153 gene. - The ability of vMyx-Triple to elicit cytokine production by human peripheral blood mononuclear cells (PBMCs) was tested. Human PBMCs were infected with MYXV, each at an MOT of 10. The MYXV used were vMyx-Triple (“Human triple”), parental virus vMyx-GFP (“Parental MYXV”), vMyx-hTNFa-GFP (“TNF single”), and a MYXV that expresses TNF on the cell surface (“Membrane bound TNF”). The MYXV that expresses TNF on the cell surface encodes the TNFα of SEQ ID NO: 45, which contains an altered TNFα sequence that will remain membrane bound.
- Untreated PBMCs were used as a negative control, and PBMCs activated by anti-CD3/anti-CD28 co-stimulation were used as a positive control. At 4 hours and 16 hours post-infection, supernatant was harvested, and analyzed for the concentration of IFN-γ, IL-10, IL-12p70, IL-2, IL-4, and TNFα using MesoScale Discovery (MSD) U-Plex 6-assay 96-Well SECTOR plates.
FIG. 12A illustrates the mean (+/−SD) concentrations of the cytokines in supernatant at 4 hours post-infection, whileFIG. 12B illustrates the mean (+/−SD) concentrations of the cytokines in supernatant at 16 hours post-infection. Where no bar is present, this indicates the cytokine level was below the limit of detection for the assay. - The results demonstrate that the vMyx-Triple virus elicits production of cytokines by human PBMCs, including IL-12 and TNFα. The levels of IL-12 observed in response to infection with vMyx-Triple were higher than levels observed for any of the other viruses. Additionally, higher levels of IFN-γ were observed in response to the vMyx-Triple virus, particularly at 4 hours post-infection.
- The ability of vMYX Triple to inhibit growth of human tumors in vivo was tested in xenograft models. The human cancer cell lines NCI-H1971 (lung cancer), A673 (sarcoma), and SJSA-1 (sarcoma) were implanted with 5 million tumor cells per mouse subcutaneously into the flanks of immunodeficient mice (athymic nude mice for NCI-H1975 and SJSA-1, CD17.SCID mice for A673). Tumor bearing animals were randomized into treatment groups of 7-8 animals per group with an average tumor volume of 100-150 mm3. Animals were treated with intratumoral injection of vMyx-Triple at doses of 1×107 focus forming units (FFU) or 2×107 FFU. Doses were administered once per week (QW), once every 4 days (Q4D), or once every two days (Q2D). Tumor volume and body weight were measured three times per week.
-
FIG. 13A plots the volume of NCI-H1971 (lung cancer) xenograft tumors over time, showing that intra-tumoral injection of vMYX Triple inhibits tumor growth in a dose-dependent manner in this model. -
FIG. 13B plots the volume of A673 (sarcoma) xenograft tumors over time, showing that administering vMYX Triple more frequently results in greater inhibition of tumor growth in this model. -
FIG. 13C plots the volume of SJSA-1 (sarcoma) xenograft tumors over time, showing that administering vMYX Triple more frequently results in greater inhibition of tumor growth in this model. - These results demonstrate that vMYX-Triple can inhibit growth of human tumors in vivo, even in the context of an immunodeficient host.
- The ability of vMYX Triple to elicit IL-12 and TNFα production in vivo was tested in xenograft models. The human sarcoma cancer cell lines SJSA-1 and A673 were implanted subcutaneously into the flanks of immunodeficient mice (athymic nude mice for SJSA-1, CD17.SCID mice for A673). Tumor bearing animals were treated via intratumoral (IT) or intravenous (IV) injection of 2×107 FFU of vMYX Triple on
day 1 post-implant (n=3 animals per group). Serum samples were collected 4 and 24 hours post-treatment. Tumors were collected at 24 hours post treatment and processed for cytokine measurement. Cytokine analysis was performed using MesoScale Discovery (MSD) U-Plex 6-assay 96-Well SECTOR plates. -
FIG. 14A shows the concentrations of IL-12 and TNFα detected in serum at 4 and 24 hours post-treatment, and in tumors at 24 hours post-treatment, in animals bearing SJSA-1 tumors. Mean±SD is plotted. When no bar is present, the level of the analyte was below the limit of detection for the assay. -
FIG. 14B shows the concentrations of IL-12 and TNFα detected in serum at 4 and 24 hours post-treatment, and in tumors at 24 hours post-treatment, in animals bearing A673 tumors. Mean±SD is plotted. When no bar is present, the level of the analyte was below the limit of detection for the assay. - The results demonstrate that intravenous and intra-tumor treatment with vMYX Triple can elicit IL-12 and TNFα production within tumors, as well as increasing levels of the cytokines in circulation.
- This example compared the degree of tumor growth inhibition achieved by a MYXV with the M153 gene knocked out versus a MYXV that expresses a wild type M153. Both MYXV viruses contained transgenes for expression of TNF inserted in between the M135 and M136 region.
- B16-F10 mouse melanoma cells were implanted into C57BL/6 mice. Tumor bearing animals were randomized into treatment groups of 8 animals per group with an average tumor volume of 75-100 mm3. Animals were treated via intratumoral injection of the indicated myxoma virus at 2×107 FFU/dose on
day 1 andday 8 post-randomization. -
FIG. 15 plots tumor volume over time, and shows that the virus with M153 knocked out inhibited tumor growth to a greater extent than the virus that expresses wild type M153. - The anti-cancer efficacy of vMyx-Triple was evaluated in an MC38 mouse model. C57BL/6 mice were implanted with MC38 mouse colorectal cancer cells. Tumor-bearing animals were randomized into treatment groups of 8 animals per group with an average tumor volume of 75-100 mm3. Animals were treated via intratumoral (IT) injection of 2×107 FFU/dose once every 4 days for four doses with the indicated myxoma virus.
- msTriple low refers to a vMyx-Triple that expresses murine rather than human IL-12, at a relatively low level. msTriple high refers to a vMyx-Triple that expresses murine rather than human IL-12, at a relatively higher level (as a single polypeptide with an elastin linker joining the IL-12 subunits). The msTriple viruses also express human Decorin and TNF, and have the M153 gene knocked out. GFP refers to vMyx-GFP, which does not encode any of the cytokines, and contains an intact wild type M153 gene.
- Tumor volume measurements were recorded three times per week, and are plotted in
FIG. 16A . Survival is plotted inFIG. 16B . Survival endpoints were met when tumor volume was ≥1500 mm3 (for an individual animal), or when the animal met IACUC guidelines for terminal sacrifice. - These results show that MYXV can inhibit tumor growth in vivo, and that the MYXV that expresses higher levels of mouse IL-12 exhibits greater inhibition of tumor growth in this model.
- The anti-cancer efficacy of vMyx-Triple that expresses mouse IL-12 was evaluated in a B16-F10 mouse model. C57BL/6 mice were implanted with B16-F10 mouse melanoma cells. Tumor bearing animals were randomized into treatment groups of 8 animals per group with an average tumor volume of 75-100 mm3. Animals were treated via intratumoral injection of 2×107 FFU/dose on
Day 1 andDay 8 with the indicated myxoma virus. - msTriple low refers to a vMyx-Triple that expresses murine rather than human IL-12, at a relatively low level. msTriple high refers to a vMyx-Triple that expresses murine rather than human IL-12, at a relatively higher level (as a single polypeptide with an elastin linker joining the IL-12 subunits). The msTriple viruses also express human Decorin and TNF, and have the M153 gene knocked out. GFP refers to vMyx-GFP, which does not encode any of the cytokines, and contains an intact M153 gene.
- Tumor volume measurements were recorded three times per week, and are plotted in 17A. Survival is plotted in
FIG. 17B . Survival endpoints were met when tumor volume was ≥1500 mm3 (for an individual animal), or when the animal met IACUC guidelines for terminal sacrifice. - The results show that MYXV can inhibit tumor growth in vivo and enhance survival. The MYXV that expresses higher levels of mouse IL-12 exhibited greater inhibition of tumor growth in this model, and conferred a greater survival benefit compared to the other two myxoma viruses.
- The anti-tumor efficacy of vMyx mouse Triple was evaluated in mouse syngeneic cancer models, with comparison of intravenous and intratumoral routes of administration. C57BL/6 mice were implanted subcutaneously with B16-F10 melanoma cells, and Balb/c mice were implanted subcutaneously with CT26 colorectal cancer cells. Tumor bearing animals were randomized into treatment groups of 8 animals per group with an average tumor volume of 75-100 mm3. Animals were treated via intratumoral (IT) or intravenous (IV) injection msTriple high, a MYXV that expresses a relatively high level of murine IL-12 (as a single polypeptide with an elastin linker joining the IL-12 subunits). msTriple high also express human Decorin and TNF, and has the M153 gene knocked out. Four doses of 2×107 focus forming units (FFU) or 1×108 FFU were administered to each mouse, with doses administered every four days. Tumor volume measurements were recorded three times per week.
-
FIG. 18A shows tumor volumes of the C57BL/6 mice with B16-F10 tumors. -
FIG. 18B shows tumor volumes of the Balb/c mice with CT26 tumors. - msTriple high inhibited tumor growth at all doses and routes of administration tested compared to vehicle control. In the B16-F10 model, intra-tumoral injection of 2×107 FFU per dose exhibited greater inhibition of tumor growth than intravenous administration at either 1×108 or 2×107 FFU per dose.
- Balb/c mice were implanted with K7M2 sarcoma cells via intravenous injection into the tail vein. Starting on
day 3 post tumor inoculation, animals (n=10 per group) were treated via injection into the retro-orbital sinus of 2×107 FFU/dose of the vMyx-mouse Triple (low IL-12). This myxoma virus expresses human Decorin, human TNF, and a relatively low level of mouse IL-12. vMyx-mouse Triple (low IL-12) also has the M153 gene knocked out. The virus was administered once every four days for four doses. Some groups were injected intraperitoneally with anti-PD-1 or anti-PD-L1 antibodies at 10 mg/kg, once every four days for four doses. -
FIG. 19 displays survival curves the groups. All animals in the untreated control group had succumbed to infection by approximatelyday 80 post-implant. At day 130 post-implant, approximately 30-40% of animals that received anti-PD-1 or anti-PD-L1 had survived, over 50% of animals treated with vMyx-mouse Triple (low IL-12) had survived, and animals treated with a combination of vMyx-mouse Triple (low IL-12) and either anti-PD-1 or anti-PD-L1 exhibited the highest survival, with more than about 80% alive. - These data show that myxoma viruses of the disclosure can improve survival of subjects with cancer, and that combination therapy with immune checkpoint inhibitors can improve survival further still.
- In a separate experiment, C57BL/6 mice were implanted with MC38 mouse colorectal cancer cells subcutaneously on the flank. Tumor bearing animals were randomized into treatment groups of 8 animals per group with an average tumor volume of 75-100 mm3.
- Animals were treated via intratumoral injection of 2×107 FFU/dose on
day 1 andday 8 post-randomization with vMyx-mouse Triple (low IL-12). Some groups were injected intraperitoneally with anti-PD-1 antibody at 10 mg/kg, once every four days for four doses. Tumor volume and body weight was measured three times per week. -
FIG. 20A plots tumor volume over time. Tumor volume for vehicle-treated control mice is shown by circles connected by solid lines. Mice treated with vMyx-mouse Triple alone (squares) exhibited reduced tumor volume and delayed tumor growth compared to vehicle-treated controls, as did mice treated with anti-PD-1 alone (circles with dashed line). The greatest inhibition of tumor growth was observed in the group that received both vMyx-mouse Triple and anti-PD-1 (triangles). -
FIG. 20B shows survival curves for the groups. Similar to tumor volume, the group that received both vMyx-mouse Triple and anti-PD-1 exhibited the best survival profile. - These data show that myxoma viruses of the disclosure can inhibit tumor growth and enhance survival of subjects with cancer, and that combination therapy with an immune checkpoint inhibitors can have a synergistic effect.
- Exemplary sequences corresponding to the compositions and methods described herein are shown in Table 5.
-
TABLE 5 SEQ ID NO Name Sequence 11 Synthetic early/late TTAAAAATTGAAATTTTATTTTTTTTTTTTGGAATATAA promoter ATA 54 Synthetic early/late AAAAATTGAAATTTTATTTTTTTTTTTTGGAATATAAA promoter TA 12 hTNFa ATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGG CCGAGGAGGCGCTCCCCAAGAAGACAGGGGGGCCCC AGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCC TTCCTGATCGTGGCAGGCGCCACCACGCTCTTCTGCCT GCTGCACTTTGGAGTGATCGGCCCCCAGAGGGAAGAG TTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCA GGCAGTCAGATCATCTTCTCGAACCCCGAGTGACAAG CCTGTAGCCCATGTTGTAGCAAACCCTCAAGCTGAGG GGCAGCTCCAGTGGCTGAACCGCCGGGCCAATGCCCT CCTGGCCAATGGCGTGGAGCTGAGAGATAACCAGCTG GTGGTGCCATCAGAGGGCCTGTACCTCATCTACTCCCA GGTCCTCTTCAAGGGCCAAGGCTGCCCCTCCACCCATG TGCTCCTCACCCACACCATCAGCCGCATCGCCGTCTCC TACCAGACCAAGGTCAACCTCCTCTCTGCCATCAAGA GCCCCTGCCAGAGGGAGACCCCAGAGGGGGCTGAGG CCAAGCCCTGGTATGAGCCCATCTATCTGGGAGGGGT CTTCCAGCTGGAGAAGGGTGACCGACTCAGCGCTGAG ATCAATCGGCCCGACTATCTCGACTTTGCCGAGTCTGG GCAGGTCTACTTTGGGATCATTGCCCTGTGA 13 GFP ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGG TGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGG CCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGAT GCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCA CCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGT GACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGC TACCCCGACCACATGAAGCAGCACGACTTCTTCAAGT CCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCAT CTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCC GAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCA TCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAA CATCCTGGGGCACAAGCTGGAGTACAACTACAACAGC CACAACGTCTATATCATGGCCGACAAGCAGAAGAACG GCATCAAGGTGAACTTCAAGATCCGCCACAACATCGA GGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAG AACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCG ACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAA AGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTG GAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGG ACGAGCTGTACAAGTAA 14 Human Decorin, MKATIILLLLAQVSWAGPFQQRGLFDFMLEDEASGIGPE isoform A VPDDRDFEPSLGPVCPFRCQCHLRVVQCSDLGLDKVPKD LPPDTTLLDLQNNKITEIKDGDFKNLKNLHALILVNNKIS KVSPGAFTPLVKLERLYLSKNQLKELPEKMPKTLQELRA HENEITKVRKVTFNGLNQMIVIELGTNPLKSSGIENGAFQ GMKKLSYIRIADTNITSIPQGLPPSLTELHLDGNKISRVDA ASLKGLNNLAKLGLSFNSISAVDNGSLANTPHLRELHLD NNKLTRVPGGLAEHKYIQVVYLHNNNISVVGSSDFCPPG HNTKKASYSGVSLFSNPVQYWEIQPSTFRCVYVRSAIQL GNYK 15 Human Decorin, MKATIILLLLAQVSWAGPFQQRGLFDFMLEDEASGIGPE isoform B VPDDRDFEPSLGPVCPFRCQCHLRVVQCSDLELGTNPLK SSGIENGAFQGMKKLSYIRIADTNITSIPQGLPPSLTELHL DGNKISRVDAASLKGLNNLAKLGLSFNSISAVDNGSLAN TPHLRELHLDNNKLTRVPGGLAEHKYIQVVYLHNNNISV VGSSDFCPPGHNTKKASYSGVSLFSNPVQYWEIQPSTFRC VYVRSAIQLGNYK 16 Human Decorin, MKATIILLLLAQVSWAGPFQQRGLFDFMLEDEASGIGPE isoform C VPDDRDFEPSLGPVCPFRCQCHLRVVQCSDLGLPPSLTEL HLDGNKISRVDAASLKGLNNLAKLGLSFNSISAVDNGSL ANTPHLRELHLDNNKLTRVPGGLAEHKYIQVVYLHNNN ISVVGSSDFCPPGHNTKKASYSGVSLFSNPVQYWEIQPST FRCVYVRSAIQLGNYK 17 Huma Decorin, MKATIILLLLAQVSWAGPFQQRGLFDFMLEDEASGIGPE isoform D VPDDRDFEPSLGPVCPFRCQCHLRVVQCSDLGLDKVPKD LPPDTTLLDLQNNKITEIKDGDFKNLKNLHVVYLHNNNI SVVGSSDFCPPGHNTKKASYSGVSLFSNPVQYWEIQPSTF RCVYVRSAIQLGNYK 18 Human Decorin, MKATIILLLLAQVSWAGPFQQRGLFDFMLEDEASGIGPE isoform E VPDDRDFEPSLGPVCPFRCQCHLRVVQCSDLGCLPS 19 Mouse Decorin MKATLIFFLLAQVSWAGPFEQRGLFDFMLEDEASGIIPYD PDNPLISMCPYRCQCHLRVVQCSDLGLDKVPWDFPPDTT LLDLQNNKITEIKEGAFKNLKDLHTLILVNNKISKISPEAF KPLVKLERLYLSKNQLKELPEKMPRTLQELRVHENEITK LRKSDFNGLNNVLVIELGGNPLKNSGIENGAFQGLKSLS YIRISDTNITAIPQGLPTSLTEVHLDGNKITKVDAPSLKGLI NLSKLGLSFNSITVMENGSLANVPHLRELHLDNNKLLRV PAGLAQHKYIQVVYLHNNNISAVGQNDFCRAGHPSRKA SYSAVSLYGNPVRYWEIFPNTFRCVYVRSAIQLGNYK 20 P11 (promoter) GAATTTCATTTTGTTTTTTTCTATGCTATAA 21 IRES (ECMV) TATGCTAGTACGTCTCTCAAGGATAAGTAAGTAATATT AAGGTACGGGAGGTATTGGACAGGCCGCAATAAAATA TCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGT GAATCGATAGTACTAACATACGCTCTCCATCAAAACA AAACGAAACAAAACAAACTAGCAAAATAGGCTGTCCC CAGTGCAAGTGCAGGTGCCAGAACATTTCTCTGGCCT AACTGGCCGGTACCTGAGCTCTAGTTTCACTTTCCCTA GTTTCACTTTCCCTAGTTTCACTTTCCCTAGTTTCACTT TCCCTAGTTTCACTTTCCCCTCGAGGATATCAAGATCT GGCCTCGGCGGCCAG 22 hu IL-12 A (p35) ATGTGGCCCCCTGGGTCAGCCTCCCAGCCACCGCCCTC ACCTGCCGCGGCCACAGGTCTGCATCCAGCGGCTCGC CCTGTGTCCCTGCAGTGCCGGCTCAGCATGTGTCCAGC GCGCAGCCTCCTCCTTGTGGCTACCCTGGTCCTCCTGG ACCACCTCAGTTTGGCCAGAAACCTCCCCGTGGCCACT CCAGACCCAGGAATGTTCCCATGCCTTCACCACTCCCA AAACCTGCTGAGGGCCGTCAGCAACATGCTCCAGAAG GCCAGACAAACTCTAGAATTTTACCCTTGCACTTCTGA AGAGATTGATCATGAAGATATCACAAAAGATAAAACC AGCACAGTGGAGGCCTGTTTACCATTGGAATTAACCA AGAATGAGAGTTGCCTAAATTCCAGAGAGACCTCTTT CATAACTAATGGGAGTTGCCTGGCCTCCAGAAAGACC TCTTTTATGATGGCCCTGTGCCTTAGTAGTATTTATGA AGACTTGAAGATGTACCAGGTGGAGTTCAAGACCATG AATGCAAAGCTTCTGATGGATCCTAAGAGGCAGATCT TTCTAGATCAAAACATGCTGGCAGTTATTGATGAGCTG ATGCAGGCCCTGAATTTCAACAGTGAGACTGTGCCAC AAAAATCCTCCCTTGAAGAACCGGATTTTTATAAAACT AAAATCAAGCTCTGCATACTTCTTCATGCTTTCAGAAT TCGGGCAGTGACTATTGATAGAGTGATGAGCTATCTG AATGCTTCCTAA 23 dsRed ATGGTGCGCTCCTCCAAGAACGTCATCAAGGAGTTCA TGCGCTTCAAGGTGCGCATGGAGGGCACCGTGAACGG CCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCG CCCCTACGAGGGCCACAACACCGTGAAGCTGAAGGTG ACCAAGGGCGGCCCCCTGCCCTTCGCCTGGGACATCC TGTCCCCCCAGTTCCAGTACGGCTCCAAGGTGTACGTG AAGCACCCCGCCGACATCCCCGACTACAAGAAGCTGT CCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAA CTTCGAGGACGGCGGCGTGGTGACCGTGACCCAGGAC TCCTCCCTGCAGGACGGCTGCTTCATCTACAAGGTGAA GTTCATCGGCGTGAACTTCCCCTCCGACGGCCCCGTAA TGCAGAAGAAGACCATGGGCTGGGAGGCCTCCACCGA GCGCCTGTACCCCCGCGACGGCGTGCTGAAGGGCGAG ATCCACAAGGCCCTGAAGCTGAAGGACGGCGGCCACT ACCTGGTGGAGTTCAAGTCCATCTACATGGCCAAGAA GCCCGTGCAGCTGCCCGGCTACTACTACGTGGACTCC AAGCTGGACATCACCTCCCACAACGAGGACTACACCA TCGTGGAGCAGTACGAGCGCACCGAGGGCCGCCACCA CCTGTTCCTGTAG 24 Hu TNF-a ATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGG CCGAGGAGGCGCTCCCCAAGAAGACAGGGGGGCCCC AGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCC TTCCTGATCGTGGCAGGCGCCACCACGCTCTTCTGCCT GCTGCACTTTGGAGTGATCGGCCCCCAGAGGGAAGAG TTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCA GGCAGTCAGATCATCTTCTCGAACCCCGAGTGACAAG CCTGTAGCCCATGTTGTAGCAAACCCTCAAGCTGAGG GGCAGCTCCAGTGGCTGAACCGCCGGGCCAATGCCCT CCTGGCCAATGGCGTGGAGCTGAGAGATAACCAGCTG GTGGTGCCATCAGAGGGCCTGTACCTCATCTACTCCCA GGTCCTCTTCAAGGGCCAAGGCTGCCCCTCCACCCATG TGCTCCTCACCCACACCATCAGCCGCATCGCCGTCTCC TACCAGACCAAGGTCAACCTCCTCTCTGCCATCAAGA GCCCCTGCCAGAGGGAGACCCCAGAGGGGGCTGAGG CCAAGCCCTGGTATGAGCCCATCTATCTGGGAGGGGT CTTCCAGCTGGAGAAGGGTGACCGACTCAGCGCTGAG ATCAATCGGCCCGACTATCTCGACTTTGCCGAGTCTGG GCAGGTCTACTTTGGGATCATTGCCCTGTGA 25 Hu Decorin ATGAAGGCCACTATCATCCTCCTTCTGCTTGCACAAGT TTCCTGGGCTGGACCGTTTCAACAGAGAGGCTTATTTG ACTTTATGCTAGAAGATGAGGCTTCTGGGATAGGCCC AGAAGTTCCTGATGACCGCGACTTCGAGCCCTCCCTA GGCCCAGTGTGCCCCTTCCGCTGTCAATGCCATCTTCG AGTGGTCCAGTGTTCTGATTTGGGTCTGGACAAAGTGC CAAAGGATCTTCCCCCTGACACAACTCTGCTAGACCTG CAAAACAACAAAATAACCGAAATCAAAGATGGAGAC TTTAAGAACCTGAAGAACCTTCACGCATTGATTCTTGT CAACAATAAAATTAGCAAAGTTAGTCCTGGAGCATTT ACACCTTTGGTGAAGTTGGAACGACTTTATCTGTCCAA GAATCAGCTGAAGGAATTGCCAGAAAAAATGCCCAAA ACTCTTCAGGAGCTGCGTGCCCATGAGAATGAGATCA CCAAAGTGCGAAAAGTTACTTTCAATGGACTGAACCA GATGATTGTCATAGAACTGGGCACCAATCCGCTGAAG AGCTCAGGAATTGAAAATGGGGCTTTCCAGGGAATGA AGAAGCTCTCCTACATCCGCATTGCTGATACCAATATC ACCAGCATTCCTCAAGGTCTTCCTCCTTCCCTTACGGA ATTACATCTTGATGGCAACAAAATCAGCAGAGTTGAT GCAGCTAGCCTGAAAGGACTGAATAATTTGGCTAAGT TGGGATTGAGTTTCAACAGCATCTCTGCTGTTGACAAT GGCTCTCTGGCCAACACGCCTCATCTGAGGGAGCTTC ACTTGGACAACAACAAGCTTACCAGAGTACCTGGTGG GCTGGCAGAGCATAAGTACATCCAGGTTGTCTACCTTC ATAACAACAATATCTCTGTAGTTGGATCAAGTGACTTC TGCCCACCTGGACACAACACCAAAAAGGCTTCTTATT CGGGTGTGAGTCTTTTCAGCAACCCGGTCCAGTACTGG GAGATACAGCCATCCACCTTCAGATGTGTCTACGTGC GCTCTGCCATTCAACTCGGAAACTATAAGTAA 26 Insert vMyx-Triple AAAAATTGAAATTTTATTTTTTTTTTTTGGAATATAAA red (hu Decorin-hu TAATGAAGGCCACTATCATCCTCCTTCTGCTTGCACAA Il-12-dsRed) GTTTCCTGGGCTGGACCGTTTCAACAGAGAGGCTTATT TGACTTTATGCTAGAAGATGAGGCTTCTGGGATAGGC CCAGAAGTTCCTGATGACCGCGACTTCGAGCCCTCCCT AGGCCCAGTGTGCCCCTTCCGCTGTCAATGCCATCTTC GAGTGGTCCAGTGTTCTGATTTGGGTCTGGACAAAGT GCCAAAGGATCTTCCCCCTGACACAACTCTGCTAGAC CTGCAAAACAACAAAATAACCGAAATCAAAGATGGA GACTTTAAGAACCTGAAGAACCTTCACGCATTGATTCT TGTCAACAATAAAATTAGCAAAGTTAGTCCTGGAGCA TTTACACCTTTGGTGAAGTTGGAACGACTTTATCTGTC CAAGAATCAGCTGAAGGAATTGCCAGAAAAAATGCCC AAAACTCTTCAGGAGCTGCGTGCCCATGAGAATGAGA TCACCAAAGTGCGAAAAGTTACTTTCAATGGACTGAA CCAGATGATTGTCATAGAACTGGGCACCAATCCGCTG AAGAGCTCAGGAATTGAAAATGGGGCTTTCCAGGGAA TGAAGAAGCTCTCCTACATCCGCATTGCTGATACC AATATCACCAGCATTCCTCAAGGTCTTCCTCCTTCCCT TACGGAATTACATCTTGATGGCAACAAAATCAGCAGA GTTGATGCAGCTAGCCTGAAAGGACTGAATAATTTGG CTAAGTTGGGATTGAGTTTCAACAGCATCTCTGCTGTT GACAATGGCTCTCTGGCCAACACGCCTCATCTGAGGG AGCTTCACTTGGACAACAACAAGCTTACCAGAGTACC TGGTGGGCTGGCAGAGCATAAGTACATCCAGGTTGTC TACCTTCATAACAACAATATCTCTGTAGTTGGATCAAG TGACTTCTGCCCACCTGGACACAACACCAAAAAGGCT TCTTATTCGGGTGTGAGTCTTTTCAGCAACCCGGTCCA GTACTGGGAGATACAGCCATCCACCTTCAGATGTGTCT ACGTGCGCTCTGCCATTCAACTCGGAAACTATAAGTA AATGTGTCACCAGCAGTTGGTCATCTCTTGGTTTTCCC TGGTTTTTCTGGCATCTCCCCTCGTGGCCATATGGGAA CTGAAGAAAGATGTTTATGTCGTAGAATTGGATTGGT ATCCGGATGCCCCTGGAGAAATGGTGGTCCTCACCTG TGACACCCCTGAAGAAGATGGTATCACCTGGACCTTG GACCAGAGCAGTGAGGTCTTAGGCTCTGGCAAAACCC TGACCATCCAAGTCAAAGAGTTTGGAGATGCTGGCCA GTACACCTGTCACAAAGGAGGCGAGGTTCTAAGCCAT TCGCTCCTGCTGCTTCACAAAAAGGAAGATGGAATTT GGTCCACTGATATTTTAAAGGACCAGAAAGAACCCAA AAATAAGACCTTTCTAAGATGCGAGGCCAAGAATTAT TCTGGACGTTTCACCTGCTGGTGGCTGACGACAATCAG TACTGATTTGACATTCAGTGTCAAAAGCAGCAGAGGC TCTTCTGACCCCCAAGGGGTGACGTGCGGAGCTGCTA CACTCTCTGCAGAGAGAGTCAGAGGGGACAACAAGG AGTATGAGTACTCAGTGGAGTGCCAGGAGGACAGTGC CTGCCCAGCTGCTGAGGAGAGTCTGCCCATTGAGGTC ATGGTGGATGCCGTTCACAAGCTCAAGTATGAAAACT ACACCAGCAGCTTCTTCATCAGGGACATCATCAAACC TGACCCACCCAAGAACTTGCAGCTGAAGCCATTAAAG AATTCTCGGCAGGTGGAGGTCAGCTGGGAGTACCCTG ACACCTGGAGTACTCCACATTCCTACTTCTCCCTGACA TTCTGCGTTCAGGTCCAGGGCAAGAGCAAGAGAGAAA AGAAAGATAGAGTCTTCACGGACAAGACCTCAGCCAC GGTCATCTGCCGCAAAAATGCCAGCATTAGCGTGCGG GCCCAGGACCGCTACTATAGCTCATCTTGGAGCGAAT GGGCATCTGTGCCCTGCAGTTAGTATGCTAGTACGTCT CTCAAGGATAAGTAAGTAATATTAAGGTACGGGAGGT ATTGGACAGGCCGCAATAAAATATCTTTATTTTCATTA CATCTGTGTGTTGGTTTTTTGTGTGAATCGATAGTACT AACATACGCTCTCCATCAAAACAAAACGAAACAAAAC AAACTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAG GTGCCAGAACATTTCTCTGGCCTAACTGGCCGGTACCT GAGCTCTAGTTTCACTTTCCCTAGTTTCACTTTCCCTAG TTTCACTTTCCCTAGTTTCACTTTCCCTAGTTTCACTTT CCCCTCGAGGATATCAAGATCTGGCCTCGGCGGCCAG ATGTGGCCCCCTGGGTCAGCCTCCCAGCCACCGCCCTC ACCTGCCGCGGCCACAGGTCTGCATCCAGCGGCTCGC CCTGTGTCCCTGCAGTGCCGGCTCAGCATGTGTCCAGC GCGCAGCCTCCTCCTTGTGGCTACCCTGGTCCTCCTGG ACCACCTCAGTTTGGCCAGAAACCTCCCCGTGGCCAC TCCAGACCCAGGAATGTTCCCATGCCTTCACCACTCCC AAAACCTGCTGAGGGCCGTCAGCAACATGCTCCAGAA GGCCAGACAAACTCTAGAATTTTACCCTTGCACTTCTG AAGAGATTGATCATGAAGATATCACAAAAGATAAAAC CAGCACAGTGGAGGCCTGTTTACCATTGGAATTAACC AAGAATGAGAGTTGCCTAAATTCCAGAGAGACCTCTT TCATAACTAATGGGAGTTGCCTGGCCTCCAGAAAGAC CTCTTTTATGATGGCCCTGTGCCTTAGTAGTATTTATG AAGACTTGAAGATGTACCAGGTGGAGTTCAAGACCAT GAATGCAAAGCTTCTGATGGATCCTAAGAGGCAGATC TTTCTAGATCAAAACATGCTGGCAGTTATTGATGAGCT GATGCAGGCCCTGAATTTCAACAGTGAGACTGTGCCA CAAAAATCCTCCCTTGAAGAACCGGATTTTTATAAAA CTAAAATCAAGCTCTGCATACTTCTTCATGCTTTCAGA ATTCGGGCAGTGACTATTGATAGAGTGATGAGCTATC TGAATGCTTCCTAAGAATTTCATTTTGTTTTTTTCTATG CTATAAATGGTGCGCTCCTCCAAGAACGTCATCAAGG AGTTCATGCGCTTCAAGGTGCGCATGGAGGGCACCGT GAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGA GGGCCGCCCCTACGAGGGCCACAACACCGTGAAGCTG AAGGTGACCAAGGGCGGCCCCCTGCCCTTCGCCTGGG ACATCCTGTCCCCCCAGTTCCAGTACGGCTCCAAGGTG TACGTGAAGCACCCCGCCGACATCCCCGACTACAAGA AGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGT GATGAACTTCGAGGACGGCGGCGTGGTGACCGTGACC CAGGACTCCTCCCTGCAGGACGGCTGCTTCATCTACAA GGTGAAGTTCATCGGCGTGAACTTCCCCTCCGACGGC CCCGTAATGCAGAAGAAGACCATGGGCTGGGAGGCCT CCACCGAGCGCCTGTACCCCCGCGACGGCGTGCTGAA GGGCGAGATCCACAAGGCCCTGAAGCTGAAGGACGG CGGCCACTACCTGGTGGAGTTCAAGTCCATCTACATG GCCAAGAAGCCCGTGCAGCTGCCCGGCTACTACTACG TGGACTCCAAGCTGGACATCACCTCCCACAACGAGGA CTACACCATCGTGGAGCAGTACGAGCGCACCGAGGGC CGCCACCACCTGTTCCTGTAG 27 Insert vMyx-Triple AAAAATTGAAATTTTATTTTTTTTTTTTGGAATATAAA white (hu Decorin- TAATGAAGGCCACTATCATCCTCCTTCTGCTTGCACAA hu Il-12) GTTTCCTGGGCTGGACCGTTTCAACAGAGAGGCTTATT TGACTTTATGCTAGAAGATGAGGCTTCTGGGATAGGC CCAGAAGTTCCTGATGACCGCGACTTCGAGCCCTCCCT AGGCCCAGTGTGCCCCTTCCGCTGTCAATGCCATCTTC GAGTGGTCCAGTGTTCTGATTTGGGTCTGGACAAAGT GCCAAAGGATCTTCCCCCTGACACAACTCTGCTAGAC CTGCAAAACAACAAAATAACCGAAATCAAAGATGGA GACTTTAAGAACCTGAAGAACCTTCACGCATTGATTCT TGTCAACAATAAAATTAGCAAAGTTAGTCCTGGAGCA TTTACACCTTTGGTGAAGTTGGAACGACTTTATCTGTC CAAGAATCAGCTGAAGGAATTGCCAGAAAAAATGCCC AAAACTCTTCAGGAGCTGCGTGCCCATGAGAATGAGA TCACCAAAGTGCGAAAAGTTACTTTCAATGGACTGAA CCAGATGATTGTCATAGAACTGGGCACCAATCCGCTG AAGAGCTCAGGAATTGAAAATGGGGCTTTCCAGGGAA TGAAGAAGCTCTCCTACATCCGCATTGCTGATACCAAT ATCACCAGCATTCCTCAAGGTCTTCCTCCTTCCCTTAC GGAATTACATCTTGATGGCAACAAAATCAGCAGAGTT GATGCAGCTAGCCTGAAAGGACTGAATAATTTGGCTA AGTTGGGATTGAGTTTCAACAGCATCTCTGCTGTTGAC AATGGCTCTCTGGCCAACACGCCTCATCTGAGGGAGC TTCACTTGGACAACAACAAGCTTACCAGAGTACCTGG TGGGCTGGCAGAGCATAAGTACATCCAGGTTGTCTAC CTTCATAACAACAATATCTCTGTAGTTGGATCAAGTGA CTTCTGCCCACCTGGACACAACACCAAAAAGGCTTCTT ATTCGGGTGTGAGTCTTTTCAGCAACCCGGTCCAGTAC TGGGAGATACAGCCATCCACCTTCAGATGTGTCTACGT GCGCTCTGCCATTCAACTCGGAAACTATAAGTAAATG TGTCACCAGCAGTTGGTCATCTCTTGGTTTTCCCTGGT TTTTCTGGCATCTCCCCTCGTGGCCATATGGGAACTGA AGAAAGATGTTTATGTCGTAGAATTGGATTGGTATCC GGATGCCCCTGGAGAAATGGTGGTCCTCACCTGTGAC ACCCCTGAAGAAGATGGTATCACCTGGACCTTGGACC AGAGCAGTGAGGTCTTAGGCTCTGGCAAAACCCTGAC CATCCAAGTCAAAGAGTTTGGAGATGCTGGCCAGTAC ACCTGTCACAAAGGAGGCGAGGTTCTAAGCCATTCGC TCCTGCTGCTTCACAAAAAGGAAGATGGAATTTGGTC CACTGATATTTTAAAGGACCAGAAAGAACCCAAAAAT AAGACCTTTCTAAGATGCGAGGCCAAGAATTATTCTG GACGTTTCACCTGCTGGTGGCTGACGACAATCAGTACT GATTTGACATTCAGTGTCAAAAGCAGCAGAGGCTCTT CTGACCCCCAAGGGGTGACGTGCGGAGCTGCTACACT CTCTGCAGAGAGAGTCAGAGGGGACAACAAGGAGTA TGAGTACTCAGTGGAGTGCCAGGAGGACAGTGCCTGC CCAGCTGCTGAGGAGAGTCTGCCCATTGAGGTCATGG TGGATGCCGTTCACAAGCTCAAGTATGAAAACTACAC CAGCAGCTTCTTCATCAGGGACATCATCAAACCTGAC CCACCCAAGAACTTGCAGCTGAAGCCATTAAAGAATT CTCGGCAGGTGGAGGTCAGCTGGGAGTACCCTGACAC CTGGAGTACTCCACATTCCTACTTCTCCCTGACATTCT GCGTTCAGGTCCAGGGCAAGAGCAAGAGAGAAAAGA AAGATAGAGTCTTCACGGACAAGACCTCAGCCACGGT CATCTGCCGCAAAAATGCCAGCATTAGCGTGCGGGCC CAGGACCGCTACTATAGCTCATCTTGGAGCGAATGGG CATCTGTGCCCTGCAGTTAGTATGCTAGTACGTCTCTC AAGGATAAGTAAGTAATATTAAGGTACGGGAGGTATT GGACAGGCCGCAATAAAATATCTTTATTTTCATTACAT CTGTGTGTTGGTTTTTTGTGTGAATCGATAGTACTAAC ATACGCTCTCCATCAAAACAAAACGAAACAAAACAAA CTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGGTG CCAGAACATTTCTCTGGCCTAACTGGCCGGTACCTGAG CTCTAGTTTCACTTTCCCTAGTTTCACTTTCCCTAGTTT CACTTTCCCTAGTTTCACTTTCCCTAGTTTCACTTTCCC CTCGAGGATATCAAGATCTGGCCTCGGCGGCCAGATG TGGCCCCCTGGGTCAGCCTCCCAGCCACCGCCCTCACC TGCCGCGGCCACAGGTCTGCATCCAGCGGCTCGCCCT GTGTCCCTGCAGTGCCGGCTCAGCATGTGTCCAGCGC GCAGCCTCCTCCTTGTGGCTACCCTGGTCCTCCTGGAC CACCTCAGTTTGGCCAGAAACCTCCCCGTGGCCACTCC AGACCCAGGAATGTTCCCATGCCTTCACCACTCCCAA AACCTGCTGAGGGCCGTCAGCAACATGCTCCAGAAGG CCAGACAAACTCTAGAATTTTACCCTTGCACTTCTGAA GAGATTGATCATGAAGATATCACAAAAGATAAAACCA GCACAGTGGAGGCCTGTTTACCATTGGAATTAACCAA GAATGAGAGTTGCCTAAATTCCAGAGAGACCTCTTTC ATAACTAATGGGAGTTGCCTGGCCTCCAGAAAGACCT CTTTTATGATGGCCCTGTGCCTTAGTAGTATTTATGAA GACTTGAAGATGTACCAGGTGGAGTTCAAGACCATGA ATGCAAAGCTTCTGATGGATCCTAAGAGGCAGATCTT TCTAGATCAAAACATGCTGGCAGTTATTGATGAGCTG ATGCAGGCCCTGAATTTCAACAGTGAGACTGTGCCAC AAAAATCCTCCCTTGAAGAACCGGATTTTTATAAAACT AAAATCAAGCTCTGCATACTTCTTCATGCTTTCAGAAT TCGGGCAGTGACTATTGATAGAGTGATGAGCTATCTG AATGCTTCCTAA 28 hu IL-12 A (p40) MVVPPGSASQPPPSPAAATGLHPAARPVSLQCRLSMCPAR SLLLVATLVLLDHLSLARNLPVATPDPGMFPCLHHSQNL LRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVE ACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALC LSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLA VIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHA FRIRAVTIDRVMSYLNAS* 29 hu IL-12 B (p35) MCHQQLVISWFSLVFLASPLVAIWELKKDVYVVELDWY PDAPGEMVVLTCDTPEEDGITWTLDQSSEVLGSGKTLTI QVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDI LKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFS VKSSRGSSDPQGVTCGAATLSAERVRGDNKEYEYSVEC QEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDII KPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLT FCVQVQGKSKREKKDRVFTDKTSATVICRKNASISVRAQ DRYYSSSWSEWASVPCS* 30 dsRed MVRSSKNVIKEFMRFKVRMEGTVNGHEFEIEGEGEGRPY EGHNTVKLKVTKGGPLPFAWDILSPQFQYGSKVYVKHP ADIPDYKKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQ DGCFIYKVKFIGVNFPSDGPVMQKKTMGWEASTERLYP RDGVLKGEIHKALKLKDGGHYLVEFKSIYMAKKPVQLP GYYYVDSKLD1TSHNEDYT1VEQYERTEGRHHLFL 31 hu TNF-a MSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLI VAGATTLFCLLHFGVIGPQREEFPRDLSLISPLAQAVRSSS RTPSDKPVAHVVANPQAEGQLOWLNRRANALLANGVE LRDNQLVVPSEGLYLIYSOVLFKGQGCPSTHVLLTHTISR IAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGG VFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL 32 Hu Decorin MKATIILLLLAQVSWAGPFQQRGLFDFMLEDEASGIGPE VPDDRDFEPSLGPVCPFRCOCHLRVVQCSDLGLDKVPKD LPPDTTLLDLQNNKITEIKDGDFKNLKNLHALILVNNKIS KVSPGAFTPLVKLERLYLSKNQLKELPEKMPKTLQELRA HENEITKVRKVTFNGLNQMIVIELGTNPLKSSGIENGAFQ GMKKLSYIRIADTNITSIPQGLPPSLTELHLDGNKISRVDA ASLKGLNNLAKLGLSFNSISAVDNGSLANTPHLRELHLD NNKLTRVPGGLAEHKYIQVVYLHNNNISVVGSSDFCPPG HNTKKASYSGVSLFSNPVQYWEIQPSTFRCVYVRSAIQL GNYK* 33 Linker GGGGSGGGS 34 Linker GGGS 35 Linker GG 36 Linker KESGSVSSEQLAQFRSLD 37 Linker EGKSSGSGSESKST 38 Linker GSAGSAAGSGEF 39 Linker EAAAK 40 Linker EAAAR 41 Linker PAPAP 42 Linker AEAAAKEAAAKA 43 Linker VPGVGVPGVG 44 hu IL-12B (p40) ATGTGTCACCAGCAGTTGGTCATCTCTTGGTTTTCCCT GGTTTTTCTGGCATCTCCCCTCGTGGCCATATGGGAAC TGAAGAAAGATGTTTATGTCGTAGAATTGGATTGGTA TCCGGATGCCCCTGGAGAAATGGTGGTCCTCACCTGT GACACCCCTGAAGAAGATGGTATCACCTGGACCTTGG ACCAGAGCAGTGAGGTCTTAGGCTCTGGCAAAACCCT GACCATCCAAGTCAAAGAGTTTGGAGATGCTGGCCAG TACACCTGTCACAAAGGAGGCGAGGTTCTAAGCCATT CGCTCCTGCTGCTTCACAAAAAGGAAGATGGAATTTG GTCCACTGATATTTTAAAGGACCAGAAAGAACCCAAA AATAAGACCTTTCTAAGATGCGAGGCCAAGAATTATT CTGGACGTTTCACCTGCTGGTGGCTGACGACAATCAGT ACTGATTTGACATTCAGTGTCAAAAGCAGCAGAGGCT CTTCTGACCCCCAAGGGGTGACGTGCGGAGCTGCTAC ACTCTCTGCAGAGAGAGTCAGAGGGGACAACAAGGA GTATGAGTACTCAGTGGAGTGCCAGGAGGACAGTGCC TGCCCAGCTGCTGAGGAGAGTCTGCCCATTGAGGTCA TGGTGGATGCCGTTCACAAGCTCAAGTATGAAAACTA CACCAGCAGCTTCTTCATCAGGGACATCATCAAACCT GACCCACCCAAGAACTTGCAGCTGAAGCCATTAAAGA ATTCTCGGCAGGTGGAGGTCAGCTGGGAGTACCCTGA CACCTGGAGTACTCCACATTCCTACTTCTCCCTGACAT TCTGCGTTCAGGTCCAGGGCAAGAGCAAGAGAGAAAA GAAAGATAGAGTCTTCACGGACAAGACCTCAGCCACG GTCATCTGCCGCAAAAATGCCAGCATTAGCGTGCGGG CCCAGGACCGCTACTATAGCTCATCTTGGAGCGAATG GGCATCTGTGCCCTGCAGTTAG 45 Membrane bound MSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLI hu TNF-a VAGATTLFCLLHFGVIGPQREEFPRDLSLISPLAQADEPV AHVVANPQAEGQLQWLNRRANALLANGVELRDNQLVV PSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTK VNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKG DRLSAEINRPDYLDFAESGQVYFGIIAL 46 Membrane bound ATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGG hu TNF-a CCGAGGAGGCGCTCCCCAAGAAGACAGGGGGGCCCC AGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCC TTCCTGATCGTGGCAGGCGCCACCACGCTCTTCTGCCT GCTGCACTTTGGAGTGATCGGCCCCCAGAGGGAAGAG TTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCA GGCAGATGAGCCTGTAGCCCATGTTGTAGCAAACCCT CAAGCTGAGGGGCAGCTCCAGTGGCTGAACCGCCGGG CCAATGCCCTCCTGGCCAATGGCGTGGAGCTGAGAGA TAACCAGCTGGTGGTGCCATCAGAGGGCCTGTACCTC ATCTACTCCCAGGTCCTCTTCAAGGGCCAAGGCTGCCC CTCCACCCATGTGCTCCTCACCCACACCATCAGCCGCA TCGCCGTCTCCTACCAGACCAAGGTCAACCTCCTCTCT GCCATCAAGAGCCCCTGCCAGAGGGAGACCCCAGAGG GGGCTGAGGCCAAGCCCTGGTATGAGCCCATCTATCT GGGAGGGGTCTTCCAGCTGGAGAAGGGTGACCGACTC AGCGCTGAGATCAATCGGCCCGACTATCTCGACTTTGC CGAGTCTGGGCAGGTCTACTTTGGGATCATTGCCCTGT AG 47 Insert vMyx-Triple AAAATTGAAATTTTATTTTTTTTTTTTGGAATATAAAT IL-12 High AATGAAGGCCACTATCATCCTCCTTCTGCTTGCACAAG (hu Decorin-mo IL- TTTCCTGGGCTGG 12-dsRed) ACCGTTTCAACAGAGAGGCTTATTTGACTTTATGCTAG AAGATGAGGCTTCTGGGATAGGCCCAGAAGTTCCTGA TGACCGCGACTTCGAGCCCTCCCTAGGCCCAGTGTGCC CCTTCCGCTGTCAATGCCATCTTCGAGTGGTCCAGTGT TCTGATTTGGGTCTGGACAAAGTGCCAAAGGATCTTCC CCCTGACACAACTCTGCTAGACCTGCAAAACAACAAA ATAACCGAAATCAAAGATGGAGACTTTAAGAACCTGA AGAACCTTCACGCATTGATTCTTGTCAACAATAAAATT AGCAAAGTTAGTCCTGGAGCATTTACACCTTTGGTGA AGTTGGAACGACTTTATCTGTCCAAGAATCAGCTGAA GGAATTGCCAGAAAAAATGCCCAAAACTCTTCAGGAG CTGCGTGCCCATGAGAATGAGATCACCAAAGTGCGAA AAGTTACTTTCAATGGACTGAACCAGATGATTGTCATA GAACTGGGCACCAATCCGCTGAAGAGCTCAGGAATTG AAAATGGGGCTTTCCAGGGAATGAAGAAGCTCTCCTA CATCCGCATTGCTGATACCAATATCACCAGCATTCCTC AAGGTCTTCCTCCTTCCCTTACGGAATTACATCTTGAT GGCAACAAAATCAGCAGAGTTGATGCAGCTAGCCTGA AAGGACTGAATAATTTGGCTAAGTTGGGATTGAGTTT CAACAGCATCTCTGCTGTTGACAATGGCTCTCTGGCCA ACACGCCTCATCTGAGGGAGCTTCACTTGGACAACAA CAAGCTTACCAGAGTACCTGGTGGGCTGGCAGAGCAT AAGTACATCCAGGTTGTCTACCTTCATAACAACAATAT CTCTGTAGTTGGATCAAGTGACTTCTGCCCACCTGGAC ACAACACCAAAAAGGCTTCTTATTCGGGTGTGAGTCTT TTCAGCAACCCGGTCCAGTACTGGGAGATACAGCCAT CCACCTTCAGATGTGTCTACGTGCGCTCTGCCATTCAA CTCGGAAACTATAAGTAAAAAATTGAAATTTTATTTTT TTTTTTTGGAATATAAATAATGTGTCCTCAGAAGCTAA CCATCTCCTGGTTTGCCATCGTTTTGCTGGTGTCTCCAC TCATGGCCATGTGGGAGCTGGAGAAAGACGTTTATGT TGTAGAGGTGGACTGGACTCCCGATGCCCCTGGAGAA ACAGTGAACCTCACCTGTGACACGCCTGAAGAAGATG ACATCACCTGGACCTCAGACCAGAGACATGGAGTCAT AGGCTCTGGAAAGACCCTGACCATCACTGTCAAAGAG TTTCTAGATGCTGGCCAGTACACCTGCCACAAAGGAG GCGAGACTCTGAGCCACTCACATCTGCTGCTCCACAA GAAGGAAAATGGAATTTGGTCCACTGAAATTTTAAAA AATTTCAAAAACAAGACTTTCCTGAAGTGTGAAGCAC CAAATTACTCCGGACGGTTCACGTGCTCATGGCTGGTG CAAAGAAACATGGACTTGAAGTTCAACATCAAGAGCA GTAGCAGTTCCCCTGACTCTCGGGCAGTGACATGTGG AATGGCGTCTCTGTCTGCAGAGAAGGTCACACTGGAC CAAAGGGACTATGAGAAGTATTCAGTGTCCTGCCAGG AGGATGTCACCTGCCCAACTGCCGAGGAGACCCTGCC CATTGAACTGGCGTTGGAAGCACGGCAGCAGAATAAA TATGAGAACTACAGCACCAGCTTCTTCATCAGGGACA TCATCAAACCAGACCCGCCCAAGAACTTGCAGATGAA GCCTTTGAAGAACTCACAGGTGGAGGTCAGCTGGGAG TACCCTGACTCCTGGAGCACTCCCCATTCCTACTTCTC CCTCAAGTTCTTTGTTCGAATCCAGCGCAAGAAAGAA AAGATGAAGGAGACAGAGGAGGGGTGTAACCAGAAA GGTGCGTTCCTCGTAGAGAAGACATCTACCGAAGTCC AATGCAAAGGCGGGAATGTCTGCGTGCAAGCTCAGGA TCGCTATTACAATTCCTCATGCAGCAAGTGGGCATGTG TTCCCTGCAGGGTCCGATCCGTTCCTGGAGTAGGGGTA CCTGGAGTGGGCATGGTCAGCGTTCCAACAGCCTCAC CCTCGGCATCCAGCAGCTCCTCTCAGTGCCGGTCCAGC ATGTGTCAATCACGCTACCTCCTCTTTTTGGCCACCCT TGCCCTCCTAAACCACCTCAGTTTGGCCAGGGTCATTC CAGTCTCTGGACCTGCCAGGTGTCTTAGCCAGTCCCGA AACCTGCTGAAGACCACAGATGACATGGTGAAGACGG CCAGAGAAAAACTGAAACATTATTCCTGCACTGCTGA AGACATCGATCATGAAGAC 48 Insert vMyx-Triple AAAATTGAAATTTTATTTTTTTTTTTTGGAATATAAAT IL-12 low AATGAAGGCCACTATCATCCTCCTTCTGCTTGCACAAG (hu Decorin-mo Il- TTTCCTGGGCTGGACCGTTTCAACAGAGAGGCTTATTT 12-dsRed) GACTTTATGCTAGAAGATGAGGCTTCTGGGATAGGCC CAGAAGTTCCTGATGACCGCGACTTCGAGCCCTCCCTA GGCCCAGTGTGCCCCTTCCGCTGTCAATGCCATCTTCG AGTGGTCCAGTGTTCTGATTTGGGTCTGGACAAAGTGC CAAAGGATCTTCCCCCTGACACAACTCTGCTAGACCTG CAAAACAACAAAATAACCGAAATCAAAGATGGAGAC TTTAAGAACCTGAAGAACCTTCACGCATTGATTCTTGT CAACAATAAAATTAGCAAAGTTAGTCCTGGAGCATTT ACACCTTTGGTGAAGTTGGAACGACTTTATCTGTCCAA GAATCAGCTGAAGGAATTGCCAGAAAAAATGCCCAAA ACTCTTCAGGAGCTGCGTGCCCATGAGAATGAGATCA CCAAAGTGCGAAAAGTTACTTTCAATGGACTGAACCA GATGATTGTCATAGAACTGGGCACCAATCCGCTGAAG AGCTCAGGAATTGAAAATGGGGCTTTCCAGGGAATGA AGAAGCTCTCCTACATCCGCATTGCTGATACCAATATC ACCAGCATTCCTCAAGGTCTTCCTCCTTCCCTTACGGA ATTACATCTTGATGGCAACAAAATCAGCAGAGTTGAT GCAGCTAGCCTGAAAGGACTGAATAATTTGGCTAAGT TGGGATTGAGTTTCAACAGCATCTCTGCTGTTGACAAT GGCTCTCTGGCCAACACGCCTCATCTGAGGGAGCTTC ACTTGGACAACAACAAGCTTACCAGAGTACCTGGTGG GCTGGCAGAGCATAAGTACATCCAGGTTGTCTACCTTC ATAACAACAATATCTCTGTAGTTGGATCAAGTGACTTC TGCCCACCTGGACACAACACCAAAAAGGCTTCTTATT CGGGTGTGAGTCTTTTCAGCAACCCGGTCCAGTACTGG GAGATACAGCCATCCACCTTCAGATGTGTCTACGTGC GCTCTGCCATTCAACTCGGAAACTATAAGTAAGCTTG GACTCCTGTTGATAGATCCAGAAAATTGAAATTTTATT TTTTTTTTTTGGAATATAAATAATGTGTCCTCAGAAGC TAACCATCTCCTGGTTTGCCATCGTTTTGCTGGTGTCTC CACTCATGGCCATGTGGGAGCTGGAGAAAGACGTTTA TGTTGTAGAGGTGGACTGGACTCCCGATGCCCCTGGA GAAACAGTGAACCTCACCTGTGACACGCCTGAAGAAG ATGACATCACCTGGACCTCAGACCAGAGACATGGAGT CATAGGCTCTGGAAAGACCCTGACCATCACTGTCAAA GAGTTTCTAGATGCTGGCCAGTACACCTGCCACAAAG GAGGCGAGACTCTGAGCCACTCACATCTGCTGCTCCA CAAGAAGGAAAATGGAATTTGGTCCACTGAAATTTTA AAAAATTTCAAAAACAAGACTTTCCTGAAGTGTGAAG CACCAAATTACTCCGGACGGTTCACGTGCTCATGGCTG GTGCAAAGAAACATGGACTTGAAGTTCAACATCAAGA GCAGTAGCAGTTCCCCTGACTCTCGGGCAGTGACATG TGGAATGGCGTCTCTGTCTGCAGAGAAGGTCACACTG GACCAAAGGGACTATGAGAAGTATTCAGTGTCCTGCC AGGAGGATGTCACCTGCCCAACTGCCGAGGAGACCCT GCCCATTGAACTGGCGTTGGAAGCACGGCAGCAGAAT AAATATGAGAACTACAGCACCAGCTTCTTCATCAGGG ACATCATCAAACCAGACCCGCCCAAGAACTTGCAGAT GAAGCCTTTGAAGAACTCACAGGTGGAGGTCAGCTGG GAGTACCCTGACTCCTGGAGCACTCCCCATTCCTACTT CTCCCTCAAGTTCTTTGTTCGAATCCAGCGCAAGAAAG AAAAGATGAAGGAGACAGAGGAGGGGTGTAACCAGA AAGGTGCGTTCCTCGTAGAGAAGACATCTACCGAAGT CCAATGCAAAGGCGGGAATGTCTGCGTGCAAGCTCAG GATCGCTATTACAATTCCTCATGCAGCAAGTGGGCAT GTGTTCCCTGCAGGGTCCGATCCTAGTATGCTAGTACG TCTCTCAAGGATAAGTAAGTAATATTAAGGTACGGGA GGTATTGGACAGGCCGCAATAAAATATCTTTATTTTCA TTACATCTGTGTGTTGGTTTTTTGTGTGAATCGATAGT ACTAACATACGCTCTCCATCAAAACAAAACGAAACAA AACAAACTAGCAAAATAGGCTGTCCCCAGTGCAAGTG CAGGTGCCAGAACATTTCTCTGGCCTAACTGGCCGGT ACCTGAGCTCTAGTTTCACTTTCCCTAGTTTCACTTTCC CTAGTTTCACTTTCCCTAGTTTCACTTTCCCTAGTTTCA CTTTCCCCTCGAGGATATCAAGATCTGGCCTCGGCGGC CAGATGGTCAGCGTTCCAACAGCCTCACCCTCGGCAT CCAGCAGCTCCTCTCAGTGCCGGTCCAGCATGTGTCAA TCACGCTACCTCCTCTTTTTGGCCACCCTTGCCCTCCTA AACCACCTCAGTTTGGCCAGGGTCATTCCAGTCTCTGG ACCTGCCAGGTGTCTTAGCCAGTCCCGAAACCTGCTG AAGACCACAGATGACATGGTGAAGACGGCCAGAGAA AAACTGAAACATTATTCCTGCACTGCTGAAGACATCG ATCATGAAGACATCACACGGGACCAAACCAGCACATT GAAGACCTGTTTACCACTGGAACTACACAAGAACGAG AGTTGCCTGGCTACTAGAGAGACTTCTTCCACAACAA GAGGGAGCTGCCTGCCCCCACAGAAGACGTCTTTGAT GATGACCCTGTGCCTTGGTAGCATCTATGAGGACTTGA AGATGTACCAGACAGAGTTCCAGGCCATCAACGCAGC ACTTCAGAATCACAACCATCAGCAGATCATTCTAGAC AAGGGCATGCTGGTGGCCATCGATGAGCTGATGCAGT CTCTGAATCATAATGGCGAGACTCTGCGCCAGAAACC TCCTGTGGGAGAAGCAGACCCTTACAGAGTGAAAATG AAGCTCTGCATCCTGCTTCACGCCTTCAGCACCCGCGT CGTGACCATCAACAGGGTGATGGGCTATCTGAGCTCC GCCTGAACAACTTTGTATAATAAAGTTGCTGAATTTCA TTTTGTTTTTTTCTATGCTATAAATGGTGCGCTCCTCCA AGAACGTCATCAAGGAGTTCATGCGCTTCAAGGTGCG CATGGAGGGCACCGTGAACGGCCACGAGTTCGAGATC GAGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCCAC AACACCGTGAAGCTGAAGGTGACCAAGGGCGGCCCCC TGCCCTTCGCCTGGGACATCCTGTCCCCCCAGTTCCAG TACGGCTCCAAGGTGTACGTGAAGCACCCCGCCGACA TCCCCGACTACAAGAAGCTGTCCTTCCCCGAGGGCTTC AAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGGCG TGGTGACCGTGACCCAGGACTCCTCCCTGCAGGACGG CTGCTTCATCTACAAGGTGAAGTTCATCGGCGTGAACT TCCCCTCCGACGGCCCCGTAATGCAGAAGAAGACCAT GGGCTGGGAGGCCTCCACCGAGCGCCTGTACCCCCGC GACGGCGTGCTGAAGGGCGAGATCCACAAGGCCCTGA AGCTGAAGGACGGCGGCCACTACCTGGTGGAGTTCAA GTCCATCTACATGGCCAAGAAGCCCGTGCAGCTGCCC GGCTACTACTACGTGGACTCCAAGCTGGACATCACCT CCCACAACGAGGACTACACCATCGTGGAGCAGTACGA GCGCACCGAGGGCCGCCACCACCTGTTCCTGTAG 49 Insert vMYX- AAAAATTGAAATTTTATTTTTTTTTTTTGGAATATAAA membrane bound TAATGAGCACTGAAAGCATGATCCGGGACGTGGAGCT TNF-eGFP GGCCGAGGAGGCGCTCCCCAAGAAGACAGGGGGGCC CCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCT CCTTCCTGATCGTGGCAGGCGCCACCACGCTCTTCTGC CTGCTGCACTTTGGAGTGATCGGCCCCCAGAGGGAAG AGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCC CAGGCAGATGAGCCTGTAGCCCATGTTGTAGCAAACC CTCAAGCTGAGGGGCAGCTCCAGTGGCTGAACCGCCG GGCCAATGCCCTCCTGGCCAATGGCGTGGAGCTGAGA GATAACCAGCTGGTGGTGCCATCAGAGGGCCTGTACC TCATCTACTCCCAGGTCCTCTTCAAGGGCCAAGGCTGC CCCTCCACCCATGTGCTCCTCACCCACACCATCAGCCG CATCGCCGTCTCCTACCAGACCAAGGTCAACCTCCTCT CTGCCATCAAGAGCCCCTGCCAGAGGGAGACCCCAGA GGGGGCTGAGGCCAAGCCCTGGTATGAGCCCATCTAT CTGGGAGGGGTCTTCCAGCTGGAGAAGGGTGACCGAC TCAGCGCTGAGATCAATCGGCCCGACTATCTCGACTTT GCCGAGTCTGGGCAGGTCTACTTTGGGATCATTGCCCT GTAGAAAAATTGAAATTTTATTTTTTTTTTTTGGAATA TAAATAATGGTGAGCAAGGGCGAGGAGCTGTTCACCG GGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGT AAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAG GGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCA TCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCAC CCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCA GCCGCTACCCCGACCACATGAAGCAGCACGACTTCTT CAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGC ACCATCTTCTTCAAGGACGACGGCAACTACAAGACCC GCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAA CCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGAC GGCAACATCCTGGGGCACAAGCTGGAGTACAACTACA ACAGCCACAACGTCTATATCATGGCCGACAAGCAGAA GAACGGCATCAAGGTGAACTTCAAGATCCGCCACAAC ATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCT GCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTG AGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCC TGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGG CATGGACGAGCTGTACAAGTAA 50 Mouse IL-12 single MCPQKLTISWFAIVLLVSPLMAMWELEKDVYVVEVDW polypeptide TPDAPGETVNLTCDTPEEDDITWTSDQRHGVIGSGKTLTI TVKEFLDAGQYTCHKGGETLSHSHLLLHKKENGIWSTEI LKNFKNKTFLKCEAPNYSGRFTCSWLVQRNMDLKFNIK SSSSSPDSRAVTCGMASLSAEKVTLDQRDYEKYSVSCQE DVTCPTAEETLPIELALEARQQNKYENYSTSFFIRDIIKPD PPKNLQMKPLKNSQVEVSWEYPDSWSTPHSYFSLKFFVR IQRKKEKMKETEEGCNQKGAFLVEKTSTEVQCKGGNVC VQAQDRYYNSSCSKWACVPCRVRSVPGVGVPGVGMVS VPTASPSASSSSSQCRSSMCQSRYLLFLATLALLNHLSLA RVIPVSGPARCLSQSRNLLKTTDDMVKTAREKLKHYSCT AEDIDHED 51 Mouse IL-12 B MCPQKLTISWFAIVLLVSPLMAMWELEKDVYVVEVDW (p40) TPDAPGETVNLTCDTPEEDDITWTSDQRHGVIGSGKTLTI TVKEFLDAGQYTCHKGGETLSHSHLLLHKKENGIWSTEI LKNFKNKTFLKCEAPNYSGRFTCSWLVQRNMDLKFNIK SSSSSPDSRAVTCGMASLSAEKVTLDQRDYEKYSVSCQE DVTCPTAEETLPIELALEARQQNKYENYSTSFFIRDIIKPD PPKNLQMKPLKNSQVEVSWEYPDSWSTPHSYFSLKFFVR IQRKKEKMKETEEGCNQKGAFLVEKTSTEVQCKGGNVC VQAQDRYYNSSCSKWACVPCRVRS 52 Truncated mouse MVSVPTASPSASSSSSQCRSSMCQSRYLLFLATLALLNHL IL-12 A (p35) SLARVIPVSGPARCLSQSRNLLKTTDDMVKTAREKLKHY SCTAEDIDHED 53 Mouse IL-12A (p35) MVSVPTASPSASSSSSQCRSSMCQSRYLLFLATLALLNHL SLARVIPVSGPARCLSQSRNLLKTTDDMVKTAREKLKHY SCTAEDIDHEDITRDQTSTLKTCLPLELHKNESCLATRET SSTTRGSCLPPQKTSLMMTLCLGSIYEDLKMYQTEFQAIN AALQNHNHQQIILDKGMLVAIDELMQSLNHNGETLRQK PPVGEADPYRVKMKLCILLHAFSTRVVTINRVMGYLSSA - While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims (20)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/357,624 US20210324014A1 (en) | 2019-09-02 | 2021-06-24 | A new oncolytic virus platform to treat cancers with myxoma virus |
US17/893,052 US20230025706A1 (en) | 2019-09-02 | 2022-08-22 | New oncolytic virus platform to treat cancers with myxoma virus |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962894925P | 2019-09-02 | 2019-09-02 | |
US201962944233P | 2019-12-05 | 2019-12-05 | |
US17/010,711 US11117934B2 (en) | 2019-09-02 | 2020-09-02 | Oncolytic virus platform to treat cancers with myxoma virus |
US17/357,624 US20210324014A1 (en) | 2019-09-02 | 2021-06-24 | A new oncolytic virus platform to treat cancers with myxoma virus |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/010,711 Continuation US11117934B2 (en) | 2019-09-02 | 2020-09-02 | Oncolytic virus platform to treat cancers with myxoma virus |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/893,052 Continuation US20230025706A1 (en) | 2019-09-02 | 2022-08-22 | New oncolytic virus platform to treat cancers with myxoma virus |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210324014A1 true US20210324014A1 (en) | 2021-10-21 |
Family
ID=74681244
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/010,711 Active US11117934B2 (en) | 2019-09-02 | 2020-09-02 | Oncolytic virus platform to treat cancers with myxoma virus |
US17/357,624 Abandoned US20210324014A1 (en) | 2019-09-02 | 2021-06-24 | A new oncolytic virus platform to treat cancers with myxoma virus |
US17/893,052 Pending US20230025706A1 (en) | 2019-09-02 | 2022-08-22 | New oncolytic virus platform to treat cancers with myxoma virus |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/010,711 Active US11117934B2 (en) | 2019-09-02 | 2020-09-02 | Oncolytic virus platform to treat cancers with myxoma virus |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/893,052 Pending US20230025706A1 (en) | 2019-09-02 | 2022-08-22 | New oncolytic virus platform to treat cancers with myxoma virus |
Country Status (11)
Country | Link |
---|---|
US (3) | US11117934B2 (en) |
EP (1) | EP4025228A4 (en) |
JP (1) | JP2022546539A (en) |
KR (1) | KR20220112241A (en) |
CN (1) | CN114615988A (en) |
AU (1) | AU2020342510A1 (en) |
CA (1) | CA3152779A1 (en) |
IL (1) | IL291009A (en) |
MX (1) | MX2022002547A (en) |
TW (1) | TW202122411A (en) |
WO (1) | WO2021046125A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020014670A1 (en) * | 2018-07-13 | 2020-01-16 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of treating cancer with tnf expressing myxoma virus |
EP3846829A4 (en) * | 2018-09-05 | 2022-09-14 | Arizona Board of Regents on behalf of Arizona State University | Oncolytic virus platform to treat hematological cancer |
CN114615988A (en) | 2019-09-02 | 2022-06-10 | 亚利桑那州立大学董事会 | Novel oncolytic viral platform for cancer treatment with myxoma virus |
CA3210350A1 (en) * | 2021-03-01 | 2022-09-09 | Leslie Lynne Sharp | Multi-armed myxoma virus |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2153284B1 (en) | 1998-06-10 | 2001-09-01 | Fundacion Para El Estudio Y De | NEW RECOMBINANT VIRUS OF ATTENATED MIXOMA AND ITS USE IN THE PREPARATION OF MIXED VACCINES AGAINST MIXOMATOSIS AND HEMORRAGICAL DISEASE OF THE RABBITS. |
WO2007143545A2 (en) * | 2006-06-01 | 2007-12-13 | Robarts Research Institute | Tnf signaling in myxoma virus treatments |
FR2946536B1 (en) * | 2009-06-11 | 2011-07-29 | Agronomique Inst Nat Rech | USE OF AN ATXURATED STRAIN OF MYXOMA VIRUS AS AN ONCOLYTIC |
EP2576581A4 (en) * | 2010-06-06 | 2015-04-15 | Sinai School Medicine | Recombinant rna viruses and uses thereof |
JP6415977B2 (en) * | 2011-04-15 | 2018-10-31 | ジェネラックス・コーポレイションGenelux Corporation | Cloned strain of attenuated vaccinia virus and method of using the same |
CN109453198A (en) | 2011-06-09 | 2019-03-12 | 佛罗里达大学研究基金会有限公司 | The treatment or prevention method of graft versus host disease |
DK3074517T3 (en) | 2013-11-28 | 2021-11-08 | Bavarian Nordic As | COMPOSITIONS AND METHODS FOR INDUCING AN IMPROVED IMMUNE RESPONSE BY USING POXVIRUS VECTORS |
CA2990133A1 (en) * | 2015-06-19 | 2017-03-09 | Sillajen, Inc. | Compositions and methods for viral embolization |
CA3011283A1 (en) | 2016-01-11 | 2017-07-20 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
US11590184B2 (en) * | 2016-08-09 | 2023-02-28 | Turnstone Limited Partnership | Oncolytic rhabdovirus expressing IL12 |
WO2020014670A1 (en) | 2018-07-13 | 2020-01-16 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of treating cancer with tnf expressing myxoma virus |
BR112021002639A2 (en) | 2018-08-16 | 2021-05-11 | Musc Foundation For Research Development | recombinant myxoma viruses and their uses |
EP3846829A4 (en) | 2018-09-05 | 2022-09-14 | Arizona Board of Regents on behalf of Arizona State University | Oncolytic virus platform to treat hematological cancer |
EP3946373A4 (en) | 2019-03-28 | 2023-01-11 | Arizona Board of Regents, a Body Corporate of the State of Arizona, acting for and on behalf of Arizona State University | Oncolytic myxoma virus expressing fast p14 to treat hematological cancer |
KR20220054865A (en) | 2019-09-02 | 2022-05-03 | 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 | Methods and compositions for ameliorating infection with oncolytic viruses for non-permissive cancers |
CN114615988A (en) | 2019-09-02 | 2022-06-10 | 亚利桑那州立大学董事会 | Novel oncolytic viral platform for cancer treatment with myxoma virus |
-
2020
- 2020-09-02 CN CN202080076788.8A patent/CN114615988A/en active Pending
- 2020-09-02 KR KR1020227010537A patent/KR20220112241A/en unknown
- 2020-09-02 EP EP20861091.5A patent/EP4025228A4/en active Pending
- 2020-09-02 AU AU2020342510A patent/AU2020342510A1/en active Pending
- 2020-09-02 TW TW109130086A patent/TW202122411A/en unknown
- 2020-09-02 JP JP2022514014A patent/JP2022546539A/en active Pending
- 2020-09-02 CA CA3152779A patent/CA3152779A1/en active Pending
- 2020-09-02 US US17/010,711 patent/US11117934B2/en active Active
- 2020-09-02 MX MX2022002547A patent/MX2022002547A/en unknown
- 2020-09-02 WO PCT/US2020/049061 patent/WO2021046125A1/en unknown
-
2021
- 2021-06-24 US US17/357,624 patent/US20210324014A1/en not_active Abandoned
-
2022
- 2022-03-01 IL IL291009A patent/IL291009A/en unknown
- 2022-08-22 US US17/893,052 patent/US20230025706A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4025228A1 (en) | 2022-07-13 |
US11117934B2 (en) | 2021-09-14 |
US20210061864A1 (en) | 2021-03-04 |
CA3152779A1 (en) | 2021-03-11 |
US20230025706A1 (en) | 2023-01-26 |
JP2022546539A (en) | 2022-11-04 |
MX2022002547A (en) | 2022-05-18 |
AU2020342510A1 (en) | 2022-03-24 |
CN114615988A (en) | 2022-06-10 |
EP4025228A4 (en) | 2023-09-06 |
WO2021046125A1 (en) | 2021-03-11 |
KR20220112241A (en) | 2022-08-10 |
TW202122411A (en) | 2021-06-16 |
IL291009A (en) | 2022-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11117934B2 (en) | Oncolytic virus platform to treat cancers with myxoma virus | |
RU2725799C2 (en) | Oncolytic adenoviruses encoding bispecific antibodies, as well as methods and applications associated therewith | |
JP6580555B2 (en) | Enhanced adoptive cell therapy | |
JP7313394B2 (en) | Anti-cancer composition comprising tumor-specific killing adenovirus and immune checkpoint inhibitor | |
JP7520511B2 (en) | Modified Virus | |
JP2022078225A (en) | Engineered oncolytic virus | |
US20210252135A1 (en) | Treatment using oncolytic virus | |
KR102056066B1 (en) | Anti-tumor composition comprising oncolytic recombinant adenovirus expressing extracellular matrix-degrading factor | |
BR112021002639A2 (en) | recombinant myxoma viruses and their uses | |
US20240092852A1 (en) | Multi-armed myxoma virus | |
CN114375331B (en) | Oncolytic type I herpes simplex virus for brain tumor treatment | |
CN114657150A (en) | Recombinant oncolytic adenovirus for improving immunotherapy and application thereof | |
TW202223085A (en) | Oncolytic herpes simplex type 1 viruses for treatment of brain tumors | |
Hogan | 403. Toca Retroviral Replicating Vector in Tumor and Blood from Clinical Trial Subjects with Recurrent High Grade Glioma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, ARIZONA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MCFADDEN, DOUGLAS GRANT;RAHMAN, MOHAMMED MASMUDUR;VILLA, NANCY;AND OTHERS;SIGNING DATES FROM 20201015 TO 20201016;REEL/FRAME:056843/0750 Owner name: ONCOMYX THERAPEUTICS, INC., ARIZONA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHARP, LESLIE LYNNE;REEL/FRAME:056843/0699 Effective date: 20201027 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: SPECIAL NEW |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |